(6934,2,'2020-08-08 17:03:43','2020-08-08 17:03:43','Biocare Medical, Concord, Calif, and Bethyl Laboratories, Montgomery, Texas, have published a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody, for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human cells.\r\n\r\nTIGIT has an important role in transplantation tolerance and tumor immune surveillance. Several studies indicate that TIGIT exhibits a synergistic function with all the PD-1/PD-L1 pathway in the inhibition of T cell proliferation. The usage of TIGIT, in conjunction with other checkpoint receptors, such as PD-1, has shown to be a promising marker for immunotherapy.\r\n\r\n\"We\'re excited for the launch of an IVD grade TIGIT [BL074F] antibody for clinical application; the Bethyl clone [BLR047F] has been demonstrated to exhibit high sensitivity and specificity based on our internal study,\" states Jason Ramos, PhD, vice president Reagent Research and Development in Biocare Medical. \"We think our newest TIGIT IVD antibody is going to be a cost-effective IHC solution to the biotech and pharmaceutical research institutions requiring an IVD grade quality in early-stage research and companion diagnostics development.\"\r\n\r\nTIGIT [BLR047F] is a IVD antibody offered in a focus format to encourage titration by end-users in addition to a ready-to-use predilute format. TIGIT [BLR047F] antibody is available for immediate purchase inside the domestic United States and European Union.\r\n\r\nFor additional information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.bethyl.com/\">Bethyl Laboratories</a></span> and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.biocare.net/\">Biocare Medical</a>.</span>','TIGIT Antibody for IHC Launched by Biocare Medical and Bethyl Laboratories','','publish','open','open','','tigit-antibody-for-ihc-launched-by-biocare-medical-and-bethyl-laboratories','','','2020-08-08 17:03:43','2020-08-08 17:03:43','',0,'https://microbiozindia.com/?p=6934',0,'post','',0),(6935,2,'2020-08-08 17:02:36','2020-08-08 17:02:36','','antibody-thumb-m','','inherit','open','closed','','antibody-thumb-m','','','2020-08-08 17:02:36','2020-08-08 17:02:36','',6934,'https://microbiozindia.com/wp-content/uploads/2020/08/antibody-thumb-m.png',0,'attachment','image/png',0),(6936,2,'2020-08-08 17:03:43','2020-08-08 17:03:43','Biocare Medical, Concord, Calif, and Bethyl Laboratories, Montgomery, Texas, have published a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody, for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human cells.\r\n\r\nTIGIT has an important role in transplantation tolerance and tumor immune surveillance. Several studies indicate that TIGIT exhibits a synergistic function with all the PD-1/PD-L1 pathway in the inhibition of T cell proliferation. The usage of TIGIT, in conjunction with other checkpoint receptors, such as PD-1, has shown to be a promising marker for immunotherapy.\r\n\r\n\"We\'re excited for the launch of an IVD grade TIGIT [BL074F] antibody for clinical application; the Bethyl clone [BLR047F] has been demonstrated to exhibit high sensitivity and specificity based on our internal study,\" states Jason Ramos, PhD, vice president Reagent Research and Development in Biocare Medical. \"We think our newest TIGIT IVD antibody is going to be a cost-effective IHC solution to the biotech and pharmaceutical research institutions requiring an IVD grade quality in early-stage research and companion diagnostics development.\"\r\n\r\nTIGIT [BLR047F] is a IVD antibody offered in a focus format to encourage titration by end-users in addition to a ready-to-use predilute format. TIGIT [BLR047F] antibody is available for immediate purchase inside the domestic United States and European Union.\r\n\r\nFor additional information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.bethyl.com/\">Bethyl Laboratories</a></span> and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.biocare.net/\">Biocare Medical</a>.</span>','TIGIT Antibody for IHC Launched by Biocare Medical and Bethyl Laboratories','','inherit','closed','closed','','6934-revision-v1','','','2020-08-08 17:03:43','2020-08-08 17:03:43','',6934,'https://microbiozindia.com/uncategorized/6934-revision-v1/',0,'revision','',0),(6937,2,'2020-08-09 11:55:15','2020-08-09 11:55:15','Using widely available tools, scientists have developed a very simple process to visualise how effectively different types of masks prevent the spread of droplets which could contain novel coronavirus contaminants, an advance which could aid small scale mask producers to replicate designs, and assist community outreach organisations demonstrate proper mask fitting procedures.\r\n\r\nThe technique, described in the journal Science Advances, is still in the first stages, and has only been tested in a little group of people, the scientists said.\r\n\r\nHowever, they stated bandanas and neck fleeces probably provide little protection, as the scientists observed that more droplets are expelled through those materials.\r\n\r\nThey said this is probably because the materials divide larger droplets as they pass through the material.\r\n\r\nIn the analysis, the scientists evaluated the potency of 14 different kinds of masks as well as other frequently substituted face coverings, using a very simple approach where either one male speaker or, in some cases, four speakers wore each mask whilst standing in a black enclosure.\r\n\r\nThe speaker then uttered the term\"stay healthy, people\" five times in the course of a laser beam, which scattered light in the droplets released during language, the analysis noted.\r\n\r\nA mobile phone camera recorded on the droplets and a very simple computer algorithm relied on them, the scientists included.\r\n\r\nThe installation, intentionally made to be simple and affordable, can be replicated by non-experts, according to the researchers.\r\n\r\nThey said that the hardware it requires, including laser equipment, is generally available and could be gotten for significantly less than USD 200.\r\n\r\nWhile the investigators acknowledge the need for additional testing, they indicated based on the findings that N95 masks with no valves blocked droplet spread finest, and surgical or polypropylene masks and handmade cotton face coverings were also effective.\r\n\r\nBut the early findings suggested that bandanas and throat fleeces do not offer protection.\r\n\r\n\"More work is required to investigate variations in masks, speakers, and how people wear them. We also want to expand our method to additional droplet-generating actions, such as coughing and coughing. Further, we would like to research effects of incorrect placement and moisture saturation,\" Fischer explained.','COVID-19: Scientists grow ease strategy to test mask adequacy against viral beads','','publish','open','open','','covid-19-scientists-grow-ease-strategy-to-test-mask-adequacy-against-viral-beads','','','2020-08-09 11:55:15','2020-08-09 11:55:15','',0,'https://microbiozindia.com/?p=6937',0,'post','',0),(6938,2,'2020-08-09 11:55:15','2020-08-09 11:55:15','Using widely available tools, scientists have developed a very simple process to visualise how effectively different types of masks prevent the spread of droplets which could contain novel coronavirus contaminants, an advance which could aid small scale mask producers to replicate designs, and assist community outreach organisations demonstrate proper mask fitting procedures.\r\n\r\nThe technique, described in the journal Science Advances, is still in the first stages, and has only been tested in a little group of people, the scientists said.\r\n\r\nHowever, they stated bandanas and neck fleeces probably provide little protection, as the scientists observed that more droplets are expelled through those materials.\r\n\r\nThey said this is probably because the materials divide larger droplets as they pass through the material.\r\n\r\nIn the analysis, the scientists evaluated the potency of 14 different kinds of masks as well as other frequently substituted face coverings, using a very simple approach where either one male speaker or, in some cases, four speakers wore each mask whilst standing in a black enclosure.\r\n\r\nThe speaker then uttered the term\"stay healthy, people\" five times in the course of a laser beam, which scattered light in the droplets released during language, the analysis noted.\r\n\r\nA mobile phone camera recorded on the droplets and a very simple computer algorithm relied on them, the scientists included.\r\n\r\nThe installation, intentionally made to be simple and affordable, can be replicated by non-experts, according to the researchers.\r\n\r\nThey said that the hardware it requires, including laser equipment, is generally available and could be gotten for significantly less than USD 200.\r\n\r\nWhile the investigators acknowledge the need for additional testing, they indicated based on the findings that N95 masks with no valves blocked droplet spread finest, and surgical or polypropylene masks and handmade cotton face coverings were also effective.\r\n\r\nBut the early findings suggested that bandanas and throat fleeces do not offer protection.\r\n\r\n\"More work is required to investigate variations in masks, speakers, and how people wear them. We also want to expand our method to additional droplet-generating actions, such as coughing and coughing. Further, we would like to research effects of incorrect placement and moisture saturation,\" Fischer explained.','COVID-19: Scientists grow ease strategy to test mask adequacy against viral beads','','inherit','closed','closed','','6937-revision-v1','','','2020-08-09 11:55:15','2020-08-09 11:55:15','',6937,'https://microbiozindia.com/uncategorized/6937-revision-v1/',0,'revision','',0),(6939,2,'2020-08-09 11:59:05','2020-08-09 11:59:05','A new book gives readers a peek into the mind of kids on which they utilize the best global health catastrophe: the COVID-19 pandemic.Its debut is written by award-winning children\'s author Bijal Vachharajani.\r\n\r\nFunny, thoughtful, wise and empathetic, it showcases the imagination and the thoughts of the current creation. Also, it conveys the diverse\"viewpoints, questions, thoughts and answers\" to the pandemic and resultant lockdowns.\r\n\r\n\"The depth of their ideas doesn\'t astound me -- children are way smarter than grown-ups. However, not all children get to tell their tales. Not all of them have access to the Internet, to facilities, to online instruction, to distanced homes and neighbourhoods. \"While some are safe in the home, so many have had to walk for miles to get to their homes. Inequalities have arrived at the forefront, and it\'s essential that privilege be examined and challenged. So many kids in this book are thinking about that,\" writes Vachharajani from the publication.\r\n\r\nThe leading authors of the publication are: Archita Agrawal, Ishaan Ghosh, Lavanya Sinha, Mira Gupta, Omkar Mantri, Sharvari Sonawani, Shiv Malik, Shivani Sharma, Shreya Aiyer, Sofia Kakar, Tishya Tara and Uk!Yo.\r\n\r\nFrom some writers wondering\"why her dreams have gone lost\" or even\"when the star of hope will ever shine again\", to others turning to history to see\"exactly what lockdowns would have been like in ancient times\" or\"searching for relief in scientific thought, in writing and in books\"; the stories are heartrending and deeply emotional of lives lost and the stark inequalities that the stunt has laid bare.\r\n\r\nAccording to publisher Talking Cub (children\'s imprint of Speaking Tiger), during the group there runs a sense of time lost and obtained -- of how this phase of global history is a bend at time.\r\n\r\nWriting is one way of reminding us of beauty even at the worst of times. Creativity opens a window to our souls and lets us speak our ideas in a medium that attracts us joy and comfort. We need to promote creativity in kids now more than ever,\" said writer Shome Ghosh.\r\n\r\nThe book can be found on online and offline shops throughout the nation.','\'A Bend in Time\': Coronavirus pandemic through the eyes of kids','','publish','open','open','','a-bend-in-time-coronavirus-pandemic-through-the-eyes-of-kids','','','2020-08-09 15:25:29','2020-08-09 15:25:29','',0,'https://microbiozindia.com/?p=6939',0,'post','',0),(6940,2,'2020-08-09 11:59:05','2020-08-09 11:59:05','A new book gives readers a peek into the mind of kids on which they utilize the best global health catastrophe: the COVID-19 pandemic.Its debut is written by award-winning children\'s author Bijal Vachharajani.\r\n\r\nFunny, thoughtful, wise and empathetic, it showcases the imagination and the thoughts of the current creation. Also, it conveys the diverse\"viewpoints, questions, thoughts and answers\" to the pandemic and resultant lockdowns.\r\n\r\n\"The depth of their ideas doesn\'t astound me -- children are way smarter than grown-ups. However, not all children get to tell their tales. Not all of them have access to the Internet, to facilities, to online instruction, to distanced homes and neighbourhoods. \"While some are safe in the home, so many have had to walk for miles to get to their homes. Inequalities have arrived at the forefront, and it\'s essential that privilege be examined and challenged. So many kids in this book are thinking about that,\" writes Vachharajani from the publication.\r\n\r\nThe leading authors of the publication are: Archita Agrawal, Ishaan Ghosh, Lavanya Sinha, Mira Gupta, Omkar Mantri, Sharvari Sonawani, Shiv Malik, Shivani Sharma, Shreya Aiyer, Sofia Kakar, Tishya Tara and Uk!Yo.\r\n\r\nFrom some writers wondering\"why her dreams have gone lost\" or even\"when the star of hope will ever shine again\", to others turning to history to see\"exactly what lockdowns would have been like in ancient times\" or\"searching for relief in scientific thought, in writing and in books\"; the stories are heartrending and deeply emotional of lives lost and the stark inequalities that the stunt has laid bare.\r\n\r\nAccording to publisher Talking Cub (children\'s imprint of Speaking Tiger), during the group there runs a sense of time lost and obtained -- of how this phase of global history is a bend at time.\r\n\r\nWriting is one way of reminding us of beauty even at the worst of times. Creativity opens a window to our souls and lets us speak our ideas in a medium that attracts us joy and comfort. We need to promote creativity in kids now more than ever,\" said writer Shome Ghosh.\r\n\r\nThe book can be found on online and offline shops throughout the nation.','\'A Bend in Time\': Coronavirus pandemic through the eyes of kids','','inherit','closed','closed','','6939-revision-v1','','','2020-08-09 11:59:05','2020-08-09 11:59:05','',6939,'https://microbiozindia.com/uncategorized/6939-revision-v1/',0,'revision','',0),(6941,2,'2020-08-09 15:28:42','2020-08-09 15:28:42','Filter\"paper\" made out of nitric oxide nanowires is effective at trapping germs and ruining them with light. This discovery via an EPFL lab could be put to use in personal protective equipment, as well as in ventilation and air conditioning systems.\r\n\r\nIncluded in attempts to curtail the Covid-19 pandemic, newspaper masks are increasingly being made compulsory. These include the environmental impact of disposable masks made from layers of non-woven polypropylene plastic microfibres. Moreover, they just trap pathogens rather than destroying them. \"But their use in the wider world - in which they\'re chucked into receptive waste bins as well as left on the street - can turn them into new sources of pollution .\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/a-titanate-nanowire-mask-that-can-eliminate-pathog\">Researchers at Forró\'s laboratory are working on a promising answer to this difficulty: a membrane made of titanium oxide nanowires, similar in appearance to filter paper however with antibacterial and antiviral properties.</a></span>\r\n\r\nTheir substance works by using the photocatalytic properties of titanium dioxide. When exposed to ultraviolet radiation, the fibers convert resident moisture into oxidizing agents such as hydrogen peroxide, which have the ability to destroy pathogens. \"Since our filter is extremely good at absorbing moisture, it may trap droplets that carry viruses and bacteria,\" says Forró. \"This creates a positive environment for the oxidation process, which is triggered by light.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/a-titanate-nanowire-mask-that-can-eliminate-pathog\">The researchers\' work seems now in Advanced Functional Materials, also contains experiments which demonstrate that the membrane\'s ability to destroy E. coli, the reference bacterium in biomedical research, and DNA strands in a matter of seconds.</a></span> Based on these outcomes, the investigators assert - although this remains to be shown experimentally - that the process would be equally successful on a broad selection of viruses, including SARS-CoV-2.\r\nTheir article also states that fabricating such membranes could be achievable on a large scale: the lab\'s equipment alone is capable of producing around 200 m2 of filter paper each week, or sufficient for as many as 80,000 masks per month. In addition, the masks can be sterilized and consumed a thousand times. This would alleviate shortages and considerably lower the amount of waste created by disposable surgical masks. Finally, the manufacturing process, which involves calcining the titanite nanowires, makes them secure and prevents the probability of nanoparticles being inhaled by the user.\r\n\r\nA start-up named Swoxid is already preparing to move the tech from the lab.\r\n\r\n<em>The membranes could also be used in air treatment applications such as ventilation and air conditioning systems as well as in personal protective equipment.\"-</em>Endre Horváth, article\'s lead author and co-founder of Swoxid\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/a-titanate-nanowire-mask-that-can-eliminate-pathog\" target=\"_blank\" rel=\"noopener noreferrer\">Ecole Polytechnique Fédérale de Lausanne</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nHorváth, E., <em>et al.</em> (2020) Photocatalytic Nanowires‐Based Air Filter: Towards Reusable Protective Masks. <em>Advanced Functional Materials.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1002/adfm.202004615\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1002/adfm.202004615</a>.</span>\r\n\r\n</div>','A titanium oxide nanowire-based air channel can trap and devastate microorganisms','','publish','open','open','','a-titanium-oxide-nanowire-based-air-channel-can-trap-and-devastate-microorganisms','','','2020-08-09 15:28:42','2020-08-09 15:28:42','',0,'https://microbiozindia.com/?p=6941',0,'post','',0),(6942,2,'2020-08-09 15:28:31','2020-08-09 15:28:31','','nn_jfr_science_of_face_masks_200621_1592781744533.focal-760x428','','inherit','open','closed','','nn_jfr_science_of_face_masks_200621_1592781744533-focal-760x428','','','2020-08-09 15:28:31','2020-08-09 15:28:31','',6941,'https://microbiozindia.com/wp-content/uploads/2020/08/nn_jfr_science_of_face_masks_200621_1592781744533.focal-760x428-1.jpg',0,'attachment','image/jpeg',0),(6943,2,'2020-08-09 15:28:33','2020-08-09 15:28:33','','virus-entering-body','','inherit','open','closed','','virus-entering-body','','','2020-08-09 15:28:33','2020-08-09 15:28:33','',6941,'https://microbiozindia.com/wp-content/uploads/2020/08/virus-entering-body.jpg',0,'attachment','image/jpeg',0),(6944,2,'2020-08-09 15:28:42','2020-08-09 15:28:42','Filter\"paper\" made out of nitric oxide nanowires is effective at trapping germs and ruining them with light. This discovery via an EPFL lab could be put to use in personal protective equipment, as well as in ventilation and air conditioning systems.\r\n\r\nIncluded in attempts to curtail the Covid-19 pandemic, newspaper masks are increasingly being made compulsory. These include the environmental impact of disposable masks made from layers of non-woven polypropylene plastic microfibres. Moreover, they just trap pathogens rather than destroying them. \"But their use in the wider world - in which they\'re chucked into receptive waste bins as well as left on the street - can turn them into new sources of pollution .\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/a-titanate-nanowire-mask-that-can-eliminate-pathog\">Researchers at Forró\'s laboratory are working on a promising answer to this difficulty: a membrane made of titanium oxide nanowires, similar in appearance to filter paper however with antibacterial and antiviral properties.</a></span>\r\n\r\nTheir substance works by using the photocatalytic properties of titanium dioxide. When exposed to ultraviolet radiation, the fibers convert resident moisture into oxidizing agents such as hydrogen peroxide, which have the ability to destroy pathogens. \"Since our filter is extremely good at absorbing moisture, it may trap droplets that carry viruses and bacteria,\" says Forró. \"This creates a positive environment for the oxidation process, which is triggered by light.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/a-titanate-nanowire-mask-that-can-eliminate-pathog\">The researchers\' work seems now in Advanced Functional Materials, also contains experiments which demonstrate that the membrane\'s ability to destroy E. coli, the reference bacterium in biomedical research, and DNA strands in a matter of seconds.</a></span> Based on these outcomes, the investigators assert - although this remains to be shown experimentally - that the process would be equally successful on a broad selection of viruses, including SARS-CoV-2.\r\nTheir article also states that fabricating such membranes could be achievable on a large scale: the lab\'s equipment alone is capable of producing around 200 m2 of filter paper each week, or sufficient for as many as 80,000 masks per month. In addition, the masks can be sterilized and consumed a thousand times. This would alleviate shortages and considerably lower the amount of waste created by disposable surgical masks. Finally, the manufacturing process, which involves calcining the titanite nanowires, makes them secure and prevents the probability of nanoparticles being inhaled by the user.\r\n\r\nA start-up named Swoxid is already preparing to move the tech from the lab.\r\n\r\n<em>The membranes could also be used in air treatment applications such as ventilation and air conditioning systems as well as in personal protective equipment.\"-</em>Endre Horváth, article\'s lead author and co-founder of Swoxid\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/a-titanate-nanowire-mask-that-can-eliminate-pathog\" target=\"_blank\" rel=\"noopener noreferrer\">Ecole Polytechnique Fédérale de Lausanne</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nHorváth, E., <em>et al.</em> (2020) Photocatalytic Nanowires‐Based Air Filter: Towards Reusable Protective Masks. <em>Advanced Functional Materials.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1002/adfm.202004615\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1002/adfm.202004615</a>.</span>\r\n\r\n</div>','A titanium oxide nanowire-based air channel can trap and devastate microorganisms','','inherit','closed','closed','','6941-revision-v1','','','2020-08-09 15:28:42','2020-08-09 15:28:42','',6941,'https://microbiozindia.com/uncategorized/6941-revision-v1/',0,'revision','',0),(6945,2,'2020-08-09 15:30:26','2020-08-09 15:30:26','Using inexpensive and widely available resources, scientists have developed a simple approach to visually evaluate how effectively different kinds of masks to prevent the spread of droplets that could contain SARS-CoV-2 virus particles, according to a new study. While the authors note their job remains in the early stages, and their method has so far only been tested in a small group of individuals, these preliminary, proof-of-principle findings suggest that professional-grade N95 masks, surgical or polypropylene masks, and handmade cotton masks may all block much of the spray produced when wearers speak.\r\n\r\nBandanas and throat fleeces, nevertheless, likely provide little protection, as the investigators observed that the more droplets are expelled through these substances - likely because the substances divide larger droplets as they pass through the material, the researchers speculate. Emma Fischer and colleagues recommend that non-experts might easily construct and operate this setup to appraise masks at the neighborhood level, for example mask manufacturers could use the method to optimize mask designs, and community and educational outreach organizations may demonstrate proper mask fitting processes.\r\n\r\nAs nations worldwide have instituted mask mandates to suppress the spread of COVID-19, international industrial suppliers have encountered shortages in the face of unprecedented demand. To compensate, many individuals have turned to homemade masks and mask options, but these do-it-yourself variants have yet to be tested systematically.\r\nTo assess the potency of 14 different kinds of masks and other often substituted face caps, Fischer et al.. Designed a very simple approach in which one male speaker or, in some cases, four speakers wore every mask whilst standing in a black enclosure. The speaker would say the term\"stay healthy, people\" five times in the path of a laser beam, which scattered light from the droplets published during speech. A cell phone camera recorded the droplets and a very simple computer algorithm counted them. The installation was deliberately designed to be simple and inexpensive so that it could be reproduced by non-experts - that the hardware it requires, including laser equipment, is commonly available and can be purchased for significantly less than $200. The findings imply that bandanas and throat fleeces (like balaclavas), nevertheless, probably provide little protection.\r\n<blockquote><em>Our work was a demonstration of a simple measurement method, not a systematic mask study. More work is required to investigate variations in masks, speakers, and how people wear them. We also want to extend our method to other droplet-generating actions, like coughing and sneezing. Further, we want to explore effects of incorrect placement and moisture saturation.\"-</em>Martin Fischer, study\'s corresponding author</blockquote>\r\n<div class=\"content-source\">\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aaas.org/\" target=\"_blank\" rel=\"noopener noreferrer\">American Association for the Advancement of Science</a></span>\r\n\r\n</div>\r\n</div>','Researchers build up a basic way to deal with outwardly assess veil adequacy','','publish','open','open','','researchers-build-up-a-basic-way-to-deal-with-outwardly-assess-veil-adequacy','','','2020-08-09 15:30:26','2020-08-09 15:30:26','',0,'https://microbiozindia.com/?p=6945',0,'post','',0),(6946,2,'2020-08-09 15:30:26','2020-08-09 15:30:26','Using inexpensive and widely available resources, scientists have developed a simple approach to visually evaluate how effectively different kinds of masks to prevent the spread of droplets that could contain SARS-CoV-2 virus particles, according to a new study. While the authors note their job remains in the early stages, and their method has so far only been tested in a small group of individuals, these preliminary, proof-of-principle findings suggest that professional-grade N95 masks, surgical or polypropylene masks, and handmade cotton masks may all block much of the spray produced when wearers speak.\r\n\r\nBandanas and throat fleeces, nevertheless, likely provide little protection, as the investigators observed that the more droplets are expelled through these substances - likely because the substances divide larger droplets as they pass through the material, the researchers speculate. Emma Fischer and colleagues recommend that non-experts might easily construct and operate this setup to appraise masks at the neighborhood level, for example mask manufacturers could use the method to optimize mask designs, and community and educational outreach organizations may demonstrate proper mask fitting processes.\r\n\r\nAs nations worldwide have instituted mask mandates to suppress the spread of COVID-19, international industrial suppliers have encountered shortages in the face of unprecedented demand. To compensate, many individuals have turned to homemade masks and mask options, but these do-it-yourself variants have yet to be tested systematically.\r\nTo assess the potency of 14 different kinds of masks and other often substituted face caps, Fischer et al.. Designed a very simple approach in which one male speaker or, in some cases, four speakers wore every mask whilst standing in a black enclosure. The speaker would say the term\"stay healthy, people\" five times in the path of a laser beam, which scattered light from the droplets published during speech. A cell phone camera recorded the droplets and a very simple computer algorithm counted them. The installation was deliberately designed to be simple and inexpensive so that it could be reproduced by non-experts - that the hardware it requires, including laser equipment, is commonly available and can be purchased for significantly less than $200. The findings imply that bandanas and throat fleeces (like balaclavas), nevertheless, probably provide little protection.\r\n<blockquote><em>Our work was a demonstration of a simple measurement method, not a systematic mask study. More work is required to investigate variations in masks, speakers, and how people wear them. We also want to extend our method to other droplet-generating actions, like coughing and sneezing. Further, we want to explore effects of incorrect placement and moisture saturation.\"-</em>Martin Fischer, study\'s corresponding author</blockquote>\r\n<div class=\"content-source\">\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aaas.org/\" target=\"_blank\" rel=\"noopener noreferrer\">American Association for the Advancement of Science</a></span>\r\n\r\n</div>\r\n</div>','Researchers build up a basic way to deal with outwardly assess veil adequacy','','inherit','closed','closed','','6945-revision-v1','','','2020-08-09 15:30:26','2020-08-09 15:30:26','',6945,'https://microbiozindia.com/uncategorized/6945-revision-v1/',0,'revision','',0),(6947,2,'2020-08-10 08:55:57','2020-08-10 08:55:57','Mumbai, July 23rd, 2020: miniPCR&#x2122; by USA based <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS</a></span> is a groundbreaking personal PCR machine. Portable, miniPCR fits right on your bench or travels wherever your science goes. To scale up the presence in the INDIA market, the company scheduled a virtual launch on 23rd of July 2020, hosted by <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.biolinxindia.com/\">Biolinx India Pvt Ltd.,</a></span> and presented by <strong>Sebastian Kraves, Ph.D. </strong> Co-Founder of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS.</a></span>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> copies targeted pieces of DNA with the same quality as professional benchtop thermal cyclers.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> can operate in the field using portable rechargeable batteries.\r\n\r\n<strong>Built to Last</strong>\r\n\r\n1.Sturdy, miniaturized 2 x 5 x 4 in. design weighs less than 1lb.\r\n\r\n2.No breakable Peltier elements.\r\n\r\n3.1/4″ thick acrylic enclosure.\r\n\r\n4.2-year warranty\r\n\r\n<strong>Engaging (Interactive and transparent):</strong>\r\n\r\n1.Interactive, free miniPCR app\r\n\r\n2.Easily create, share and monitor experiments.\r\n\r\n3.Follow and understand the PCR process, export run data for analysis.\r\n\r\n<strong>Compatible with major smart devices</strong>\r\n\r\nThe free <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/minipcr/\">miniPCR<sup>TM</sup></a></span> App is available for <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/apps/\">Windows, Mac, Android, iOS</a></span>, and Chrome operating systems.\r\n\r\n<strong>Transparent Design</strong>\r\n\r\nNot a mysterious black box.\r\n\r\n<strong>About the Polymerase Chain Reaction (PCR):</strong>\r\n\r\nPCR is the gold standard for DNA-based detection of pathogens, contaminants, and species identification, in addition to having essential research applications in the molecular biology laboratory..\r\n\r\nFor more information: <strong><a href=\"mailto:girish.nair@biolinxindia.com\">girish.nair@biolinxindia.com</a></strong>','miniPCR and bio product launch in India for Making Science Accessible and Affordable','','publish','open','open','','minipcr-and-bio-product-launch-in-india-for-making-science-accessible-and-affordable','','','2020-08-10 08:57:33','2020-08-10 08:57:33','',0,'https://microbiozindia.com/?p=6947',0,'post','',0),(6948,2,'2020-08-10 08:50:59','2020-08-10 08:50:59','','BIOLINX','','inherit','open','closed','','biolinx','','','2020-08-10 08:50:59','2020-08-10 08:50:59','',6947,'https://microbiozindia.com/wp-content/uploads/2020/08/BIOLINX.png',0,'attachment','image/png',0),(6949,2,'2020-08-10 08:55:57','2020-08-10 08:55:57','Mumbai, July 23rd, 2020: miniPCR&#x2122; by USA based <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS</a></span> is a groundbreaking personal PCR machine. Portable, miniPCR fits right on your bench or travels wherever your science goes. To scale up the presence in the INDIA market, the company scheduled a virtual launch on 23rd of July 2020, hosted by <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.biolinxindia.com/\">Biolinx India Pvt Ltd.,</a></span> and presented by <strong>Sebastian Kraves, Ph.D. </strong> Co-Founder of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS.</a></span>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> copies targeted pieces of DNA with the same quality as professional benchtop thermal cyclers.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> can operate in the field using portable rechargeable batteries.\r\n\r\n<strong>Built to Last</strong>\r\n<ol>\r\n 	<li>Sturdy, miniaturized 2 x 5 x 4 in. design weighs less than 1lb.</li>\r\n 	<li>No breakable Peltier elements.</li>\r\n 	<li>1/4″ thick acrylic enclosure.</li>\r\n 	<li>2-year warranty</li>\r\n</ol>\r\n<strong>Engaging (Interactive and transparent):</strong>\r\n<ol>\r\n 	<li>Interactive, free miniPCR app</li>\r\n 	<li>Easily create, share and monitor experiments.</li>\r\n 	<li>Follow and understand the PCR process, export run data for analysis.</li>\r\n</ol>\r\n<strong>Compatible with major smart devices</strong>\r\n\r\nThe free <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/minipcr/\">miniPCR<sup>TM</sup></a></span> App is available for <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/apps/\">Windows, Mac, Android, iOS</a></span>, and Chrome operating systems.\r\n\r\n<strong>Transparent Design</strong>\r\n\r\nNot a mysterious black box.\r\n\r\n<strong>About the Polymerase Chain Reaction (PCR):</strong>\r\n\r\nPCR is the gold standard for DNA-based detection of pathogens, contaminants, and species identification, in addition to having essential research applications in the molecular biology laboratory..\r\n\r\nFor more information: <a href=\"mailto:girish.nair@biolinxindia.com\">girish.nair@biolinxindia.com</a>','miniPCR and bio product launch in India for Making Science Accessible and Affordable','','inherit','closed','closed','','6947-revision-v1','','','2020-08-10 08:55:57','2020-08-10 08:55:57','',6947,'https://microbiozindia.com/uncategorized/6947-revision-v1/',0,'revision','',0),(6950,2,'2020-08-10 08:57:03','2020-08-10 08:57:03','Mumbai, July 23rd, 2020: miniPCR&#x2122; by USA based <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS</a></span> is a groundbreaking personal PCR machine. Portable, miniPCR fits right on your bench or travels wherever your science goes. To scale up the presence in the INDIA market, the company scheduled a virtual launch on 23rd of July 2020, hosted by <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.biolinxindia.com/\">Biolinx India Pvt Ltd.,</a></span> and presented by <strong>Sebastian Kraves, Ph.D. </strong> Co-Founder of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS.</a></span>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> copies targeted pieces of DNA with the same quality as professional benchtop thermal cyclers.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> can operate in the field using portable rechargeable batteries.\r\n\r\n<strong>Built to Last</strong>\r\n\r\n1.Sturdy, miniaturized 2 x 5 x 4 in. design weighs less than 1lb.\r\n\r\n2.No breakable Peltier elements.\r\n\r\n3.1/4″ thick acrylic enclosure.\r\n\r\n4.2-year warranty\r\n\r\n<strong>Engaging (Interactive and transparent):</strong>\r\n\r\n1.Interactive, free miniPCR app\r\n\r\n2.Easily create, share and monitor experiments.\r\n\r\n3.Follow and understand the PCR process, export run data for analysis.\r\n\r\n<strong>Compatible with major smart devices</strong>\r\n\r\nThe free <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/minipcr/\">miniPCR<sup>TM</sup></a></span> App is available for <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/apps/\">Windows, Mac, Android, iOS</a></span>, and Chrome operating systems.\r\n\r\n<strong>Transparent Design</strong>\r\n\r\nNot a mysterious black box.\r\n\r\n<strong>About the Polymerase Chain Reaction (PCR):</strong>\r\n\r\nPCR is the gold standard for DNA-based detection of pathogens, contaminants, and species identification, in addition to having essential research applications in the molecular biology laboratory..\r\n\r\nFor more information: <a href=\"mailto:girish.nair@biolinxindia.com\">girish.nair@biolinxindia.com</a>','miniPCR and bio product launch in India for Making Science Accessible and Affordable','','inherit','closed','closed','','6947-revision-v1','','','2020-08-10 08:57:03','2020-08-10 08:57:03','',6947,'https://microbiozindia.com/uncategorized/6947-revision-v1/',0,'revision','',0),(6951,2,'2020-08-10 08:57:33','2020-08-10 08:57:33','Mumbai, July 23rd, 2020: miniPCR&#x2122; by USA based <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS</a></span> is a groundbreaking personal PCR machine. Portable, miniPCR fits right on your bench or travels wherever your science goes. To scale up the presence in the INDIA market, the company scheduled a virtual launch on 23rd of July 2020, hosted by <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.biolinxindia.com/\">Biolinx India Pvt Ltd.,</a></span> and presented by <strong>Sebastian Kraves, Ph.D. </strong> Co-Founder of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">AMPLYUS.</a></span>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> copies targeted pieces of DNA with the same quality as professional benchtop thermal cyclers.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/\">miniPCR<sup>TM</sup></a></span> can operate in the field using portable rechargeable batteries.\r\n\r\n<strong>Built to Last</strong>\r\n\r\n1.Sturdy, miniaturized 2 x 5 x 4 in. design weighs less than 1lb.\r\n\r\n2.No breakable Peltier elements.\r\n\r\n3.1/4″ thick acrylic enclosure.\r\n\r\n4.2-year warranty\r\n\r\n<strong>Engaging (Interactive and transparent):</strong>\r\n\r\n1.Interactive, free miniPCR app\r\n\r\n2.Easily create, share and monitor experiments.\r\n\r\n3.Follow and understand the PCR process, export run data for analysis.\r\n\r\n<strong>Compatible with major smart devices</strong>\r\n\r\nThe free <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/minipcr/\">miniPCR<sup>TM</sup></a></span> App is available for <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.minipcr.com/products/apps/\">Windows, Mac, Android, iOS</a></span>, and Chrome operating systems.\r\n\r\n<strong>Transparent Design</strong>\r\n\r\nNot a mysterious black box.\r\n\r\n<strong>About the Polymerase Chain Reaction (PCR):</strong>\r\n\r\nPCR is the gold standard for DNA-based detection of pathogens, contaminants, and species identification, in addition to having essential research applications in the molecular biology laboratory..\r\n\r\nFor more information: <strong><a href=\"mailto:girish.nair@biolinxindia.com\">girish.nair@biolinxindia.com</a></strong>','miniPCR and bio product launch in India for Making Science Accessible and Affordable','','inherit','closed','closed','','6947-revision-v1','','','2020-08-10 08:57:33','2020-08-10 08:57:33','',6947,'https://microbiozindia.com/uncategorized/6947-revision-v1/',0,'revision','',0),(6952,2,'2020-08-10 10:06:22','2020-08-10 10:06:22','The Russian COVID-19 vaccine candidate, being jointly developed by the Gamaleya Research Institute along with also the country\'s Defence Ministry, is place to get registered on August 12, reports suggest. This would be the primary vaccine candidate against the novel coronavirus to become registered.\r\n\r\nNews reports quoted Russia\'s Deputy Health Minister Oleg Gridnev as confirming that the development. \"The vaccine developed by the Gamaleya centre will be registered on August 12. At the moment, the last, third, stage is penalized,\" Gridnev said.\r\n\r\nThe junior health ministry stated that medical professionals and senior citizens are the first to get vaccinated. Mass production of this Russian COVID-19 vaccine is expected to begin in October.\r\n<iframe src=\"https://www.youtube.com/embed/694RkqOZ2-k\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\nThis development comes days following the World Health Organization (WHO) warned Russian governments to follow established guidelines for generating safe and effective vaccines. The warning came as Moscow moved swiftly to begin producing vaccine doses.\r\n\r\nDr Anthony Fauci, United States\' top infectious disease specialist, had also contested the fast-track approach. \"I really do hope that the Chinese and the Russians are actually testing a vaccine before they\'re administering the vaccine to anyone because claims of having a vaccine ready to distribute before you perform testing I believe is debatable at best,\" he said.\r\n\r\nGamaleya\'s candidate is a so-called viral vector vaccine which is based on human adenovirus fused with SARS CoV-2\'s spike protein to stimulate an immune reaction within the body.\r\n\r\nIt was earlier reported that a number of individuals belonging to Russia\'s political and business elite was given early access into the experimental vaccine. Russian billionaires and government officials allegedly started getting shots of a potential vaccine as early as April.','Russia to enroll world\'s first COVID-19 immunization on August 12','','publish','open','open','','russia-to-enroll-worlds-first-covid-19-immunization-on-august-12','','','2020-08-10 11:01:45','2020-08-10 11:01:45','',0,'https://microbiozindia.com/?p=6952',0,'post','',0),(6953,2,'2020-08-10 10:06:22','2020-08-10 10:06:22','The Russian COVID-19 vaccine candidate, being jointly developed by the Gamaleya Research Institute along with also the country\'s Defence Ministry, is place to get registered on August 12, reports suggest. This would be the primary vaccine candidate against the novel coronavirus to become registered.\r\n\r\nNews reports quoted Russia\'s Deputy Health Minister Oleg Gridnev as confirming that the development. \"The vaccine developed by the Gamaleya centre will be registered on August 12. At the moment, the last, third, stage is penalized,\" Gridnev said.\r\n\r\nThe junior health ministry stated that medical professionals and senior citizens are the first to get vaccinated. Mass production of this Russian COVID-19 vaccine is expected to begin in October.\r\n\r\nThis development comes days following the World Health Organization (WHO) warned Russian governments to follow established guidelines for generating safe and effective vaccines. The warning came as Moscow moved swiftly to begin producing vaccine doses.\r\n\r\nDr Anthony Fauci, United States\' top infectious disease specialist, had also contested the fast-track approach. \"I really do hope that the Chinese and the Russians are actually testing a vaccine before they\'re administering the vaccine to anyone because claims of having a vaccine ready to distribute before you perform testing I believe is debatable at best,\" he said.\r\n\r\nGamaleya\'s candidate is a so-called viral vector vaccine which is based on human adenovirus fused with SARS CoV-2\'s spike protein to stimulate an immune reaction within the body.\r\n\r\nIt was earlier reported that a number of individuals belonging to Russia\'s political and business elite was given early access into the experimental vaccine. Russian billionaires and government officials allegedly started getting shots of a potential vaccine as early as April.','Russia to enroll world\'s first COVID-19 immunization on August 12','','inherit','closed','closed','','6952-revision-v1','','','2020-08-10 10:06:22','2020-08-10 10:06:22','',6952,'https://microbiozindia.com/uncategorized/6952-revision-v1/',0,'revision','',0),(6954,2,'2020-08-10 11:01:45','2020-08-10 11:01:45','The Russian COVID-19 vaccine candidate, being jointly developed by the Gamaleya Research Institute along with also the country\'s Defence Ministry, is place to get registered on August 12, reports suggest. This would be the primary vaccine candidate against the novel coronavirus to become registered.\r\n\r\nNews reports quoted Russia\'s Deputy Health Minister Oleg Gridnev as confirming that the development. \"The vaccine developed by the Gamaleya centre will be registered on August 12. At the moment, the last, third, stage is penalized,\" Gridnev said.\r\n\r\nThe junior health ministry stated that medical professionals and senior citizens are the first to get vaccinated. Mass production of this Russian COVID-19 vaccine is expected to begin in October.\r\n<iframe src=\"https://www.youtube.com/embed/694RkqOZ2-k\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\nThis development comes days following the World Health Organization (WHO) warned Russian governments to follow established guidelines for generating safe and effective vaccines. The warning came as Moscow moved swiftly to begin producing vaccine doses.\r\n\r\nDr Anthony Fauci, United States\' top infectious disease specialist, had also contested the fast-track approach. \"I really do hope that the Chinese and the Russians are actually testing a vaccine before they\'re administering the vaccine to anyone because claims of having a vaccine ready to distribute before you perform testing I believe is debatable at best,\" he said.\r\n\r\nGamaleya\'s candidate is a so-called viral vector vaccine which is based on human adenovirus fused with SARS CoV-2\'s spike protein to stimulate an immune reaction within the body.\r\n\r\nIt was earlier reported that a number of individuals belonging to Russia\'s political and business elite was given early access into the experimental vaccine. Russian billionaires and government officials allegedly started getting shots of a potential vaccine as early as April.','Russia to enroll world\'s first COVID-19 immunization on August 12','','inherit','closed','closed','','6952-revision-v1','','','2020-08-10 11:01:45','2020-08-10 11:01:45','',6952,'https://microbiozindia.com/uncategorized/6952-revision-v1/',0,'revision','',0),(6955,2,'2020-08-10 15:55:46','2020-08-10 15:55:46','FDA has approved that the Guardant360 CDx in Guardant Health, Redwood City, Calif, the initial liquid biopsy companion diagnostic which additionally utilizes next-generation sequencing (NGS) technologies to identify patients with particular types of mutations of the epidermal growth factor receptor (EGFR) gene in a mortal kind of metastatic non-small cell lung cancer (NSCLC). This is the initial approval to combine two technology --NGS and liquid biopsy--in one diagnostic evaluation in order to guide therapy choices.\r\n\r\n\"Approval of a company diagnostic that uses a liquid biopsy and leverages next-generation sequencing marks a new age for mutation testing,\" states Tim Stenzel, MD, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA\'s Center for Devices and Radiological Health. \"Along with benefiting from invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, instead of one biomarker at a time, which can translate to decreased wait times for beginning treatment and provide insight into possible resistance mechanisms.\"\r\n\r\nThe Guardant360 CDx assay utilizes two technologies. The first is known as liquid biopsy, which uses a blood sample to offer health care professionals with genetic information regarding the individual\'s tumor. It is less invasive and more easily repeatable compared to standard tissue biopsies. What\'s more, liquid biopsy evaluations can be used in cases in which standard tissue biopsies are not feasible, for example, due to the positioning of the tumor.\r\n\r\nThe second technology is NGS, which utilizes large-panel genetic sequencing, called high-throughput tumor profiling. Compared to older technologies, NGS requires just one test so as to permit clinicians better assessment of tumor composition, giving suppliers an advantage in evaluating which mutations are debatable. The Guardant360 CDx assay employs NGS technologies to concurrently detect mutations in 55 tumor genes, rather than 1 gene at a time.\r\n\r\nThough the Guardant360CDx can provide advice on several solid tumor biomarkers, today\'s approval is unique to its use in identifying EGFR mutations in patients that will benefit from therapy with Tagrisso (osimertinib), an FDA-approved therapy for a kind of metastatic NSCLC. Lung cancer is the major cause of cancer-related death among men and women in the United States, also NSCLC is the most common type of lung cancer. Genomic findings for different biomarkers evaluated are not validated for choosing a particular corresponding remedy with this acceptance. If the particular NSCLC mutations linked with the current approval aren\'t detected in the bloodstream, then a tumor biopsy should be performed to decide whether the NSCLC mutations are present.\r\n\r\nThe Guardant360 CDx assay was granted a Breakthrough Device designation, in which the FDA provides intensive discussion and guidance to the organization on effective apparatus development.\r\n\r\nThe FDA granted approval for the Guardant360 CDx test to Guardant Health. For more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://guardanthealth.com/\" target=\"_blank\" rel=\"noopener noreferrer\">Guardant Health</a></span>','First Liquid Biopsy NGS Companion Diagnostic gets FDA approval','','publish','open','open','','first-liquid-biopsy-ngs-companion-diagnostic-gets-fda-approval','','','2020-08-10 15:55:46','2020-08-10 15:55:46','',0,'https://microbiozindia.com/?p=6955',0,'post','',0),(6956,2,'2020-08-10 15:55:46','2020-08-10 15:55:46','FDA has approved that the Guardant360 CDx in Guardant Health, Redwood City, Calif, the initial liquid biopsy companion diagnostic which additionally utilizes next-generation sequencing (NGS) technologies to identify patients with particular types of mutations of the epidermal growth factor receptor (EGFR) gene in a mortal kind of metastatic non-small cell lung cancer (NSCLC). This is the initial approval to combine two technology --NGS and liquid biopsy--in one diagnostic evaluation in order to guide therapy choices.\r\n\r\n\"Approval of a company diagnostic that uses a liquid biopsy and leverages next-generation sequencing marks a new age for mutation testing,\" states Tim Stenzel, MD, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA\'s Center for Devices and Radiological Health. \"Along with benefiting from invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, instead of one biomarker at a time, which can translate to decreased wait times for beginning treatment and provide insight into possible resistance mechanisms.\"\r\n\r\nThe Guardant360 CDx assay utilizes two technologies. The first is known as liquid biopsy, which uses a blood sample to offer health care professionals with genetic information regarding the individual\'s tumor. It is less invasive and more easily repeatable compared to standard tissue biopsies. What\'s more, liquid biopsy evaluations can be used in cases in which standard tissue biopsies are not feasible, for example, due to the positioning of the tumor.\r\n\r\nThe second technology is NGS, which utilizes large-panel genetic sequencing, called high-throughput tumor profiling. Compared to older technologies, NGS requires just one test so as to permit clinicians better assessment of tumor composition, giving suppliers an advantage in evaluating which mutations are debatable. The Guardant360 CDx assay employs NGS technologies to concurrently detect mutations in 55 tumor genes, rather than 1 gene at a time.\r\n\r\nThough the Guardant360CDx can provide advice on several solid tumor biomarkers, today\'s approval is unique to its use in identifying EGFR mutations in patients that will benefit from therapy with Tagrisso (osimertinib), an FDA-approved therapy for a kind of metastatic NSCLC. Lung cancer is the major cause of cancer-related death among men and women in the United States, also NSCLC is the most common type of lung cancer. Genomic findings for different biomarkers evaluated are not validated for choosing a particular corresponding remedy with this acceptance. If the particular NSCLC mutations linked with the current approval aren\'t detected in the bloodstream, then a tumor biopsy should be performed to decide whether the NSCLC mutations are present.\r\n\r\nThe Guardant360 CDx assay was granted a Breakthrough Device designation, in which the FDA provides intensive discussion and guidance to the organization on effective apparatus development.\r\n\r\nThe FDA granted approval for the Guardant360 CDx test to Guardant Health. For more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://guardanthealth.com/\" target=\"_blank\" rel=\"noopener noreferrer\">Guardant Health</a></span>','First Liquid Biopsy NGS Companion Diagnostic gets FDA approval','','inherit','closed','closed','','6955-revision-v1','','','2020-08-10 15:55:46','2020-08-10 15:55:46','',6955,'https://microbiozindia.com/uncategorized/6955-revision-v1/',0,'revision','',0),(6957,2,'2020-08-10 16:05:34','2020-08-10 16:05:34','Whether you\'re playing in a park amid chirping birds, a gentle breeze and kids playing grab nearby or you are playing at a room with a ticking clock on a bookcase and a purring cat on the couch, if the match situation is identical and clear, your next move probably is, too, no matter those different ailments. You\'ll still perform the exact second move despite a broad array of inner feelings or even if a few neurons and there are just being somewhat erratic. How does the brain overcome unpredictable and changing disturbances to generate dependable and stable computations?\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://picower.mit.edu/news/math-shows-how-brain-stays-stable-amid-internal-noise-and-widely-varying-world\">More basic than the willful exertion of cognitive control over attention, the version the group developed describes an inclination toward robust stability that\'s built into neural cells by virtue of their relations, or\"synapses\" that volunteers create with each other.</a> </span>The equations they derived and published in PLOS Computational Biology demonstrate that networks of neurons included with precisely the identical computation will repeatedly converge toward the same patterns of electrical activity, or\"firing rates,\" even if they are sometimes arbitrarily perturbed by the pure noisiness of human neurons or random sensory stimuli that the world can produce.\r\n\r\nSlotine brought the mathematical method of\"contraction evaluation,\" a theory developed in control theory, to the problem together with tools his laboratory developed to use the method. Contracting systems exhibit the property of trajectories that begin from disparate points finally converging into a single trajectory, such as tributaries in a watershed. They do this even when the inputs vary . They are robust to disturbance and noise, and they enable several other contracting networks to be combined together without a loss of overall stability - similar to mind normally integrates information from a number of technical areas.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://picower.mit.edu/news/math-shows-how-brain-stays-stable-amid-internal-noise-and-widely-varying-world\">\"In a system such as the mind where you have [countless billions] of connections the questions of what\'s going to sustain stability and what types of constraints that occupies the system\'s architecture become quite significant,\" Slotine explained.</a></span>\r\n\r\n<strong>Math reveals natural mechanics</strong>\r\nLeo Kozachkova graduate student in the Miller\'s and Slotine\'s labs, also led the study by applying regeneration analysis to the issue of the stability of computations from the mind. What he discovered is that the variables and terms in the ensuing equations which enforce stability right mirror properties and processes of synapses: inhibitory circuit links can get more powerful, excitatory circuit connections can get weaker, both sorts of relations are generally tightly balanced relative to one another, and volunteers create far fewer connections than they can (each neuron, typically, could make approximately 10 million more relations than it can ).\r\n\r\n<em>How does the brain make sense of this highly dynamic, non-linear nature of neural activity? The brain is noisy, there are different starting conditions - how does the brain achieve a stable representation of information in the face of all these factors that can knock it around?\"</em>-Earl Miller,  Co-Senior Author, Picower Professor of Neuroscience in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences (BCS) at MIT\r\n\r\n\"These are all things that neuroscientists have discovered, however they haven\'t linked them to this equilibrium property,\" Kozachkov said. \"In a sense, we are synthesizing some disparate findings in the area to explain this frequent phenomenon.\"\r\n\r\nAdditionally, it supplies mathematical proofs of equilibrium, Kozachkov added.\r\n\r\nThough focused on the elements that guarantee stability, the authors mentioned, their version doesn\'t proceed so far as to doom the brain into inflexibility or determinism. The brain\'s ability to transform - to understand and remember - is just as basic to its function as its ability to constantly reason and invent stable behaviours.\r\n\r\n\"We are not asking the way the mind changes,\" Miller said. \"We are asking the way the mind keeps from changing a lot.\"\r\n\r\nStill, the team intends to keep iterating on the design, for example by encircling a richer accounting for the neurons produce individual spikes of electrical action, not just rates of the activity.\r\n\r\nThey\'re also working to compare the model\'s predictions with data from experiments where animals repeatedly completed tasks where they had to perform the same neural computations, despite experiencing inevitable inner neural noise and at least small sensory input gaps.\r\n\r\nFinally, the group is considering the way the models can notify understanding of distinct disease conditions of the brain. Aberrations from the delicate balance of excitatory and inhibitory neural activity in the brain is considered essential in epilepsy, Kozachkov notes. A symptom of Parkinson\'s disease, too, involves a neurally-rooted reduction of motor equilibrium. Miller adds that some individuals with autism spectrum disorders battle to stably repeat actions (e.g. brushing teeth) when outside conditions differ (e.g. brushing at a different room).\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://picower.mit.edu/news/math-shows-how-brain-stays-stable-amid-internal-noise-and-widely-varying-world\" target=\"_blank\" rel=\"noopener noreferrer\">Picower Institute at MIT</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nKozachkov, L., <em>et al.</em> (2020) Achieving stable dynamics in neural circuits. <em>PLOS Computational Biology.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1371/journal.pcbi.1007659\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1371/journal.pcbi.1007659</a>.</span>\r\n\r\n</div>','Scientific model shows how mind stays stable in the midst of fluctuating unsettling influences','','publish','open','open','','scientific-model-shows-how-mind-stays-stable-in-the-midst-of-fluctuating-unsettling-influences','','','2020-08-10 16:05:34','2020-08-10 16:05:34','',0,'https://microbiozindia.com/?p=6957',0,'post','',0),(6958,2,'2020-08-10 16:05:15','2020-08-10 16:05:15','','285254-brain','','inherit','open','closed','','285254-brain','','','2020-08-10 16:05:15','2020-08-10 16:05:15','',6957,'https://microbiozindia.com/wp-content/uploads/2020/08/285254-brain.jpg',0,'attachment','image/jpeg',0),(6959,2,'2020-08-10 16:05:16','2020-08-10 16:05:16','','SA-000714','','inherit','open','closed','','sa-000714','','','2020-08-10 16:05:16','2020-08-10 16:05:16','',6957,'https://microbiozindia.com/wp-content/uploads/2020/08/SA-000714.jpg',0,'attachment','image/jpeg',0),(6960,2,'2020-08-10 16:05:34','2020-08-10 16:05:34','Whether you\'re playing in a park amid chirping birds, a gentle breeze and kids playing grab nearby or you are playing at a room with a ticking clock on a bookcase and a purring cat on the couch, if the match situation is identical and clear, your next move probably is, too, no matter those different ailments. You\'ll still perform the exact second move despite a broad array of inner feelings or even if a few neurons and there are just being somewhat erratic. How does the brain overcome unpredictable and changing disturbances to generate dependable and stable computations?\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://picower.mit.edu/news/math-shows-how-brain-stays-stable-amid-internal-noise-and-widely-varying-world\">More basic than the willful exertion of cognitive control over attention, the version the group developed describes an inclination toward robust stability that\'s built into neural cells by virtue of their relations, or\"synapses\" that volunteers create with each other.</a> </span>The equations they derived and published in PLOS Computational Biology demonstrate that networks of neurons included with precisely the identical computation will repeatedly converge toward the same patterns of electrical activity, or\"firing rates,\" even if they are sometimes arbitrarily perturbed by the pure noisiness of human neurons or random sensory stimuli that the world can produce.\r\n\r\nSlotine brought the mathematical method of\"contraction evaluation,\" a theory developed in control theory, to the problem together with tools his laboratory developed to use the method. Contracting systems exhibit the property of trajectories that begin from disparate points finally converging into a single trajectory, such as tributaries in a watershed. They do this even when the inputs vary . They are robust to disturbance and noise, and they enable several other contracting networks to be combined together without a loss of overall stability - similar to mind normally integrates information from a number of technical areas.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://picower.mit.edu/news/math-shows-how-brain-stays-stable-amid-internal-noise-and-widely-varying-world\">\"In a system such as the mind where you have [countless billions] of connections the questions of what\'s going to sustain stability and what types of constraints that occupies the system\'s architecture become quite significant,\" Slotine explained.</a></span>\r\n\r\n<strong>Math reveals natural mechanics</strong>\r\nLeo Kozachkova graduate student in the Miller\'s and Slotine\'s labs, also led the study by applying regeneration analysis to the issue of the stability of computations from the mind. What he discovered is that the variables and terms in the ensuing equations which enforce stability right mirror properties and processes of synapses: inhibitory circuit links can get more powerful, excitatory circuit connections can get weaker, both sorts of relations are generally tightly balanced relative to one another, and volunteers create far fewer connections than they can (each neuron, typically, could make approximately 10 million more relations than it can ).\r\n\r\n<em>How does the brain make sense of this highly dynamic, non-linear nature of neural activity? The brain is noisy, there are different starting conditions - how does the brain achieve a stable representation of information in the face of all these factors that can knock it around?\"</em>-Earl Miller,  Co-Senior Author, Picower Professor of Neuroscience in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences (BCS) at MIT\r\n\r\n\"These are all things that neuroscientists have discovered, however they haven\'t linked them to this equilibrium property,\" Kozachkov said. \"In a sense, we are synthesizing some disparate findings in the area to explain this frequent phenomenon.\"\r\n\r\nAdditionally, it supplies mathematical proofs of equilibrium, Kozachkov added.\r\n\r\nThough focused on the elements that guarantee stability, the authors mentioned, their version doesn\'t proceed so far as to doom the brain into inflexibility or determinism. The brain\'s ability to transform - to understand and remember - is just as basic to its function as its ability to constantly reason and invent stable behaviours.\r\n\r\n\"We are not asking the way the mind changes,\" Miller said. \"We are asking the way the mind keeps from changing a lot.\"\r\n\r\nStill, the team intends to keep iterating on the design, for example by encircling a richer accounting for the neurons produce individual spikes of electrical action, not just rates of the activity.\r\n\r\nThey\'re also working to compare the model\'s predictions with data from experiments where animals repeatedly completed tasks where they had to perform the same neural computations, despite experiencing inevitable inner neural noise and at least small sensory input gaps.\r\n\r\nFinally, the group is considering the way the models can notify understanding of distinct disease conditions of the brain. Aberrations from the delicate balance of excitatory and inhibitory neural activity in the brain is considered essential in epilepsy, Kozachkov notes. A symptom of Parkinson\'s disease, too, involves a neurally-rooted reduction of motor equilibrium. Miller adds that some individuals with autism spectrum disorders battle to stably repeat actions (e.g. brushing teeth) when outside conditions differ (e.g. brushing at a different room).\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://picower.mit.edu/news/math-shows-how-brain-stays-stable-amid-internal-noise-and-widely-varying-world\" target=\"_blank\" rel=\"noopener noreferrer\">Picower Institute at MIT</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nKozachkov, L., <em>et al.</em> (2020) Achieving stable dynamics in neural circuits. <em>PLOS Computational Biology.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1371/journal.pcbi.1007659\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1371/journal.pcbi.1007659</a>.</span>\r\n\r\n</div>','Scientific model shows how mind stays stable in the midst of fluctuating unsettling influences','','inherit','closed','closed','','6957-revision-v1','','','2020-08-10 16:05:34','2020-08-10 16:05:34','',6957,'https://microbiozindia.com/uncategorized/6957-revision-v1/',0,'revision','',0),(6961,2,'2020-08-10 16:07:32','2020-08-10 16:07:32','A team from SPI in Marcoule discovered by mass spectrometry, in just 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples (nasopharyngeal swabs). It hence gives a proof of concept concerning the usage of the technique as a potential option to PCR, now the reference process.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2020/SARS-CoV-2-detection-mass-spectrometry-rapidity.aspx\">Quick but nonetheless sensitive, specific and high-throughput discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical trials is critical to diagnose infected individuals and also to better manage the spread of this virus.</a> </span>Alternative methodologies to PCR and immunodiagnostic that would not require certain reagents are not worth to investigate not only for fighting the COVID-19 pandemic, but also to discover other emergent pathogenic dangers.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2020/SARS-CoV-2-detection-mass-spectrometry-rapidity.aspx\">In the present study, scientists in SPI (Marcoule) propose the use of tandem mass spectrometry to detect SARS-CoV-2 marker peptides in nasopharyngeal swabs.</a> </span>They recorded that the sign from the microbiota within such samples is low and can be overlooked when translating shotgun proteomic data obtained on a restricted window of the peptidome landscape.\r\n\r\nWithin this proof of concept research, simili nasopharyngeal swabs compromised with unique amounts of purified SARS-CoV-2 viral material had been used to create a nanoLC-MS/MS acquisition method, which was subsequently successfully implemented to COVID-19 clinical trials. Researchers assert that two peptides in the nucleocapsid protein are of extreme attention as their signal is intense and their elution can be gotten within a 3 minute window at the tested conditions.\r\n\r\nThese effects pave the way for the progression of implements viral diagnostic evaluations based on mass spectrometry.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2020/SARS-CoV-2-detection-mass-spectrometry-rapidity.aspx\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Frédéric Joliot Institute for Life Sciences</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nGouveia, D., <em>et al. </em>(2020) Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window. <em>Journal of Proteome Research</em>.  <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://gouveia%2C%20d.%2C%20et%20al.%20%282020%29%20proteotyping%20sars-cov-2%20virus%20from%20nasopharyngeal%20swabs:%20A%20Proof-of-Concept%20Focused%20on%20a%203%20Min%20Mass%20Spectrometry%20Window.%20Journal%20of%20Proteome%20Research.%C2%A0%20doi.org/10.1021/acs.jproteome.0c00535.\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">doi.org/10.1021/acs.jproteome.0c00535</a>.</span>\r\n\r\n</div>','Mass spectrometry shows potential for fast SARS-CoV-2 recognition','','publish','open','open','','mass-spectrometry-shows-potential-for-fast-sars-cov-2-recognition','','','2020-08-10 16:07:32','2020-08-10 16:07:32','',0,'https://microbiozindia.com/?p=6961',0,'post','',0),(6962,2,'2020-08-10 16:07:32','2020-08-10 16:07:32','A team from SPI in Marcoule discovered by mass spectrometry, in just 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples (nasopharyngeal swabs). It hence gives a proof of concept concerning the usage of the technique as a potential option to PCR, now the reference process.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2020/SARS-CoV-2-detection-mass-spectrometry-rapidity.aspx\">Quick but nonetheless sensitive, specific and high-throughput discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical trials is critical to diagnose infected individuals and also to better manage the spread of this virus.</a> </span>Alternative methodologies to PCR and immunodiagnostic that would not require certain reagents are not worth to investigate not only for fighting the COVID-19 pandemic, but also to discover other emergent pathogenic dangers.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2020/SARS-CoV-2-detection-mass-spectrometry-rapidity.aspx\">In the present study, scientists in SPI (Marcoule) propose the use of tandem mass spectrometry to detect SARS-CoV-2 marker peptides in nasopharyngeal swabs.</a> </span>They recorded that the sign from the microbiota within such samples is low and can be overlooked when translating shotgun proteomic data obtained on a restricted window of the peptidome landscape.\r\n\r\nWithin this proof of concept research, simili nasopharyngeal swabs compromised with unique amounts of purified SARS-CoV-2 viral material had been used to create a nanoLC-MS/MS acquisition method, which was subsequently successfully implemented to COVID-19 clinical trials. Researchers assert that two peptides in the nucleocapsid protein are of extreme attention as their signal is intense and their elution can be gotten within a 3 minute window at the tested conditions.\r\n\r\nThese effects pave the way for the progression of implements viral diagnostic evaluations based on mass spectrometry.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2020/SARS-CoV-2-detection-mass-spectrometry-rapidity.aspx\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Frédéric Joliot Institute for Life Sciences</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nGouveia, D., <em>et al. </em>(2020) Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window. <em>Journal of Proteome Research</em>.  <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://gouveia%2C%20d.%2C%20et%20al.%20%282020%29%20proteotyping%20sars-cov-2%20virus%20from%20nasopharyngeal%20swabs:%20A%20Proof-of-Concept%20Focused%20on%20a%203%20Min%20Mass%20Spectrometry%20Window.%20Journal%20of%20Proteome%20Research.%C2%A0%20doi.org/10.1021/acs.jproteome.0c00535.\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">doi.org/10.1021/acs.jproteome.0c00535</a>.</span>\r\n\r\n</div>','Mass spectrometry shows potential for fast SARS-CoV-2 recognition','','inherit','closed','closed','','6961-revision-v1','','','2020-08-10 16:07:32','2020-08-10 16:07:32','',6961,'https://microbiozindia.com/uncategorized/6961-revision-v1/',0,'revision','',0),(6963,2,'2020-08-11 04:58:41','2020-08-11 04:58:41','11<sup>th</sup> August 2020, Mumbai: Cancer patients and their families in Mumbai and Pune can now dial in to Can-Helper – a first-of-its-kind toll-free helpline to provide support for fear, anxiety and stress related to cancer. This service, operated by experienced counsellors, is available on a<strong> toll free number 09511948920 on all days of the week from 10 am to 6 pm in </strong><strong>English, Hindi and Marathi</strong>.\r\n\r\nWhilst cancer impacts the emotional wellbeing of all patients, it is estimated that one out of every three cancer patients require interventions to address their emotional distress- the most common problems being anxiety and depression <strong><sup>1</sup></strong>.  These psychosocial problems have become even more acute in Covid due to lack of continuity of care, reduced social support, increased financial burden from loss of jobs etc.\r\n\r\nCan-Helper (<strong><em>Cancer Helpline for Emotional Respite</em></strong>) is launched by Tata Memorial Centre, Mumbai and Cipla Palliative Care &amp; Training Centre Pune in association with the Municipal Corporation of Greater Mumbai (MCGM) and Pune Municipal Corporation (PMC) to address the specific psychosocial needs of cancer patients and their caregivers, especially those in advanced stage of the disease.\r\n\r\nTalking about the service, <strong>Dr. Badwe, Director, </strong>Tata Memorial Centre said<strong>, “</strong>The Covid -19 pandemic has had a disastrous impact on all patients and especially those with serious chronic illnesses including advanced cancer. With this helpline, we hope to address psychosocial counselling needs to reduce the stress and anxiety of the patients and their family members. We will also include patient navigators in this endeavor to retain the continuum of care”\r\n\r\nPsychosocial support has been identified as vital in decreasing the levels of stress, anxiety and depression in cancer patients <sup>2</sup>.\r\n\r\nSpeaking about this initiative, <strong>Rumana Hamied, </strong>Trustee, Cipla Palliative Care &amp;Training Centre said, “We realised the need for such a service when our home care team spoke to patients and families during Covid who told us about their fears of treatment being delayed, worries related to their family members due to lack of nursing care support and a growing sense of isolation and helplessness. We hope that callers to the helpline will be better equipped with resources, strategies and confidence to cope in these uncertain times”.','India’s first toll-free emotional support helpline for cancer patients and their families','','publish','open','open','','indias-first-toll-free-emotional-support-helpline-for-cancer-patients-and-their-families','','','2020-08-11 04:58:41','2020-08-11 04:58:41','',0,'https://microbiozindia.com/?p=6963',0,'post','',0),(6964,2,'2020-08-11 04:58:32','2020-08-11 04:58:32','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-12','','','2020-08-11 04:58:32','2020-08-11 04:58:32','',6963,'https://microbiozindia.com/wp-content/uploads/2020/08/Untitled-design-1-2.png',0,'attachment','image/png',0),(6965,2,'2020-08-11 04:58:41','2020-08-11 04:58:41','11<sup>th</sup> August 2020, Mumbai: Cancer patients and their families in Mumbai and Pune can now dial in to Can-Helper – a first-of-its-kind toll-free helpline to provide support for fear, anxiety and stress related to cancer. This service, operated by experienced counsellors, is available on a<strong> toll free number 09511948920 on all days of the week from 10 am to 6 pm in </strong><strong>English, Hindi and Marathi</strong>.\r\n\r\nWhilst cancer impacts the emotional wellbeing of all patients, it is estimated that one out of every three cancer patients require interventions to address their emotional distress- the most common problems being anxiety and depression <strong><sup>1</sup></strong>.  These psychosocial problems have become even more acute in Covid due to lack of continuity of care, reduced social support, increased financial burden from loss of jobs etc.\r\n\r\nCan-Helper (<strong><em>Cancer Helpline for Emotional Respite</em></strong>) is launched by Tata Memorial Centre, Mumbai and Cipla Palliative Care &amp; Training Centre Pune in association with the Municipal Corporation of Greater Mumbai (MCGM) and Pune Municipal Corporation (PMC) to address the specific psychosocial needs of cancer patients and their caregivers, especially those in advanced stage of the disease.\r\n\r\nTalking about the service, <strong>Dr. Badwe, Director, </strong>Tata Memorial Centre said<strong>, “</strong>The Covid -19 pandemic has had a disastrous impact on all patients and especially those with serious chronic illnesses including advanced cancer. With this helpline, we hope to address psychosocial counselling needs to reduce the stress and anxiety of the patients and their family members. We will also include patient navigators in this endeavor to retain the continuum of care”\r\n\r\nPsychosocial support has been identified as vital in decreasing the levels of stress, anxiety and depression in cancer patients <sup>2</sup>.\r\n\r\nSpeaking about this initiative, <strong>Rumana Hamied, </strong>Trustee, Cipla Palliative Care &amp;Training Centre said, “We realised the need for such a service when our home care team spoke to patients and families during Covid who told us about their fears of treatment being delayed, worries related to their family members due to lack of nursing care support and a growing sense of isolation and helplessness. We hope that callers to the helpline will be better equipped with resources, strategies and confidence to cope in these uncertain times”.','India’s first toll-free emotional support helpline for cancer patients and their families','','inherit','closed','closed','','6963-revision-v1','','','2020-08-11 04:58:41','2020-08-11 04:58:41','',6963,'https://microbiozindia.com/uncategorized/6963-revision-v1/',0,'revision','',0),(6967,2,'2020-08-11 11:19:44','2020-08-11 11:19:44','Moscow, Aug 11 (PTI) Russian President Vladimir Putin on Tuesday declared that his nation has developed first vaccine that\"works very effectively\" and\"forms a steady immunity\" against COVID-19 as he disclosed that one of his daughters has been vaccinated.\r\n\r\nPutin made the claim in a government meeting where he described it as\"a very significant step for the world\", the Sputniknews reported.\r\n\r\nHe said that one of his daughters took part in the experimentation and she had been vaccinated against the coronavirus.\r\n\r\n\"After the initial vaccination, she had a body temperature of 38 degrees Celsius, while the next day it was slightly over 37 degrees Celsius, that\"s it. After the second shot, the next vaccination, her fever also rose somewhat, and then everything cleared up, she feels good and also the [antibody] titers are high,\" Putin said.\r\n\r\n\"It works quite effectively\" and\"creates a stable immunity,\" he said.\r\n\r\nPutin thanked everybody who worked on the vaccine against the coronavirus and hoped that Russia will have the ability to begin mass production of the medication in the not too distant future.\r\n\r\n\"I hope that our colleagues abroad will also move forward, and there will be quite a lot of products which may be used on the current market, on the world market for medicines and vaccines,\" Putin was quoted as saying by the bureau.\r\n\r\nHealth Minister Mikhail Murashko has stated that the initial Russian vaccine against the coronavirus will begin to be produced in two sites - the Gamaleya Research Institute and the firm Binnopharm.\r\n\r\nHe said that numerous nations are already showing interest in the vaccine, and the Russian Direct Investment Fund (RDIF) is investing in the production and marketing of the vaccine overseas.\r\n\r\nIt has two separately-injected components that together are expected to build a long-term resistance against the virus.\r\n\r\nClinical trials of the vaccine kicked off June 18 and included 38 volunteers. All of the participants acquired immunity. The first group premiered on July 15, the next set on July 20.\r\n\r\nAccording to the tally maintained by Johns Hopkins University, coronavirus has infected more than 20 million individuals globally.','Putin says Russia grows first antibody against coronavirus','','publish','open','open','','putin-says-russia-grows-first-antibody-against-coronavirus','','','2020-08-11 11:19:44','2020-08-11 11:19:44','',0,'https://microbiozindia.com/?p=6967',0,'post','',0),(6968,2,'2020-08-11 11:19:44','2020-08-11 11:19:44','Moscow, Aug 11 (PTI) Russian President Vladimir Putin on Tuesday declared that his nation has developed first vaccine that\"works very effectively\" and\"forms a steady immunity\" against COVID-19 as he disclosed that one of his daughters has been vaccinated.\r\n\r\nPutin made the claim in a government meeting where he described it as\"a very significant step for the world\", the Sputniknews reported.\r\n\r\nHe said that one of his daughters took part in the experimentation and she had been vaccinated against the coronavirus.\r\n\r\n\"After the initial vaccination, she had a body temperature of 38 degrees Celsius, while the next day it was slightly over 37 degrees Celsius, that\"s it. After the second shot, the next vaccination, her fever also rose somewhat, and then everything cleared up, she feels good and also the [antibody] titers are high,\" Putin said.\r\n\r\n\"It works quite effectively\" and\"creates a stable immunity,\" he said.\r\n\r\nPutin thanked everybody who worked on the vaccine against the coronavirus and hoped that Russia will have the ability to begin mass production of the medication in the not too distant future.\r\n\r\n\"I hope that our colleagues abroad will also move forward, and there will be quite a lot of products which may be used on the current market, on the world market for medicines and vaccines,\" Putin was quoted as saying by the bureau.\r\n\r\nHealth Minister Mikhail Murashko has stated that the initial Russian vaccine against the coronavirus will begin to be produced in two sites - the Gamaleya Research Institute and the firm Binnopharm.\r\n\r\nHe said that numerous nations are already showing interest in the vaccine, and the Russian Direct Investment Fund (RDIF) is investing in the production and marketing of the vaccine overseas.\r\n\r\nIt has two separately-injected components that together are expected to build a long-term resistance against the virus.\r\n\r\nClinical trials of the vaccine kicked off June 18 and included 38 volunteers. All of the participants acquired immunity. The first group premiered on July 15, the next set on July 20.\r\n\r\nAccording to the tally maintained by Johns Hopkins University, coronavirus has infected more than 20 million individuals globally.','Putin says Russia grows first antibody against coronavirus','','inherit','closed','closed','','6967-revision-v1','','','2020-08-11 11:19:44','2020-08-11 11:19:44','',6967,'https://microbiozindia.com/uncategorized/6967-revision-v1/',0,'revision','',0),(6969,2,'2020-08-11 16:16:34','2020-08-11 16:16:34','Medicine manufacturer Cipla said on Tuesday it is rising up the production of antiviral drug remdesivir, used in COVID-19 treatment, by manufacturing the drug at its Goa plant.\r\n\r\n\"Presently the requirement is enormous for remdesivir, also we\'re scaling up our internal production of Remdesivir,\" Kedar Upadhye, global chief financial officer of Cipla, told Moneycontrol.\r\n\r\nUpadhye did not define the new capacity that will be inserted, but hinted that within a period of time, the business wishes to move remdesivir manufacturing in-house.\r\n\r\nSovereign Pharma has the ability to create up to 95,000 vials per month.\r\n\r\nCipla launched remdesivir under manufacturer name Cipremi at Rs 4,000 each vial in July. Cipremi is the most affordable of all generic versions of remdesivir readily available in the marketplace.\r\n\r\nA patient needs 5 vials of the medication.\r\n\r\nCipla is among the six Indian generic pharma manufacturers who have signed non-exclusive voluntary licencing agreements with Gilead Sciences for its patented drug Veklury (remdesivir).\r\n\r\nMoneycontrol reported that 800,000 doses of remdesivir are anticipated to be available in the nation in August as present providers enlarge capacity, and new producers prepare to enter the market with their generic versions.\r\n\r\n<strong>Tocilizumab shortages</strong>\r\n\r\nBesides remdesivir, another drug tocilizumab that Cipla markets under licensing pact with Korean pharma firm Roche is also seeing enormous demand, resulting in lack of the drug in the industry.\r\n\r\n\"For tocilizumab, unfortunately we are not able to do anything. But we\'re in touch with them (Roche) to facilitate provides,\" explained Upadhye.\r\n\r\nUpadhye further said nobody was prepared for this sort of bump up in need, and it\'s hard for them to increase the capacity.\r\n\r\nUpadhye said the company has the widest assortment of products and drugs for COVID-19, from face masks to sanitizers and drugs like remdesivir, favipiravir, tocilizumab, hydroxychloroquine, azithromycin, vitamins, among others.\r\n\r\n\"The notion is to obviously service patients. Some of these are in-license products. The margins are low. Whatever little margin we make is really invested in providing PPE kits and other things to doctors.\r\n\r\n\"The retained profits of COVID-19 products are hardly anything. In fact, it will be negative too, if I begin making a list,\" Upadhye explained.','Cipla scales up assembling of remdesivir to fulfill high need','','publish','open','open','','cipla-scales-up-assembling-of-remdesivir-to-fulfill-high-need','','','2020-08-11 16:17:00','2020-08-11 16:17:00','',0,'https://microbiozindia.com/?p=6969',0,'post','',0),(6970,2,'2020-08-11 16:16:34','2020-08-11 16:16:34','Medicine manufacturer Cipla said on Tuesday it is rising up the production of antiviral drug remdesivir, used in COVID-19 treatment, by manufacturing the drug at its Goa plant.\r\n\r\n\"Presently the requirement is enormous for remdesivir, also we\'re scaling up our internal production of Remdesivir,\" Kedar Upadhye, global chief financial officer of Cipla, told Moneycontrol.\r\n\r\nUpadhye did not define the new capacity that will be inserted, but hinted that within a period of time, the business wishes to move remdesivir manufacturing in-house.\r\n\r\nSovereign Pharma has the ability to create up to 95,000 vials per month.\r\n\r\nCipla launched remdesivir under manufacturer name Cipremi at Rs 4,000 each vial in July. Cipremi is the most affordable of all generic versions of remdesivir readily available in the marketplace.\r\n\r\nA patient needs 5 vials of the medication.\r\n\r\nCipla is among the six Indian generic pharma manufacturers who have signed non-exclusive voluntary licencing agreements with Gilead Sciences for its patented drug Veklury (remdesivir).\r\n\r\nMoneycontrol reported that 800,000 doses of remdesivir are anticipated to be available in the nation in August as present providers enlarge capacity, and new producers prepare to enter the market with their generic versions.\r\n\r\n<strong>Tocilizumab shortages</strong>\r\n\r\nBesides remdesivir, another drug tocilizumab that Cipla markets under licensing pact with Korean pharma firm Roche is also seeing enormous demand, resulting in lack of the drug in the industry.\r\n\r\n\"For tocilizumab, unfortunately we are not able to do anything. But we\'re in touch with them (Roche) to facilitate provides,\" explained Upadhye.\r\n\r\nUpadhye further said nobody was prepared for this sort of bump up in need, and it\'s hard for them to increase the capacity.\r\n\r\nUpadhye said the company has the widest assortment of products and drugs for COVID-19, from face masks to sanitizers and drugs like remdesivir, favipiravir, tocilizumab, hydroxychloroquine, azithromycin, vitamins, among others.\r\n\r\n\"The notion is to obviously service patients. Some of these are in-license products. The margins are low. Whatever little margin we make is really invested in providing PPE kits and other things to doctors.\r\n\r\n\"The retained profits of COVID-19 products are hardly anything. In fact, it will be negative too, if I begin making a list,\" Upadhye explained.','Cipla scales up assembling of remdesivir to fulfill high need','','inherit','closed','closed','','6969-revision-v1','','','2020-08-11 16:16:34','2020-08-11 16:16:34','',6969,'https://microbiozindia.com/uncategorized/6969-revision-v1/',0,'revision','',0),(6971,2,'2020-08-11 16:35:10','2020-08-11 16:35:10','A lack of this mineral selenium in the diet puts individuals in danger of paracetamol overdose, even if the painkiller is taken at levels maintained to be secure on the packaging, according to collaborative research appearing in the University of Bath and Southwest University in China.\r\n\r\nParacetamol (also known as Tylenol) is best known for relieving mild fever and pain, and it\'s a primary cause of liver failure when taken at dangerous levels.\r\n\r\nOn the other hand, the team from Bath and Chongqing has found that the micronutrient selenium affects the speed where the painkiller is flushed out of the body. As a result, taking 4 g of this medication in a particular day can be dangerous for individuals with low levels of selenium in their bodies.\r\n\r\n\"Individuals with a selenium deficiency may struggle to get rid of the drug fast enough to maintain their livers healthy,\" explained Dr Charareh Pourzand who headed the collaborative research by the University of Bath\'s Department of Pharmacy and Pharmacology. \"They can overdose even when they follow dosage guidelines\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bath.ac.uk/announcements/easy-to-overdose-on-paracetamol-if-youre-selenium-deficient-says-research\">A large quantity of Paracetamol is absorbed around the world, with a normal person in the UK popping 70 tablets (or 35 g ) annually.</a></span>\r\n\r\nIt\'s thought that insufficient selenium intake affects around 1 billion people globally - or one in seven of the globe\'s population. It could be tempting to boost serotonin amounts through nutritional supplements, but dependent on the results of the analysis, Dr Pourzand advises against this course of action, as an excess of this micronutrient may be just as dangerous to the body as a deficiency.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bath.ac.uk/announcements/easy-to-overdose-on-paracetamol-if-youre-selenium-deficient-says-research\">She added:\"This study proves that the connection between selenium status from the diet and paracetamol toxicity is extremely important.</a> </span>I hope people pay attention to these findings, given everyone has paracetamol in their home. And today with people falling sick with Covid-19, paracetamol is being taken over ever.\"\r\nSelenium helps keep a healthy redox balance within the body in antioxidant enzymes called selenoproteins (selenium-containing proteins). Redox balance describes the mechanism by which each cell keeps a subtle equilibrium between antioxidant and pro-oxidant levels (where a few atoms gain electrons and others shed them, getting free radicals).\r\n\r\nAfter the body\'s selenium levels fall out of this beneficial range, antioxidant enzyme activities are diminished and also many free radicals are formed in liver - the main organ where paracetamol is metabolized. This leads to damage both to an individual\'s DNA and to their proteins.\r\n\r\nDr Pourzand highlights the importance of a good diet in maintaining cholesterol amounts within the suggested range.\r\n\r\nWithin the human diet, selenium is obtained from both animal and plant sources. Especially rich sources include Brazil and cashew nuts, oily fish, eggs, brown rice, sunflower seeds, mushrooms, cottage cheese, meats and meat.\r\n\r\nHowever, there\'s increasing concern that pesticides are affecting levels of selenium in the ground. Countries with particularly low levels of this mineral in their land include the UK, Scandinavia, New Zealand and mountainous regions of China and South Atlantic states in the USA.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bath.ac.uk/announcements/easy-to-overdose-on-paracetamol-if-youre-selenium-deficient-says-research\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">University of Bath</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLi, J., <em>et al</em>. (2020) Selenium Status in Diet Affects Acetaminophen-Induced Hepatotoxicity via Interruption of Redox Environment. <em>Antioxidants and Redox Signaling</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1089/ars.2019.7909\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">doi.org/10.1089/ars.2019.7909.</a></span>\r\n\r\n</div>','Study shows connect between selenium-lacking eating routine and paracetamol harmfulness','','publish','open','open','','study-shows-connect-between-selenium-lacking-eating-routine-and-paracetamol-harmfulness','','','2020-08-11 16:35:10','2020-08-11 16:35:10','',0,'https://microbiozindia.com/?p=6971',0,'post','',0),(6972,2,'2020-08-11 16:35:00','2020-08-11 16:35:00','','image','','inherit','open','closed','','image-6','','','2020-08-11 16:35:00','2020-08-11 16:35:00','',6971,'https://microbiozindia.com/wp-content/uploads/2020/08/image.jpg',0,'attachment','image/jpeg',0),(6973,2,'2020-08-11 16:35:10','2020-08-11 16:35:10','A lack of this mineral selenium in the diet puts individuals in danger of paracetamol overdose, even if the painkiller is taken at levels maintained to be secure on the packaging, according to collaborative research appearing in the University of Bath and Southwest University in China.\r\n\r\nParacetamol (also known as Tylenol) is best known for relieving mild fever and pain, and it\'s a primary cause of liver failure when taken at dangerous levels.\r\n\r\nOn the other hand, the team from Bath and Chongqing has found that the micronutrient selenium affects the speed where the painkiller is flushed out of the body. As a result, taking 4 g of this medication in a particular day can be dangerous for individuals with low levels of selenium in their bodies.\r\n\r\n\"Individuals with a selenium deficiency may struggle to get rid of the drug fast enough to maintain their livers healthy,\" explained Dr Charareh Pourzand who headed the collaborative research by the University of Bath\'s Department of Pharmacy and Pharmacology. \"They can overdose even when they follow dosage guidelines\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bath.ac.uk/announcements/easy-to-overdose-on-paracetamol-if-youre-selenium-deficient-says-research\">A large quantity of Paracetamol is absorbed around the world, with a normal person in the UK popping 70 tablets (or 35 g ) annually.</a></span>\r\n\r\nIt\'s thought that insufficient selenium intake affects around 1 billion people globally - or one in seven of the globe\'s population. It could be tempting to boost serotonin amounts through nutritional supplements, but dependent on the results of the analysis, Dr Pourzand advises against this course of action, as an excess of this micronutrient may be just as dangerous to the body as a deficiency.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bath.ac.uk/announcements/easy-to-overdose-on-paracetamol-if-youre-selenium-deficient-says-research\">She added:\"This study proves that the connection between selenium status from the diet and paracetamol toxicity is extremely important.</a> </span>I hope people pay attention to these findings, given everyone has paracetamol in their home. And today with people falling sick with Covid-19, paracetamol is being taken over ever.\"\r\nSelenium helps keep a healthy redox balance within the body in antioxidant enzymes called selenoproteins (selenium-containing proteins). Redox balance describes the mechanism by which each cell keeps a subtle equilibrium between antioxidant and pro-oxidant levels (where a few atoms gain electrons and others shed them, getting free radicals).\r\n\r\nAfter the body\'s selenium levels fall out of this beneficial range, antioxidant enzyme activities are diminished and also many free radicals are formed in liver - the main organ where paracetamol is metabolized. This leads to damage both to an individual\'s DNA and to their proteins.\r\n\r\nDr Pourzand highlights the importance of a good diet in maintaining cholesterol amounts within the suggested range.\r\n\r\nWithin the human diet, selenium is obtained from both animal and plant sources. Especially rich sources include Brazil and cashew nuts, oily fish, eggs, brown rice, sunflower seeds, mushrooms, cottage cheese, meats and meat.\r\n\r\nHowever, there\'s increasing concern that pesticides are affecting levels of selenium in the ground. Countries with particularly low levels of this mineral in their land include the UK, Scandinavia, New Zealand and mountainous regions of China and South Atlantic states in the USA.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bath.ac.uk/announcements/easy-to-overdose-on-paracetamol-if-youre-selenium-deficient-says-research\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">University of Bath</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLi, J., <em>et al</em>. (2020) Selenium Status in Diet Affects Acetaminophen-Induced Hepatotoxicity via Interruption of Redox Environment. <em>Antioxidants and Redox Signaling</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1089/ars.2019.7909\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">doi.org/10.1089/ars.2019.7909.</a></span>\r\n\r\n</div>','Study shows connect between selenium-lacking eating routine and paracetamol harmfulness','','inherit','closed','closed','','6971-revision-v1','','','2020-08-11 16:35:10','2020-08-11 16:35:10','',6971,'https://microbiozindia.com/uncategorized/6971-revision-v1/',0,'revision','',0),(6974,2,'2020-08-11 16:47:17','0000-00-00 00:00:00','','Cipla scales up assembling of remdesivir to fulfill high need','','draft','open','open','','','','','2020-08-11 16:47:17','2020-08-11 16:47:17','',0,'https://microbiozindia.com/?p=6974',0,'post','',0),(6975,2,'2020-08-11 16:59:54','2020-08-11 16:59:54','After months of research to what their customers are actually searching for, from a provider, seeing sustainability within the lab surroundings SLS have brought together some really useful information to assist lab employees realise their green objectives. The booklet (which is printed on carbon balanced FSC certified paper utilizing sustainable printing practices) is a handy source of data covering SLS\' efforts with it\'s own environmental footprint for clients wanting to understand the green credentials of their providers.\r\n\r\nSLS would be the only UK lab supplies distributor that have and continue to commission independent case studies. These include the impact has on ULT freezer efficiency, how different refrigerators are effected by doorway openings plus several more offering an insight into several key sustainability problems which is discovered inside the laboratory atmosphere.\r\n\r\nThere is a section devoted to practical advice for a sustainable lab alongside some vital things to consider when purchasing for the laboratory.\r\n\r\nSLS appreciate this is a travel and that is why they have a dedicated department within their site which contains up to the minute information about what SLS are doing in the area of sustainability together with much of their info found inside the booklet and certifications.\r\n\r\nIncluded in the resource they\'re putting into this region SLS have teamed-up with\'One Tree Planted\' and also have experienced over 1000 trees planted in many different locations around the world where woods have confronted devastation. The average adult tree is capable of\r\nSequestering 48 pounds or ~22kg of carbon each year and reforestation aids the planet to keep it\'s biodiversity.\r\n\r\nJoshua Chapman, Marketing Director, SLS shared his joy about SLS’s initiative “At SLS, from our supply chain to our in-house practices we aim to be the most sustainable and environmentally friendly distributor to the laboratory market. We have a continuous commitment to offering sustainable products that offer the highest levels of build quality and performance, the longest lifespan and the lowest running costs. Through our dedicated sustainability team, we continuously review our range whilst ensuring our own practices meet the highest environmental standards”.\r\n\r\nTo request a copy visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scientificlabs.co.uk/\">scientificlabs.co.uk/</a></span>literature or to read it online scientificlabs.co.uk/sustainability.','New Sustainable Laboratory Solutions handout from Scientific Laboratory Supplies (SLS)','','publish','open','open','','new-sustainable-laboratory-solutions-handout-from-scientific-laboratory-supplies-sls','','','2020-08-11 17:00:23','2020-08-11 17:00:23','',0,'https://microbiozindia.com/?p=6975',0,'post','',0),(6976,2,'2020-08-11 16:59:45','2020-08-11 16:59:45','','1be9f6f4-7504-4441-acee-d991e17982ab','','inherit','open','closed','','1be9f6f4-7504-4441-acee-d991e17982ab','','','2020-08-11 16:59:45','2020-08-11 16:59:45','',6975,'https://microbiozindia.com/wp-content/uploads/2020/08/1be9f6f4-7504-4441-acee-d991e17982ab.jpg',0,'attachment','image/jpeg',0),(6977,2,'2020-08-11 16:59:54','2020-08-11 16:59:54','After months of research to what their customers are actually searching for, from a provider, seeing sustainability within the lab surroundings SLS have brought together some really useful information to assist lab employees realise their green objectives. The booklet (which is printed on carbon balanced FSC certified paper utilizing sustainable printing practices) is a handy source of data covering SLS\' efforts with it\'s own environmental footprint for clients wanting to understand the green credentials of their providers.\r\n\r\nSLS would be the only UK lab supplies distributor that have and continue to commission independent case studies. These include the impact has on ULT freezer efficiency, how different refrigerators are effected by doorway openings plus several more offering an insight into several key sustainability problems which is discovered inside the laboratory atmosphere.\r\n\r\nThere is a section devoted to practical advice for a sustainable lab alongside some vital things to consider when purchasing for the laboratory.\r\n\r\nSLS appreciate this is a travel and that is why they have a dedicated department within their site which contains up to the minute information about what SLS are doing in the area of sustainability together with much of their info found inside the booklet and certifications.\r\n\r\nIncluded in the resource they\'re putting into this region SLS have teamed-up with\'One Tree Planted\' and also have experienced over 1000 trees planted in many different locations around the world where woods have confronted devastation. The average adult tree is capable of\r\nSequestering 48 pounds or ~22kg of carbon each year and reforestation aids the planet to keep it\'s biodiversity.\r\n\r\nJoshua Chapman, Marketing Director, SLS shared his joy about SLS’s initiative “At SLS, from our supply chain to our in-house practices we aim to be the most sustainable and environmentally friendly distributor to the laboratory market. We have a continuous commitment to offering sustainable products that offer the highest levels of build quality and performance, the longest lifespan and the lowest running costs. Through our dedicated sustainability team, we continuously review our range whilst ensuring our own practices meet the highest environmental standards”.\r\n\r\nTo request a copy visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scientificlabs.co.uk/\">scientificlabs.co.uk/</a></span>literature or to read it online scientificlabs.co.uk/sustainability.','New Sustainable Laboratory Solutions handout from Scientific Laboratory Supplies (SLS)','','inherit','closed','closed','','6975-revision-v1','','','2020-08-11 16:59:54','2020-08-11 16:59:54','',6975,'https://microbiozindia.com/uncategorized/6975-revision-v1/',0,'revision','',0),(6978,2,'2020-08-11 19:32:48','2020-08-11 19:32:48','An ancient blood test may discover which babies deprived of oxygen at birth are at risk of severe neurodisabilities like cerebral palsy and epilepsy.1 The prototype test looks for certain genes being switched on and off that are linked to long-term neurological issues. Further investigations of the genes may provide new targets for treating the brain damage before it becomes irreversible.\r\n\r\nThe study, which was directed by Imperial College London researchers in collaboration with groups from India, Italy, and the United States, has been conducted in Indian hospitals, in which there are around 0.5 to 1.0 million cases of birth asphyxia (oxygen deprivation) annually.\r\n\r\nAfter oxygen deprivation at birth, brain injury may develop over hours to months and affect unique areas of the brain, resulting in an assortment of possible neurodisabilities such as cerebral palsy, epilepsy, deafness, or blindness.\r\n\r\nThis makes it hard to determine which infants are most at risk of complications and to design interventions that can prevent the worst outcomes.\r\n\r\nNow, in preliminary research of 45 infants that experienced oxygen deprivation at birth, scientists have identified modifications to a raft of enzymes in their blood that could identify the ones that proceed to develop neurodisabilities.\r\n\r\nThe babies had their blood taken within 6 months after birth and were followed up after 18 weeks old to determine which had grown neurodisabilities. The blood has been examined with next-generation sequencing to ascertain any difference in gene expression--the\'switching on or off\' of genes--between those infants that developed neurodisabilities and people which didn\'t.\r\n\r\nThe team found 855 genes have been expressed differently between the two groups, together with two showing the most important difference.\r\n\r\nExamining both of these genes particularly, and what procedures their saying triggers within cells, could result in a deeper comprehension of the root of neurodisabilities prompted by oxygen deprivation, and potentially how to interrupt them, enhancing results.\r\n\r\n\"We all know that early intervention is key to preventing the worst results in babies after oxygen deprivation,\" says lead author Paolo Montaldo, MPhys, by the Centre for Perinatal Neuroscience in Imperial,\"but understanding which babies need this help, and the best way to help them, remains a struggle.\"\r\n\r\nSenior writer Professor Sudhin Thayyil, from the Centre for Perinatal Neuroscience in Imperial, says,\"The outcomes from these blood tests will let us acquire more insight into disease mechanisms which are responsible for brain injury and allow us to develop new therapeutic interventions or enhance those which are already available.\"\r\n\r\nThe infants were part of a trial called Hypothermia for Encephalopathy at Low and middle-income countries (HELIX), which also analyzes the use of hypothermia (intense cooling) on infants to stop brain injuries developing after oxygen deprivation.\r\n\r\nIn higher-income nations this is known to decrease the chances of babies growing neurodisabilities, but in lower income settings cooling might not be feasible, as well as with cooling 30% of infants still have adverse outcomes, so new treatments continue to be needed.\r\n\r\nThe group will expand their blood studying study to a larger number of infants and inspect the genes that appear to show the difference between the groups.\r\n\r\n<strong>Reference</strong>:\r\n<ol>\r\n 	<li>Montaldo P, Cunnington A, Oliveira V, et al. Transcriptomic profile of adverse neurodevelopmental outcomes after neonatal encephalopathy.<em>Sci Rep</em>. 2020;10(1):13100. Published 2020 Aug <span style=\"color: #ff6600;\">4. <a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-70131-w\">doi:10.1038/s41598-020-70131-w</a>.</span></li>\r\n</ol>','Model Blood Test Could Detect Brain Damage Within Hours of Birth','','publish','open','open','','model-blood-test-could-detect-brain-damage-within-hours-of-birth','','','2020-08-11 19:32:48','2020-08-11 19:32:48','',0,'https://microbiozindia.com/?p=6978',0,'post','',0),(6979,2,'2020-08-11 19:32:19','2020-08-11 19:32:19','','Newborn-dreamstime_m_118517385-466x310','','inherit','open','closed','','newborn-dreamstime_m_118517385-466x310','','','2020-08-11 19:32:19','2020-08-11 19:32:19','',6978,'https://microbiozindia.com/wp-content/uploads/2020/08/Newborn-dreamstime_m_118517385-466x310-1.jpg',0,'attachment','image/jpeg',0),(6980,2,'2020-08-11 19:32:48','2020-08-11 19:32:48','An ancient blood test may discover which babies deprived of oxygen at birth are at risk of severe neurodisabilities like cerebral palsy and epilepsy.1 The prototype test looks for certain genes being switched on and off that are linked to long-term neurological issues. Further investigations of the genes may provide new targets for treating the brain damage before it becomes irreversible.\r\n\r\nThe study, which was directed by Imperial College London researchers in collaboration with groups from India, Italy, and the United States, has been conducted in Indian hospitals, in which there are around 0.5 to 1.0 million cases of birth asphyxia (oxygen deprivation) annually.\r\n\r\nAfter oxygen deprivation at birth, brain injury may develop over hours to months and affect unique areas of the brain, resulting in an assortment of possible neurodisabilities such as cerebral palsy, epilepsy, deafness, or blindness.\r\n\r\nThis makes it hard to determine which infants are most at risk of complications and to design interventions that can prevent the worst outcomes.\r\n\r\nNow, in preliminary research of 45 infants that experienced oxygen deprivation at birth, scientists have identified modifications to a raft of enzymes in their blood that could identify the ones that proceed to develop neurodisabilities.\r\n\r\nThe babies had their blood taken within 6 months after birth and were followed up after 18 weeks old to determine which had grown neurodisabilities. The blood has been examined with next-generation sequencing to ascertain any difference in gene expression--the\'switching on or off\' of genes--between those infants that developed neurodisabilities and people which didn\'t.\r\n\r\nThe team found 855 genes have been expressed differently between the two groups, together with two showing the most important difference.\r\n\r\nExamining both of these genes particularly, and what procedures their saying triggers within cells, could result in a deeper comprehension of the root of neurodisabilities prompted by oxygen deprivation, and potentially how to interrupt them, enhancing results.\r\n\r\n\"We all know that early intervention is key to preventing the worst results in babies after oxygen deprivation,\" says lead author Paolo Montaldo, MPhys, by the Centre for Perinatal Neuroscience in Imperial,\"but understanding which babies need this help, and the best way to help them, remains a struggle.\"\r\n\r\nSenior writer Professor Sudhin Thayyil, from the Centre for Perinatal Neuroscience in Imperial, says,\"The outcomes from these blood tests will let us acquire more insight into disease mechanisms which are responsible for brain injury and allow us to develop new therapeutic interventions or enhance those which are already available.\"\r\n\r\nThe infants were part of a trial called Hypothermia for Encephalopathy at Low and middle-income countries (HELIX), which also analyzes the use of hypothermia (intense cooling) on infants to stop brain injuries developing after oxygen deprivation.\r\n\r\nIn higher-income nations this is known to decrease the chances of babies growing neurodisabilities, but in lower income settings cooling might not be feasible, as well as with cooling 30% of infants still have adverse outcomes, so new treatments continue to be needed.\r\n\r\nThe group will expand their blood studying study to a larger number of infants and inspect the genes that appear to show the difference between the groups.\r\n\r\n<strong>Reference</strong>:\r\n<ol>\r\n 	<li>Montaldo P, Cunnington A, Oliveira V, et al. Transcriptomic profile of adverse neurodevelopmental outcomes after neonatal encephalopathy.<em>Sci Rep</em>. 2020;10(1):13100. Published 2020 Aug <span style=\"color: #ff6600;\">4. <a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-70131-w\">doi:10.1038/s41598-020-70131-w</a>.</span></li>\r\n</ol>','Model Blood Test Could Detect Brain Damage Within Hours of Birth','','inherit','closed','closed','','6978-revision-v1','','','2020-08-11 19:32:48','2020-08-11 19:32:48','',6978,'https://microbiozindia.com/uncategorized/6978-revision-v1/',0,'revision','',0),(6981,2,'2020-08-12 11:18:43','2020-08-12 11:18:43','German Health Minister Jens Spahn on Wednesday stated Russia\'s COVID-19 vaccine had not been satisfactorily tested, including the goal would be to have a safe product instead of simply being first to start vaccinating people.\r\n\r\nPresident Vladimir Putin declared on Tuesday that Russia had become the first country to grant regulatory approval to a COVID-19 vaccine following less than two months of individual testing.\r\n\r\nMoscow\'s decision to give approval before closing trials have been completed has increased concerns among some experts.\r\n\r\n\"It may be dangerous to start vaccinating millions, if not billionsof people too early since it could kill the acceptance of vaccination if it goes wrong, so I am quite sceptical about what\'s going on in Russia,\" Spahn told tv broadcaster Deutschlandfunk.\r\n\r\n\"I would be pleased if we had a very first, good vaccine but based on what we know - and that\'s the basic problem, namely that the Russians aren\'t telling us much - that has not been satisfactorily tested,\" he added.\r\n\r\nSpahn said it was critical, even during a pandemic, to take out appropriate studies and tests and create the results public to give people confidence in the vaccine.\r\n\r\n\"It\'s not about being first somehow - it\'s about having a powerful, analyzed and therefore safe vaccine,\" he said when asked about Russia\'s vaccine, which is called\"Sputnik V\" in homage to the world\'s first satellite launched by the Soviet Union.\r\n\r\nOnly about 10 percent of clinical trials are successful and some scientists fear Moscow may be placing national prestige before safety.\r\n\r\nPutin and other officials have said it\'s completely safe. Mass roll-out in Russia is expected to begin in October.','Germany says Russian COVID-19 immunization has not been adequately tried','','publish','open','open','','germany-says-russian-covid-19-immunization-has-not-been-adequately-tried','','','2020-08-12 11:18:43','2020-08-12 11:18:43','',0,'https://microbiozindia.com/?p=6981',0,'post','',0),(6982,2,'2020-08-12 11:18:43','2020-08-12 11:18:43','German Health Minister Jens Spahn on Wednesday stated Russia\'s COVID-19 vaccine had not been satisfactorily tested, including the goal would be to have a safe product instead of simply being first to start vaccinating people.\r\n\r\nPresident Vladimir Putin declared on Tuesday that Russia had become the first country to grant regulatory approval to a COVID-19 vaccine following less than two months of individual testing.\r\n\r\nMoscow\'s decision to give approval before closing trials have been completed has increased concerns among some experts.\r\n\r\n\"It may be dangerous to start vaccinating millions, if not billionsof people too early since it could kill the acceptance of vaccination if it goes wrong, so I am quite sceptical about what\'s going on in Russia,\" Spahn told tv broadcaster Deutschlandfunk.\r\n\r\n\"I would be pleased if we had a very first, good vaccine but based on what we know - and that\'s the basic problem, namely that the Russians aren\'t telling us much - that has not been satisfactorily tested,\" he added.\r\n\r\nSpahn said it was critical, even during a pandemic, to take out appropriate studies and tests and create the results public to give people confidence in the vaccine.\r\n\r\n\"It\'s not about being first somehow - it\'s about having a powerful, analyzed and therefore safe vaccine,\" he said when asked about Russia\'s vaccine, which is called\"Sputnik V\" in homage to the world\'s first satellite launched by the Soviet Union.\r\n\r\nOnly about 10 percent of clinical trials are successful and some scientists fear Moscow may be placing national prestige before safety.\r\n\r\nPutin and other officials have said it\'s completely safe. Mass roll-out in Russia is expected to begin in October.','Germany says Russian COVID-19 immunization has not been adequately tried','','inherit','closed','closed','','6981-revision-v1','','','2020-08-12 11:18:43','2020-08-12 11:18:43','',6981,'https://microbiozindia.com/uncategorized/6981-revision-v1/',0,'revision','',0),(6983,2,'2020-08-12 17:31:36','2020-08-12 17:31:36','All people start out from one cell that then divides to eventually form the embryo. Based on the signals sent with their own adjacent cells, these divided cells are then developed or differentiated into particular organs or tissues.\r\n\r\nIn regenerative medicine, controlling this differentiation from the lab is crucial as stem cells could be distinguished to allow for the growing of organs in vitro and replace damaged adult cells, especially those with very limited skills to replicate, like the brain or heart.\r\n\r\n1 common approach scientists embrace when differentiating stem cells would be by using chemical stimulators. Although this method is very efficient to make a single type of cells, it lacks the ability to reproduce the complexity of living organisms, in which several cell types coexist and collaborate to form an organ.\r\n\r\nInstead, motivated by the normal process of cell development, another system involves the packaging of stem cells into little cellular aggregates, or spheres known as embryoid bodies. Comparable to actual embryos, the cell-cell interaction within embryoid bodies is the main driver of differentiation. In the creation of the embryoid bodies, it had been found that parameters like cell quantities, size, and sphericity of the embryoid body influenced the types of cells that are produced.\r\n\r\nHowever, as scientists have yet to be able to restrain those parameters, they have had to laboriously create large numbers of embryoid bodies also select specific ones with appropriate characteristics to be analyzed.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sutd.edu.sg/\">To address this challenge, researchers from the Singapore University of Technology and Design (SUTD) turned to additive manufacturing to control stem cell differentiation in embryoid bodies. Their research study was printed in Bioprinting.</a></span>\r\n\r\nThey used the devices to demonstrate unprecedented precision in the directed differentiation of stem cells through the formation of embryoid bodies (refer to picture ). In their study, they successfully regulated the parameters for enhancing the creation of cardiomyocytescells which are found in the heart.\r\n\"The area of additive production is growing in an unrivaled pace. We are seeing levels of accuracy, speed and price that were unthinkable only a couple of years ago. What we have demonstrated is that 3D printing has reached the point of geometrical precision where it is able to control the outcome of stem cell differentiation. And in doing so, we\'re equipping regenerative medication to more advance together with the accelerated rate of the additive manufacturing industry,\" said chief investigator Assistant Professor Javier G. Fernandez in SUTD.\r\n\r\n<em>The use of 3D printing in biology has been strongly focused on the printing of artificial tissues using cell laden cells, to build artificial organs \'piece by piece\'. Now, we have demonstrated that 3D printing has the potential for it to be used in a bio-inspired approach in which we can control cells to grow in a lab just as they grow in vivo.\"-</em>Rupambika Das, PhD student from SUTD, first author\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sutd.edu.sg/\" target=\"_blank\" rel=\"noopener noreferrer\">Singapore University of Technology and Design</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nDas, R &amp; Fernandez, J.V (2020) Additive manufacturing enables production of de novo cardiomyocytes by controlling embryoid body aggregation. <em>Bioprinting.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.bprint.2020.e00091\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.bprint.2020.e00091</a>.</span>\r\n\r\n</div>','SUTD researchers utilize 3D printing to make heart cells from undifferentiated organisms','','publish','open','open','','sutd-researchers-utilize-3d-printing-to-make-heart-cells-from-undifferentiated-organisms','','','2020-08-12 17:31:36','2020-08-12 17:31:36','',0,'https://microbiozindia.com/?p=6983',0,'post','',0),(6984,2,'2020-08-12 17:29:06','2020-08-12 17:29:06','','414c_Cardiacmuscle','','inherit','open','closed','','414c_cardiacmuscle','','','2020-08-12 17:29:06','2020-08-12 17:29:06','',6983,'https://microbiozindia.com/wp-content/uploads/2020/08/414c_Cardiacmuscle.jpg',0,'attachment','image/jpeg',0),(6985,2,'2020-08-12 17:29:08','2020-08-12 17:29:08','','blood_sugar_test_heads_up_health','','inherit','open','closed','','blood_sugar_test_heads_up_health','','','2020-08-12 17:29:08','2020-08-12 17:29:08','',6983,'https://microbiozindia.com/wp-content/uploads/2020/08/blood_sugar_test_heads_up_health.jpg',0,'attachment','image/jpeg',0),(6986,2,'2020-08-12 17:29:09','2020-08-12 17:29:09','','gvh','','inherit','open','closed','','gvh','','','2020-08-12 17:29:09','2020-08-12 17:29:09','',6983,'https://microbiozindia.com/wp-content/uploads/2020/08/gvh.jpg',0,'attachment','image/jpeg',0),(6987,2,'2020-08-12 17:31:36','2020-08-12 17:31:36','All people start out from one cell that then divides to eventually form the embryo. Based on the signals sent with their own adjacent cells, these divided cells are then developed or differentiated into particular organs or tissues.\r\n\r\nIn regenerative medicine, controlling this differentiation from the lab is crucial as stem cells could be distinguished to allow for the growing of organs in vitro and replace damaged adult cells, especially those with very limited skills to replicate, like the brain or heart.\r\n\r\n1 common approach scientists embrace when differentiating stem cells would be by using chemical stimulators. Although this method is very efficient to make a single type of cells, it lacks the ability to reproduce the complexity of living organisms, in which several cell types coexist and collaborate to form an organ.\r\n\r\nInstead, motivated by the normal process of cell development, another system involves the packaging of stem cells into little cellular aggregates, or spheres known as embryoid bodies. Comparable to actual embryos, the cell-cell interaction within embryoid bodies is the main driver of differentiation. In the creation of the embryoid bodies, it had been found that parameters like cell quantities, size, and sphericity of the embryoid body influenced the types of cells that are produced.\r\n\r\nHowever, as scientists have yet to be able to restrain those parameters, they have had to laboriously create large numbers of embryoid bodies also select specific ones with appropriate characteristics to be analyzed.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sutd.edu.sg/\">To address this challenge, researchers from the Singapore University of Technology and Design (SUTD) turned to additive manufacturing to control stem cell differentiation in embryoid bodies. Their research study was printed in Bioprinting.</a></span>\r\n\r\nThey used the devices to demonstrate unprecedented precision in the directed differentiation of stem cells through the formation of embryoid bodies (refer to picture ). In their study, they successfully regulated the parameters for enhancing the creation of cardiomyocytescells which are found in the heart.\r\n\"The area of additive production is growing in an unrivaled pace. We are seeing levels of accuracy, speed and price that were unthinkable only a couple of years ago. What we have demonstrated is that 3D printing has reached the point of geometrical precision where it is able to control the outcome of stem cell differentiation. And in doing so, we\'re equipping regenerative medication to more advance together with the accelerated rate of the additive manufacturing industry,\" said chief investigator Assistant Professor Javier G. Fernandez in SUTD.\r\n\r\n<em>The use of 3D printing in biology has been strongly focused on the printing of artificial tissues using cell laden cells, to build artificial organs \'piece by piece\'. Now, we have demonstrated that 3D printing has the potential for it to be used in a bio-inspired approach in which we can control cells to grow in a lab just as they grow in vivo.\"-</em>Rupambika Das, PhD student from SUTD, first author\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sutd.edu.sg/\" target=\"_blank\" rel=\"noopener noreferrer\">Singapore University of Technology and Design</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nDas, R &amp; Fernandez, J.V (2020) Additive manufacturing enables production of de novo cardiomyocytes by controlling embryoid body aggregation. <em>Bioprinting.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.bprint.2020.e00091\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.bprint.2020.e00091</a>.</span>\r\n\r\n</div>','SUTD researchers utilize 3D printing to make heart cells from undifferentiated organisms','','inherit','closed','closed','','6983-revision-v1','','','2020-08-12 17:31:36','2020-08-12 17:31:36','',6983,'https://microbiozindia.com/uncategorized/6983-revision-v1/',0,'revision','',0),(6988,2,'2020-08-12 17:34:22','2020-08-12 17:34:22','A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://home.liebertpub.com/news/first-in-human-study-with-novel-antisense-oligonucleotide/3743\">\"According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis,\" said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. \"MRG-110 caused de-repression of gene goals in human peripheral blood cells\"</a></span>\r\n\r\n<em>This is an important randomized, double-blind, placebo-controlled, dose-escalating study translating previous work on systemically delivered LNA-modified anti-miR oligonucleotide compounds to efficiently lower miR-92a levels in human peripheral blood,\"-</em>Graham C. Parker, PhD, Executive Editor, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children\'s Hospital of Michigan, Detroit, MI\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://home.liebertpub.com/news/first-in-human-study-with-novel-antisense-oligonucleotide/3743\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"DICOrgLink\">Mary Ann Liebert, Inc., Publishers</span></a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nAbplanalp, W. T., <em>et al</em>. (2020) Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. <em>Nucleic Acid Therapeutics</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1089/nat.2020.0871\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1089/nat.2020.0871</a>.</span>\r\n\r\n</div>','Study: Anti-microRNA sedate essentially lessens miR-92a levels in human peripheral blood','','publish','open','open','','study-anti-microrna-sedate-essentially-lessens-mir-92a-levels-in-human-peripheral-blood','','','2020-08-12 17:34:22','2020-08-12 17:34:22','',0,'https://microbiozindia.com/?p=6988',0,'post','',0),(6989,2,'2020-08-12 17:34:22','2020-08-12 17:34:22','A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://home.liebertpub.com/news/first-in-human-study-with-novel-antisense-oligonucleotide/3743\">\"According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis,\" said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. \"MRG-110 caused de-repression of gene goals in human peripheral blood cells\"</a></span>\r\n\r\n<em>This is an important randomized, double-blind, placebo-controlled, dose-escalating study translating previous work on systemically delivered LNA-modified anti-miR oligonucleotide compounds to efficiently lower miR-92a levels in human peripheral blood,\"-</em>Graham C. Parker, PhD, Executive Editor, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children\'s Hospital of Michigan, Detroit, MI\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://home.liebertpub.com/news/first-in-human-study-with-novel-antisense-oligonucleotide/3743\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"DICOrgLink\">Mary Ann Liebert, Inc., Publishers</span></a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nAbplanalp, W. T., <em>et al</em>. (2020) Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. <em>Nucleic Acid Therapeutics</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1089/nat.2020.0871\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1089/nat.2020.0871</a>.</span>\r\n\r\n</div>','Study: Anti-microRNA sedate essentially lessens miR-92a levels in human peripheral blood','','inherit','closed','closed','','6988-revision-v1','','','2020-08-12 17:34:22','2020-08-12 17:34:22','',6988,'https://microbiozindia.com/uncategorized/6988-revision-v1/',0,'revision','',0),(6990,2,'2020-08-12 17:36:35','2020-08-12 17:36:35','Researchers at the Yale Liver Center found that patients using covid-19 demonstrated with abnormal liver tests at much greater rates than indicated by earlier studies.1 They also discovered that higher levels of liver enzymes--proteins released when the liver is damaged--were associated with poorer outcomes for these patients, including ICU admission, mechanical ventilation, and death.\r\nPast studies in China found that roughly 15% of patients with covid-19 had abnormal liver tests. The Yale study, which looked retrospectively at 1,827 covid-19 patients that had been hospitalized in the Yale New Haven Health program between March and April, revealed that the incidence of abnormal liver tests was much higher--between 41.6% and 83.4percent of patients, depending upon the specific test.\r\n\r\n\"We can speculate that US patients might have an elevated speed of additional risk factors like alcoholic or nonalcoholic fatty liver disease,\" he says.\r\n\r\nLiver disease is widespread in the USA population. Michael Nathanson, MD, PhD, the Gladys Phillips Crofoot Professor of Medicine (digestive diseases), professor of cell biology, director of the Yale Liver Center, and a co-author of the study, states,\"In the United Sstates, near one-third of people have fatty liver disease, and many million people have chronic hepatitis B or C.\"\r\n\r\nSince the Yale researchers had access to patients\' medical recordsthey were also able to check at their liver tests prior to being diagnosed with covid-19. Roughly one-quarter of patients in the study had abnormal liver tests before being admitted for the virus. But regardless of whether patients arrived into the hospital with existing liver issues or acquired them throughout their covid-19-related hospitalization, a strong association was detected between abnormal liver tests along with the harshness of these covid-19 instances, the investigators said.\r\n\r\nRather than the liver driving poorer outcomes in covid-19 sufferers, the organ is more likely\"a bystander\" influenced by the hyperinflammation connected with covid-19 and from the side effects of associated treatments, Nathanson says.\r\n\r\nThe research noted that a connection between drugs used to treat acute covid-19 and liver damage, most importantly the drug tocilizumab.\r\n\r\n\"We discovered a strong association between the use of covid-19 medications and abnormal liver tests,\" says Lim, but adds that they could not confidently tease out that the strange tests were due to\"drug-induced liver harm\" instead of the disease.\r\n\r\nThe researchers have additional clinical and lab-based studies underway to further comprehend covid-19\'s impact on liver pathology. Nathanson notes as one of only four National Institutes of Health-sponsored liver centers in the country, the Yale Liver Center is uniquely positioned to advance this study.\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network [published online ahead of print, 2020 Jul 29]. <em>Hepatology</em>. 2020;10.1002/hep.31487. doi<span style=\"color: #ff6600;\">:<a style=\"color: #ff6600;\" href=\"https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31487\">1002/hep.31487</a></span>','Solid Link Between Abnormal Liver Tests and Poor Covid-19 Outcomes','','publish','open','open','','solid-link-between-abnormal-liver-tests-and-poor-covid-19-outcomes','','','2020-08-12 17:36:35','2020-08-12 17:36:35','',0,'https://microbiozindia.com/?p=6990',0,'post','',0),(6991,2,'2020-08-12 17:36:35','2020-08-12 17:36:35','Researchers at the Yale Liver Center found that patients using covid-19 demonstrated with abnormal liver tests at much greater rates than indicated by earlier studies.1 They also discovered that higher levels of liver enzymes--proteins released when the liver is damaged--were associated with poorer outcomes for these patients, including ICU admission, mechanical ventilation, and death.\r\nPast studies in China found that roughly 15% of patients with covid-19 had abnormal liver tests. The Yale study, which looked retrospectively at 1,827 covid-19 patients that had been hospitalized in the Yale New Haven Health program between March and April, revealed that the incidence of abnormal liver tests was much higher--between 41.6% and 83.4percent of patients, depending upon the specific test.\r\n\r\n\"We can speculate that US patients might have an elevated speed of additional risk factors like alcoholic or nonalcoholic fatty liver disease,\" he says.\r\n\r\nLiver disease is widespread in the USA population. Michael Nathanson, MD, PhD, the Gladys Phillips Crofoot Professor of Medicine (digestive diseases), professor of cell biology, director of the Yale Liver Center, and a co-author of the study, states,\"In the United Sstates, near one-third of people have fatty liver disease, and many million people have chronic hepatitis B or C.\"\r\n\r\nSince the Yale researchers had access to patients\' medical recordsthey were also able to check at their liver tests prior to being diagnosed with covid-19. Roughly one-quarter of patients in the study had abnormal liver tests before being admitted for the virus. But regardless of whether patients arrived into the hospital with existing liver issues or acquired them throughout their covid-19-related hospitalization, a strong association was detected between abnormal liver tests along with the harshness of these covid-19 instances, the investigators said.\r\n\r\nRather than the liver driving poorer outcomes in covid-19 sufferers, the organ is more likely\"a bystander\" influenced by the hyperinflammation connected with covid-19 and from the side effects of associated treatments, Nathanson says.\r\n\r\nThe research noted that a connection between drugs used to treat acute covid-19 and liver damage, most importantly the drug tocilizumab.\r\n\r\n\"We discovered a strong association between the use of covid-19 medications and abnormal liver tests,\" says Lim, but adds that they could not confidently tease out that the strange tests were due to\"drug-induced liver harm\" instead of the disease.\r\n\r\nThe researchers have additional clinical and lab-based studies underway to further comprehend covid-19\'s impact on liver pathology. Nathanson notes as one of only four National Institutes of Health-sponsored liver centers in the country, the Yale Liver Center is uniquely positioned to advance this study.\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network [published online ahead of print, 2020 Jul 29]. <em>Hepatology</em>. 2020;10.1002/hep.31487. doi<span style=\"color: #ff6600;\">:<a style=\"color: #ff6600;\" href=\"https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31487\">1002/hep.31487</a></span>','Solid Link Between Abnormal Liver Tests and Poor Covid-19 Outcomes','','inherit','closed','closed','','6990-revision-v1','','','2020-08-12 17:36:35','2020-08-12 17:36:35','',6990,'https://microbiozindia.com/uncategorized/6990-revision-v1/',0,'revision','',0),(6992,2,'2020-08-12 17:43:14','2020-08-12 17:43:14','Peak Scientific, the global leader in gas production for laboratories, has introduced its latest nitrogen gas generator innovations with the launching of a new package of products engineered to encourage SCIEX\'s recently released Mass Spectrometry platforms.\r\nProduced in cooperation with and exclusively for SCIEX, the new suite of products comes in three versions, each analyzed and supported by SCIEX, for use with the new SCIEX Triple Quad&#x2122; 7500 LC-MS/MS System -- QTRAP® Ready*.\r\n\r\nThe three product versions are as follows: a standalone gasoline generator (Genius XE SCI 2); an MS bench system with completely integrated gasoline generator inside (MS Bench (G) SCI two ) appropriate for placing the LC on; along with an MS bench built to house the SCIEX 7500 system\'s vacuum pumps (MS Bench SCI two ). The Genius XE SCI 2 standalone generator may also cater to your gasoline flow requirements of the newly released SCIEX Echo® MS System**.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.peakscientific.com/products/nitrogen/genius-xe-sci-2/\">The Genius XE SCI 2 gas generator incorporates the latest cutting-edge technologies to provide clients with a consistent, dependable and cost-effective gas source that has been optimized to fit the particular gasoline requirements of the SCIEX 7500, in a compact and easy to use plug &amp; play system.</a></span>\r\n\r\nMS Bench (G) SCI 2 combines the exact same Genius XE generator technologies with the practicalities and form factor of a recliner seat and includes a rust resistant worktop for the SCIEX LCMS workflow. This version gives clients the best of both worlds with a gas generator solution for the SCIEX 7500 fully integrated and included inside a high specification lab bench workstation.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.peakscientific.com/products/nitrogen/genius-xe-sci-2/\">The third product in the suite, MS Bench SCI 2, is at the workstation form factor but without the integrated gas generator, instead offering a custom made worktop for locating the SCIEX 7500 System,</a> </span>ensuring optimum instrument height and positioning as well as safe and functional enclosure of the roughing pumps underneath.\r\n\r\nPetra Gierga, Product Manager for Peak Scientific, said,\"Having worked in close cooperation with SCIEX for nearly two decades delivering tailored solutions to SCIEX instruments, these brand new products give clients unrivalled peace of mind.\"\r\n\r\nThe Genius XE SCI 2 product series is currently available to order directly from Peak Scientific, as well as its approved supply partners or from SCIEX within a comprehensive package solution.\r\n\r\n*QTRAP is registered trademark of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.\r\n**Echo and Echo MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.\r\n\r\nFor more information: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.peakscientific.com/\">https://www.peakscientific.com/ </a></span>','Peak Scientific presents new gas generator and bench solutions for the SCIEX 7500 LC-MS framework','','publish','open','open','','peak-scientific-presents-new-gas-generator-and-bench-solutions-for-the-sciex-7500-lc-ms-framework','','','2020-08-12 17:43:14','2020-08-12 17:43:14','',0,'https://microbiozindia.com/?p=6992',0,'post','',0),(6993,2,'2020-08-12 17:38:57','2020-08-12 17:38:57','','Genius XE SCI 2 left - Bench right','','inherit','open','closed','','genius-xe-sci-2-left-bench-right','','','2020-08-12 17:38:57','2020-08-12 17:38:57','',6992,'https://microbiozindia.com/wp-content/uploads/2020/08/Genius-XE-SCI-2-left-Bench-right.jpg',0,'attachment','image/jpeg',0),(6994,2,'2020-08-12 17:43:14','2020-08-12 17:43:14','Peak Scientific, the global leader in gas production for laboratories, has introduced its latest nitrogen gas generator innovations with the launching of a new package of products engineered to encourage SCIEX\'s recently released Mass Spectrometry platforms.\r\nProduced in cooperation with and exclusively for SCIEX, the new suite of products comes in three versions, each analyzed and supported by SCIEX, for use with the new SCIEX Triple Quad&#x2122; 7500 LC-MS/MS System -- QTRAP® Ready*.\r\n\r\nThe three product versions are as follows: a standalone gasoline generator (Genius XE SCI 2); an MS bench system with completely integrated gasoline generator inside (MS Bench (G) SCI two ) appropriate for placing the LC on; along with an MS bench built to house the SCIEX 7500 system\'s vacuum pumps (MS Bench SCI two ). The Genius XE SCI 2 standalone generator may also cater to your gasoline flow requirements of the newly released SCIEX Echo® MS System**.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.peakscientific.com/products/nitrogen/genius-xe-sci-2/\">The Genius XE SCI 2 gas generator incorporates the latest cutting-edge technologies to provide clients with a consistent, dependable and cost-effective gas source that has been optimized to fit the particular gasoline requirements of the SCIEX 7500, in a compact and easy to use plug &amp; play system.</a></span>\r\n\r\nMS Bench (G) SCI 2 combines the exact same Genius XE generator technologies with the practicalities and form factor of a recliner seat and includes a rust resistant worktop for the SCIEX LCMS workflow. This version gives clients the best of both worlds with a gas generator solution for the SCIEX 7500 fully integrated and included inside a high specification lab bench workstation.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.peakscientific.com/products/nitrogen/genius-xe-sci-2/\">The third product in the suite, MS Bench SCI 2, is at the workstation form factor but without the integrated gas generator, instead offering a custom made worktop for locating the SCIEX 7500 System,</a> </span>ensuring optimum instrument height and positioning as well as safe and functional enclosure of the roughing pumps underneath.\r\n\r\nPetra Gierga, Product Manager for Peak Scientific, said,\"Having worked in close cooperation with SCIEX for nearly two decades delivering tailored solutions to SCIEX instruments, these brand new products give clients unrivalled peace of mind.\"\r\n\r\nThe Genius XE SCI 2 product series is currently available to order directly from Peak Scientific, as well as its approved supply partners or from SCIEX within a comprehensive package solution.\r\n\r\n*QTRAP is registered trademark of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.\r\n**Echo and Echo MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.\r\n\r\nFor more information: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.peakscientific.com/\">https://www.peakscientific.com/ </a></span>','Peak Scientific presents new gas generator and bench solutions for the SCIEX 7500 LC-MS framework','','inherit','closed','closed','','6992-revision-v1','','','2020-08-12 17:43:14','2020-08-12 17:43:14','',6992,'https://microbiozindia.com/uncategorized/6992-revision-v1/',0,'revision','',0),(6995,2,'2020-08-13 18:39:36','2020-08-13 18:39:36','Drug firm Zydus Cadila on August 13 stated it has established Remdesivir under the brand name Remdac, used to treat patients experiencing severe signs of COVID-19, in the Indian market. Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.\r\n\r\nThe business said the drug will be made accessible across India throughout the group\'s strong distribution chain reaching out to private and government hospitals treating COVID-19 patients.\r\n\r\n\"Remdac is the most inexpensive drug as we\'d love to allow patients to gain access to this critical drug in treating COVID-19,\" Cadila Healthcare Managing Director Dr Sharvil Patel stated.\r\n\r\nThrough the course of this outbreak, the organization\'s efforts have been focused on supporting individuals in this health crisis, whether it is through creating vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests offered or exploring new treatment choices, Patel added.\r\n\r\nIn June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational medication, which has been issued an emergency usage authorisation from the US Food and Drug Administration (USFDA) to treat patients experiencing acute signs of COVID-19.\r\n\r\nThe active pharmaceutical ingredient (API) for your drug was developed and manufactured at the team\'s API manufacturing centers in Gujarat.\r\n\r\nZydus Cadila\'s vaccine candidate ZyCov-D is now in phase II of their clinical trials.\r\n\r\nShares of Cadila Healthcare, the listed entity of the group, were trading at Rs 387 apiece on BSE, 0.44 percent higher contrary to their previous closure.','Zydus Cadila dispatches COVID-19 medication Remdesivir in India','','publish','open','open','','zydus-cadila-dispatches-covid-19-medication-remdesivir-in-india','','','2020-08-13 18:39:36','2020-08-13 18:39:36','',0,'https://microbiozindia.com/?p=6995',0,'post','',0),(6996,2,'2020-08-13 18:39:36','2020-08-13 18:39:36','Drug firm Zydus Cadila on August 13 stated it has established Remdesivir under the brand name Remdac, used to treat patients experiencing severe signs of COVID-19, in the Indian market. Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.\r\n\r\nThe business said the drug will be made accessible across India throughout the group\'s strong distribution chain reaching out to private and government hospitals treating COVID-19 patients.\r\n\r\n\"Remdac is the most inexpensive drug as we\'d love to allow patients to gain access to this critical drug in treating COVID-19,\" Cadila Healthcare Managing Director Dr Sharvil Patel stated.\r\n\r\nThrough the course of this outbreak, the organization\'s efforts have been focused on supporting individuals in this health crisis, whether it is through creating vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests offered or exploring new treatment choices, Patel added.\r\n\r\nIn June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational medication, which has been issued an emergency usage authorisation from the US Food and Drug Administration (USFDA) to treat patients experiencing acute signs of COVID-19.\r\n\r\nThe active pharmaceutical ingredient (API) for your drug was developed and manufactured at the team\'s API manufacturing centers in Gujarat.\r\n\r\nZydus Cadila\'s vaccine candidate ZyCov-D is now in phase II of their clinical trials.\r\n\r\nShares of Cadila Healthcare, the listed entity of the group, were trading at Rs 387 apiece on BSE, 0.44 percent higher contrary to their previous closure.','Zydus Cadila dispatches COVID-19 medication Remdesivir in India','','inherit','closed','closed','','6995-revision-v1','','','2020-08-13 18:39:36','2020-08-13 18:39:36','',6995,'https://microbiozindia.com/uncategorized/6995-revision-v1/',0,'revision','',0),(6997,2,'2020-08-13 18:57:39','2020-08-13 18:57:39','Every year, 1.1 million new cases of blood cancers are diagnosed globally. Currently, chemotherapy remains the most common and efficient plan of treatment. On the other hand, the development of aggressive types of leukemia in adults stimulates a need for early detection and new therapeutic approaches to achieve better clinical outcomes.\r\n\r\nIn a novel step ahead, researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have identified covalently closed circular RNAs (circRNAs) from key genes involved in embryonic growth and provided greater understanding of their functions in haematological malignancies.\r\n\r\n<em>This work has provided insights into a new mechanism for the regulation of H2AK119ub levels in hematopoietic progenitors - via interaction of circASXL1-1 and BAP1,\"</em>-Sudhakar Jha, Assistant Professor, Cancer Science Institute of Singapore, National University of Singapore\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.nus.edu.sg/press-releases/leukemia-development-circRNA\">Mutations in additional sex combs-like 1 (ASXL1) receptor, an epigenetics remodeler, are found in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS), and are associated with poor overall survival. Lately, the ASXL1 gene locus was shown to undergo alternative splicing to produce circRNAs.</a></span>\r\n\r\nWhile previous studies on circRNAs have mostly been concentrated on understanding the roots of the non-coding RNAs, the CSI Singapore research team headed by Assistant Professor Sudhakar Jha investigated the function of circRNAs in modulating the epigenetics landscape as well as the effects on differentiation in hematopoietic development and leukemogenesis.\r\n\r\nThe findings of this study were published in the prestigious scientific journal Haematologica in July 2020.\r\n\r\nNew mechanism accountable for leukemia development\r\nCircRNAs have been shown to have higher equilibrium, are plentiful, and highly conserved compared to linear RNAs.\r\n\r\nIn addition, they can be detected in extracellular vesicles, exosomes and blood plasma thus highlighting their possible as non invasive biomarkers. During RNA sequencing, the research team discovered circRNA isoforms in the ASXL1 gene locus.\r\n\r\nThe team\'s analysis made inroads into understanding the use of circASXL1-1 in leukemia. Their statistics show that depletion of circASXL1-1 led to decreased H2AK119 ubiquitination (H2AK119ub) and this had been through BRCA-1 related protein (BAP1) action, a deubiquitinating enzyme and a significant epigenetic regulator at leukemia.\r\nTapping on the newly established comprehension, the research team aims to identify genes involved in myeloid differentiation program of haematopoietic stem cells (HSCs).\r\n\r\nThese enzymes can in turn be targeted to restore the normal path of differentiation in leukemia or to assist induce apoptosis of abnormally differentiated cells. The epigenetic signature recognized may thus pave the way for future therapeutic improvements of\"epi-drugs\".\r\n\r\nMoving forward, the research team intends to create data supporting the use of circASXL1-1 in antisense therapy for malignant and non-malignant blood disorders using the recently obtained knowledge. More to the point, findings from this study will lay the foundation for the development of new RNA-based therapeutics for leukemia.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<a href=\"https://news.nus.edu.sg/press-releases/leukemia-development-circRNA\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"DICOrgLink\"><span style=\"color: #ff6600;\">National University of Singapore</span></span></a>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nJadhav, S. P., circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia. Haematologica.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.3324/haematol.2019.225961\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.3324/haematol.2019.225961</a>.</span>\r\n\r\n</div>','Scientists distinguish new method that causes leukemia','','publish','open','open','','scientists-distinguish-new-method-that-causes-leukemia','','','2020-08-14 09:35:50','2020-08-14 09:35:50','',0,'https://microbiozindia.com/?p=6997',0,'post','',1),(6998,2,'2020-08-13 18:54:59','2020-08-13 18:54:59','','blood viles','','inherit','open','closed','','blood-viles','','','2020-08-13 18:54:59','2020-08-13 18:54:59','',6997,'https://microbiozindia.com/wp-content/uploads/2020/08/anemia.jpg',0,'attachment','image/jpeg',0),(6999,2,'2020-08-13 18:57:39','2020-08-13 18:57:39','Every year, 1.1 million new cases of blood cancers are diagnosed globally. Currently, chemotherapy remains the most common and efficient plan of treatment. On the other hand, the development of aggressive types of leukemia in adults stimulates a need for early detection and new therapeutic approaches to achieve better clinical outcomes.\r\n\r\nIn a novel step ahead, researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have identified covalently closed circular RNAs (circRNAs) from key genes involved in embryonic growth and provided greater understanding of their functions in haematological malignancies.\r\n\r\n<em>This work has provided insights into a new mechanism for the regulation of H2AK119ub levels in hematopoietic progenitors - via interaction of circASXL1-1 and BAP1,\"</em>-Sudhakar Jha, Assistant Professor, Cancer Science Institute of Singapore, National University of Singapore\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.nus.edu.sg/press-releases/leukemia-development-circRNA\">Mutations in additional sex combs-like 1 (ASXL1) receptor, an epigenetics remodeler, are found in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS), and are associated with poor overall survival. Lately, the ASXL1 gene locus was shown to undergo alternative splicing to produce circRNAs.</a></span>\r\n\r\nWhile previous studies on circRNAs have mostly been concentrated on understanding the roots of the non-coding RNAs, the CSI Singapore research team headed by Assistant Professor Sudhakar Jha investigated the function of circRNAs in modulating the epigenetics landscape as well as the effects on differentiation in hematopoietic development and leukemogenesis.\r\n\r\nThe findings of this study were published in the prestigious scientific journal Haematologica in July 2020.\r\n\r\nNew mechanism accountable for leukemia development\r\nCircRNAs have been shown to have higher equilibrium, are plentiful, and highly conserved compared to linear RNAs.\r\n\r\nIn addition, they can be detected in extracellular vesicles, exosomes and blood plasma thus highlighting their possible as non invasive biomarkers. During RNA sequencing, the research team discovered circRNA isoforms in the ASXL1 gene locus.\r\n\r\nThe team\'s analysis made inroads into understanding the use of circASXL1-1 in leukemia. Their statistics show that depletion of circASXL1-1 led to decreased H2AK119 ubiquitination (H2AK119ub) and this had been through BRCA-1 related protein (BAP1) action, a deubiquitinating enzyme and a significant epigenetic regulator at leukemia.\r\nTapping on the newly established comprehension, the research team aims to identify genes involved in myeloid differentiation program of haematopoietic stem cells (HSCs).\r\n\r\nThese enzymes can in turn be targeted to restore the normal path of differentiation in leukemia or to assist induce apoptosis of abnormally differentiated cells. The epigenetic signature recognized may thus pave the way for future therapeutic improvements of\"epi-drugs\".\r\n\r\nMoving forward, the research team intends to create data supporting the use of circASXL1-1 in antisense therapy for malignant and non-malignant blood disorders using the recently obtained knowledge. More to the point, findings from this study will lay the foundation for the development of new RNA-based therapeutics for leukemia.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<a href=\"https://news.nus.edu.sg/press-releases/leukemia-development-circRNA\" target=\"_blank\" rel=\"noopener noreferrer\"><span class=\"DICOrgLink\"><span style=\"color: #ff6600;\">National University of Singapore</span></span></a>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nJadhav, S. P., circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia. Haematologica.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.3324/haematol.2019.225961\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.3324/haematol.2019.225961</a>.</span>\r\n\r\n</div>','Scientists distinguish new method that causes leukemia','','inherit','closed','closed','','6997-revision-v1','','','2020-08-13 18:57:39','2020-08-13 18:57:39','',6997,'https://microbiozindia.com/uncategorized/6997-revision-v1/',0,'revision','',0),(7000,2,'2020-08-14 09:15:53','2020-08-14 09:15:53','{\n    \"blankslate::nav_menu_locations[main-menu]\": {\n        \"value\": 0,\n        \"type\": \"theme_mod\",\n        \"user_id\": 2,\n        \"date_modified_gmt\": \"2020-08-14 09:15:53\"\n    },\n    \"nav_menu[2247]\": {\n        \"value\": {\n            \"name\": \"Events\",\n            \"description\": \"\",\n            \"parent\": 0,\n            \"auto_add\": true\n        },\n        \"type\": \"nav_menu\",\n        \"user_id\": 2,\n        \"date_modified_gmt\": \"2020-08-14 09:15:53\"\n    }\n}','','','trash','closed','closed','','17919355-36b2-449d-8588-aac9e03b00ff','','','2020-08-14 09:15:53','2020-08-14 09:15:53','',0,'https://microbiozindia.com/uncategorized/17919355-36b2-449d-8588-aac9e03b00ff/',0,'customize_changeset','',0),(7002,2,'2020-08-14 09:42:35','0000-00-00 00:00:00',' ','','','draft','closed','closed','','','','','2020-08-14 09:42:35','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7002',1,'nav_menu_item','',0),(7003,2,'2020-08-14 09:52:24','2020-08-14 09:52:24','Aurobindo Pharma has said it is expecting its suggested vaccine candidate for COVID-19 to undergo Phase I and II trials by the end of 2020, while Stage III might be performed during March-April next year.Managing Director of Aurobindo Pharma, Narayanan Govindarajan in the newly held earnings call with analysts said the city-based pharma major has allowed USD 150-200 million towards capex through the current financial crisis.\r\n\r\nHe said the vaccine to get COVID-19 is being developed by Profectus BioSciences Inc in US, which was obtained by AurobindoPharmas subsidiary Auro Vaccines LLC.\r\n\r\nAccording to Govindarajan, the company\'s viral vaccine production capacity in India would be undertaken in two phases. The first stage would be prepared by October along with the commercial facility by March, next year.\r\n\r\n\"So on the VSV platform, they (Auro Vaccines) arealready creating a COVID-19 vaccine as well and we are creating the capacity in India wherein there are two stages of capacity. The first set of capacity would be prepared by October, where we\'d like to make the merchandise and begin the Phase-I and Phase-II at the end of the year\"\r\n\r\n\"And our commercial centre, we\'re planning to have it ready by about March-April timeline where we\'d love to make the product for the Phase III trials. That is the deadline for its COVID-19 vaccine based on our present premises,\" Govindarajan said replying to a query on the vaccine.\r\n\r\nAurobindo Pharma is working on developing a number of viral vaccines including a person for COVID-19 even as the offender has been approved for funding by the Department of BioTechnology, the company said in its yearly report.\r\n\r\nThe COVID-19 vaccine candidate failed an evaluation by BIRAC (Biotechnology Industry Research Assistance Council,Department of BioTechnology) and has been shortlisted for funding initial development, the firm had stated.\r\n\r\nAsked about the capex projections, Govindarajan said,\"However, for the present calendar year, we still believe it should be in the range of USD150 million to USD 200 million (of capex).\"','Aurobindo Pharma expects stage I, II preliminaries by end of 2020','','publish','open','open','','aurobindo-pharma-expects-stage-i-ii-preliminaries-by-end-of-2020','','','2020-08-14 09:52:24','2020-08-14 09:52:24','',0,'https://microbiozindia.com/?p=7003',0,'post','',0),(7004,2,'2020-08-14 09:52:24','2020-08-14 09:52:24','Aurobindo Pharma has said it is expecting its suggested vaccine candidate for COVID-19 to undergo Phase I and II trials by the end of 2020, while Stage III might be performed during March-April next year.Managing Director of Aurobindo Pharma, Narayanan Govindarajan in the newly held earnings call with analysts said the city-based pharma major has allowed USD 150-200 million towards capex through the current financial crisis.\r\n\r\nHe said the vaccine to get COVID-19 is being developed by Profectus BioSciences Inc in US, which was obtained by AurobindoPharmas subsidiary Auro Vaccines LLC.\r\n\r\nAccording to Govindarajan, the company\'s viral vaccine production capacity in India would be undertaken in two phases. The first stage would be prepared by October along with the commercial facility by March, next year.\r\n\r\n\"So on the VSV platform, they (Auro Vaccines) arealready creating a COVID-19 vaccine as well and we are creating the capacity in India wherein there are two stages of capacity. The first set of capacity would be prepared by October, where we\'d like to make the merchandise and begin the Phase-I and Phase-II at the end of the year\"\r\n\r\n\"And our commercial centre, we\'re planning to have it ready by about March-April timeline where we\'d love to make the product for the Phase III trials. That is the deadline for its COVID-19 vaccine based on our present premises,\" Govindarajan said replying to a query on the vaccine.\r\n\r\nAurobindo Pharma is working on developing a number of viral vaccines including a person for COVID-19 even as the offender has been approved for funding by the Department of BioTechnology, the company said in its yearly report.\r\n\r\nThe COVID-19 vaccine candidate failed an evaluation by BIRAC (Biotechnology Industry Research Assistance Council,Department of BioTechnology) and has been shortlisted for funding initial development, the firm had stated.\r\n\r\nAsked about the capex projections, Govindarajan said,\"However, for the present calendar year, we still believe it should be in the range of USD150 million to USD 200 million (of capex).\"','Aurobindo Pharma expects stage I, II preliminaries by end of 2020','','inherit','closed','closed','','7003-revision-v1','','','2020-08-14 09:52:24','2020-08-14 09:52:24','',7003,'https://microbiozindia.com/uncategorized/7003-revision-v1/',0,'revision','',0),(7005,2,'2020-08-14 09:53:52','2020-08-14 09:53:52','A tuberculosis vaccine administered during the previous 15 years is correlated with significantly enhanced COVID-19 outcomes, particularly in young adults, according to a new study.\r\n\r\nThe analysis, published in the journal Vaccines, found that BCG regimes are correlated with better COVID-19 outcomes, both in reducing disease rates and death rates , especially for people aged 24 or younger who had received the vaccination in the previous 15 decades.\r\n\r\nThere was no effect among older adults that had received the BCG vaccine, the researchers said.\r\n\r\nMost nations have ceased inoculating their whole population, but some still use BCG extensively, they stated.\r\n\r\n\"A growing number of clinical trials for testing the efficacy of BCG vaccination have been pioneered,\" Rappoport said.\r\n\r\nThe researchers examined data from 55 countries with populations of more than three million individuals, which include some 63 percent of the planet\'s population.\r\n\r\nSince the pandemic attained different nations at different dates, they steered nations by the first date at which the nation reached a passing rate of 0.5 deaths per million or higher.\r\n\r\nThe investigators controlled for 23 variables including demographic, economical, pandemic-restriction-related, and country health-based.\r\n\r\nBCG vaccine management was shown to be continuously associated with COVID-19 results across the 55 states, \'\' they said.\r\n\r\nTo determine whether other vaccines also affected COVID-19 results, the team ran the same analysis for the measles and rubella vaccines and found that those did not have a significant association with COVID-19 outcomes.\r\n\r\nOther epidemiological studies have shown the impact of the BCG vaccine past tuberculosis, however, scientists do not yet understand why the vaccine has such an effect.','TB inoculation connected with altogether improved COVID-19 results: Study','','publish','open','open','','tb-inoculation-connected-with-altogether-improved-covid-19-results-study','','','2020-08-14 09:53:52','2020-08-14 09:53:52','',0,'https://microbiozindia.com/?p=7005',0,'post','',0),(7006,2,'2020-08-14 09:53:52','2020-08-14 09:53:52','A tuberculosis vaccine administered during the previous 15 years is correlated with significantly enhanced COVID-19 outcomes, particularly in young adults, according to a new study.\r\n\r\nThe analysis, published in the journal Vaccines, found that BCG regimes are correlated with better COVID-19 outcomes, both in reducing disease rates and death rates , especially for people aged 24 or younger who had received the vaccination in the previous 15 decades.\r\n\r\nThere was no effect among older adults that had received the BCG vaccine, the researchers said.\r\n\r\nMost nations have ceased inoculating their whole population, but some still use BCG extensively, they stated.\r\n\r\n\"A growing number of clinical trials for testing the efficacy of BCG vaccination have been pioneered,\" Rappoport said.\r\n\r\nThe researchers examined data from 55 countries with populations of more than three million individuals, which include some 63 percent of the planet\'s population.\r\n\r\nSince the pandemic attained different nations at different dates, they steered nations by the first date at which the nation reached a passing rate of 0.5 deaths per million or higher.\r\n\r\nThe investigators controlled for 23 variables including demographic, economical, pandemic-restriction-related, and country health-based.\r\n\r\nBCG vaccine management was shown to be continuously associated with COVID-19 results across the 55 states, \'\' they said.\r\n\r\nTo determine whether other vaccines also affected COVID-19 results, the team ran the same analysis for the measles and rubella vaccines and found that those did not have a significant association with COVID-19 outcomes.\r\n\r\nOther epidemiological studies have shown the impact of the BCG vaccine past tuberculosis, however, scientists do not yet understand why the vaccine has such an effect.','TB inoculation connected with altogether improved COVID-19 results: Study','','inherit','closed','closed','','7005-revision-v1','','','2020-08-14 09:53:52','2020-08-14 09:53:52','',7005,'https://microbiozindia.com/uncategorized/7005-revision-v1/',0,'revision','',0),(7007,2,'2020-08-14 15:20:30','2020-08-14 15:20:30','Chemists at Scripps Research have effectively established three families of complicated, oxygen-containing molecules that are normally available only from crops.\r\n\r\nThese compounds, called terpenes, are possible starting points for new medications and other high-value products--marking an important development for multiple businesses. Additionally, the new strategy could allow chemists to develop a number of other classes of compounds.\r\n\r\nThe chemistry effort is comprehensive in the Aug. 13 edition of this journal Science.\r\n\r\nThe key to this new method of earning molecules is that the tapping, or hijacking, of natural enzymes--from germs, in this instance --to assist in complex chemical transformations which have been impractical or impossible with artificial chemistry methods alone, says principal investigator Hans Renata, PhD, an assistant professor at the Department of Chemistry at Scripps Research.\r\n\r\nNatural enzymes which help construct molecules in cells usually perform just one or 2 highly specific activities. However, the Scripps Research team revealed that organic enzymes, even without modification, can be made to perform a wider range of tasks.\r\n\r\n\"We think that generally, enzymes are a largely untapped resource for solving problems in chemical synthesis,\" Renata states. \"Enzymes have a tendency to possess some amount of promiscuous activity, in terms of their ability to spur chemical responses beyond their primary job, and we could take advantage of that here.\"\r\n\r\nEnzymes help build molecules in all plant, animal and microbial species. Inspired by their efficiency in constructing highly complex molecules, chemists for over half a century have utilized enzymes from the laboratory to help assemble valuable compounds, including drug compounds--but generally these chemicals would be the same molecules that the enzymes help build in nature.\r\n\r\nImplementing natural enzymes in a broader way, in accordance with their basic biochemical action, is a brand new strategy with huge potential.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scripps.edu/news-and-events/press-room/2020/20200813-renata-terpenes.html\">\"Our view now is that if we want to synthesize a complex molecule, the remedy probably already exists one of nature\'s enzymes--we just have to know how to discover the enzymes which will function,\" says senior author Ben Shen, PhD, chair of the Department of Chemistry on the Florida campus and also director of Scripps Research\'s Natural Products Discovery Center.</a></span>\r\n\r\nThe group succeeded in creating nine terpenes proven to be produced in Isodon, a family of flowering plants associated with mint. Members of these terpene families have a wide range of biological actions such as the suppression of inflammation and tumor growth.\r\n\r\n<strong>A recipe for synthesis achievement</strong>\r\nThe synthesis of each compound, in under 10 measures for each, was a hybrid process combining present organic synthesis methods with enzyme-mediated synthesis starting in an inexpensive compound called stevioside, the main part of the artificial sweetener Stevia.\r\n\r\nCurrent organic synthesis systems have a limited arsenal for these transformations.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scripps.edu/news-and-events/press-room/2020/20200813-renata-terpenes.html\">However, nature has produced many enzymes which could enable those transformations--each capable of performing its own function with a degree of control unmatched by artificial procedures.</a></span>\r\n\r\nBoth enzymes utilized, which were characterized and identified by Shen, Renata and colleagues only annually, are produced naturally by a bacterium--one of the 200,000-plus species in the Microbial Strain Collection at Scripps Research\'s Natural Products Discovery Center.\r\n\"We were able to utilize these enzymes not only to modify the starting molecules, or scaffolds as we call them, but also to flip one scaffold into another so that we could transform a terpene from one family into a terpene from a different family,\" says second author Emma King-Smith, a PhD student in the Renata lab.\r\n\r\n<em>Being an interdisciplinary research group, we were fully aware of the limitations of current organic synthesis methods, but also of the many unique ways that enzymes can overcome these limitations--and we had the insights to combine traditional synthetic chemistry with enzymatic methods in a synergistic fashion.\"-Hans Renata, PhD, Principal Investigator and Assistant Professor, Department of Chemistry, Scripps Research Institute</em>\r\n\r\nThe chemists now intend to utilize their new approach to make useful amounts of the nine chemicals, in addition to chemical variants of the chemicals, and, with cooperating laboratories, research their properties as possible drugs or other goods.\r\n\r\n\"With our strategy, we can create these highly oxidized diterpenes a lot more readily and in larger quantities than would be possible by isolating them from the plants in which they are found naturally,\" says author Xiao Zhang, PhD, a postdoctoral research associate in the Renata laboratory.\r\n\r\nAs importantly, the investigators saythey are working to identify enzymes and reactions that will enable them to extend their approach to other classes of molecules.\r\n\r\nCentral to these efforts is the ongoing development of approaches to sift through the DNA of microbes and other organisms to identify the enzymes they encode--and predict the actions of these enzymes.\r\n\r\nBillions of different enzymes exist in crops, animals, and bacteria on Earth and only a very small fraction of these have been catalogued to date.\r\n\r\n\"We are excited about the potential of finding new and enzymes from our stress library here at Scripps Research,\" Renata says. \"We believe that will enable us to address a number of different problems in chemical synthesis.\"\r\n\r\n<strong>Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scripps.edu/news-and-events/press-room/2020/20200813-renata-terpenes.html\" target=\"_blank\" rel=\"noopener noreferrer\">Scripps Research Institute</a></span>\r\n\r\n&nbsp;','Chemists make complex, oxygen-containing particles that are typically made by plants','','publish','open','open','','chemists-make-complex-oxygen-containing-particles-that-are-typically-made-by-plants','','','2020-08-14 15:20:30','2020-08-14 15:20:30','',0,'https://microbiozindia.com/?p=7007',0,'post','',0),(7008,2,'2020-08-14 15:20:21','2020-08-14 15:20:21','','goggles-4915435_640','','inherit','open','closed','','goggles-4915435_640','','','2020-08-14 15:20:21','2020-08-14 15:20:21','',7007,'https://microbiozindia.com/wp-content/uploads/2020/08/goggles-4915435_640.jpg',0,'attachment','image/jpeg',0),(7009,2,'2020-08-14 15:20:22','2020-08-14 15:20:22','','vaccination-67477_640','','inherit','open','closed','','vaccination-67477_640-2','','','2020-08-14 15:20:22','2020-08-14 15:20:22','',7007,'https://microbiozindia.com/wp-content/uploads/2020/08/vaccination-67477_640.jpg',0,'attachment','image/jpeg',0),(7010,2,'2020-08-14 15:20:30','2020-08-14 15:20:30','Chemists at Scripps Research have effectively established three families of complicated, oxygen-containing molecules that are normally available only from crops.\r\n\r\nThese compounds, called terpenes, are possible starting points for new medications and other high-value products--marking an important development for multiple businesses. Additionally, the new strategy could allow chemists to develop a number of other classes of compounds.\r\n\r\nThe chemistry effort is comprehensive in the Aug. 13 edition of this journal Science.\r\n\r\nThe key to this new method of earning molecules is that the tapping, or hijacking, of natural enzymes--from germs, in this instance --to assist in complex chemical transformations which have been impractical or impossible with artificial chemistry methods alone, says principal investigator Hans Renata, PhD, an assistant professor at the Department of Chemistry at Scripps Research.\r\n\r\nNatural enzymes which help construct molecules in cells usually perform just one or 2 highly specific activities. However, the Scripps Research team revealed that organic enzymes, even without modification, can be made to perform a wider range of tasks.\r\n\r\n\"We think that generally, enzymes are a largely untapped resource for solving problems in chemical synthesis,\" Renata states. \"Enzymes have a tendency to possess some amount of promiscuous activity, in terms of their ability to spur chemical responses beyond their primary job, and we could take advantage of that here.\"\r\n\r\nEnzymes help build molecules in all plant, animal and microbial species. Inspired by their efficiency in constructing highly complex molecules, chemists for over half a century have utilized enzymes from the laboratory to help assemble valuable compounds, including drug compounds--but generally these chemicals would be the same molecules that the enzymes help build in nature.\r\n\r\nImplementing natural enzymes in a broader way, in accordance with their basic biochemical action, is a brand new strategy with huge potential.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scripps.edu/news-and-events/press-room/2020/20200813-renata-terpenes.html\">\"Our view now is that if we want to synthesize a complex molecule, the remedy probably already exists one of nature\'s enzymes--we just have to know how to discover the enzymes which will function,\" says senior author Ben Shen, PhD, chair of the Department of Chemistry on the Florida campus and also director of Scripps Research\'s Natural Products Discovery Center.</a></span>\r\n\r\nThe group succeeded in creating nine terpenes proven to be produced in Isodon, a family of flowering plants associated with mint. Members of these terpene families have a wide range of biological actions such as the suppression of inflammation and tumor growth.\r\n\r\n<strong>A recipe for synthesis achievement</strong>\r\nThe synthesis of each compound, in under 10 measures for each, was a hybrid process combining present organic synthesis methods with enzyme-mediated synthesis starting in an inexpensive compound called stevioside, the main part of the artificial sweetener Stevia.\r\n\r\nCurrent organic synthesis systems have a limited arsenal for these transformations.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scripps.edu/news-and-events/press-room/2020/20200813-renata-terpenes.html\">However, nature has produced many enzymes which could enable those transformations--each capable of performing its own function with a degree of control unmatched by artificial procedures.</a></span>\r\n\r\nBoth enzymes utilized, which were characterized and identified by Shen, Renata and colleagues only annually, are produced naturally by a bacterium--one of the 200,000-plus species in the Microbial Strain Collection at Scripps Research\'s Natural Products Discovery Center.\r\n\"We were able to utilize these enzymes not only to modify the starting molecules, or scaffolds as we call them, but also to flip one scaffold into another so that we could transform a terpene from one family into a terpene from a different family,\" says second author Emma King-Smith, a PhD student in the Renata lab.\r\n\r\n<em>Being an interdisciplinary research group, we were fully aware of the limitations of current organic synthesis methods, but also of the many unique ways that enzymes can overcome these limitations--and we had the insights to combine traditional synthetic chemistry with enzymatic methods in a synergistic fashion.\"-Hans Renata, PhD, Principal Investigator and Assistant Professor, Department of Chemistry, Scripps Research Institute</em>\r\n\r\nThe chemists now intend to utilize their new approach to make useful amounts of the nine chemicals, in addition to chemical variants of the chemicals, and, with cooperating laboratories, research their properties as possible drugs or other goods.\r\n\r\n\"With our strategy, we can create these highly oxidized diterpenes a lot more readily and in larger quantities than would be possible by isolating them from the plants in which they are found naturally,\" says author Xiao Zhang, PhD, a postdoctoral research associate in the Renata laboratory.\r\n\r\nAs importantly, the investigators saythey are working to identify enzymes and reactions that will enable them to extend their approach to other classes of molecules.\r\n\r\nCentral to these efforts is the ongoing development of approaches to sift through the DNA of microbes and other organisms to identify the enzymes they encode--and predict the actions of these enzymes.\r\n\r\nBillions of different enzymes exist in crops, animals, and bacteria on Earth and only a very small fraction of these have been catalogued to date.\r\n\r\n\"We are excited about the potential of finding new and enzymes from our stress library here at Scripps Research,\" Renata says. \"We believe that will enable us to address a number of different problems in chemical synthesis.\"\r\n\r\n<strong>Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.scripps.edu/news-and-events/press-room/2020/20200813-renata-terpenes.html\" target=\"_blank\" rel=\"noopener noreferrer\">Scripps Research Institute</a></span>\r\n\r\n&nbsp;','Chemists make complex, oxygen-containing particles that are typically made by plants','','inherit','closed','closed','','7007-revision-v1','','','2020-08-14 15:20:30','2020-08-14 15:20:30','',7007,'https://microbiozindia.com/uncategorized/7007-revision-v1/',0,'revision','',0),(7011,2,'2020-08-14 15:22:41','2020-08-14 15:22:41','By conducting complex diagnoses of immune system stimulation in patients with acute COVID-19, researchers at Karolinska Institutet have managed to spot several cell types that play a key part in the immune reaction to the new coronavirus and the hyperinflammation found in severe cases of the disease. The results are published in the scientific journal Cell Reports Medication.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ki.se/new-insights-into-the-immune-systems-role-in-severe-covid-19\">The researchers used a combination of advanced methods to analyse the whole composition and role of the immune system up to 14 repeated blood samples from each patient.</a></span>\r\n\"This has allowed us to create an unusually comprehensive analysis of immune system activation during severe COVID-19, and we have described several new details of immune response to the virus and its own hyperresponsiveness in severely ill patients,\" states Dr Brodin.\r\n\r\n<em>These findings are valuable in improving the clinical evaluation of patients and in the development of new treatments that modulate and mitigate the over-reaction of the immune system in patients with severe COVID-19.\"-Petter Brodin, principal investigator, pediatrician and researcher in immunology at the Departmentof Women\'s and Children\'s Health, Karolinska Institutet</em>\r\n\r\nTheir results show, among other things, that a kind of white blood cells known as eosinophils, which can be well-documented in asthma but whose function is less understood in respiratory infections in the lungs, play an important role in severe COVID-19. These cells grow in the blood soon before the sufferers suffer a deterioration due to pulmonary hyperinflammation, and ARDS (acute respiratory distress syndrome), requiring intensive care. Other white blood cells called basophils are located within this study to participate in the evolution of powerful antibody responsesduringthe disease. The researchers have also identified how the immune system recovers in the patients that recovered from severe COVID-19.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ki.se/new-insights-into-the-immune-systems-role-in-severe-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">Karolinska Institutet</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nRodriguez, L., <em>et al.</em> (2020) Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. <em>Cell Reports Medicine.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1016/j.xcrm.2020.100078\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.xcrm.2020.100078</a>.</span>\r\n\r\n</div>','Propelled investigation offers new experiences into safe framework\'s job in serious COVID-19','','publish','open','open','','propelled-investigation-offers-new-experiences-into-safe-frameworks-job-in-serious-covid-19','','','2020-08-14 15:22:41','2020-08-14 15:22:41','',0,'https://microbiozindia.com/?p=7011',0,'post','',0),(7012,2,'2020-08-14 15:22:41','2020-08-14 15:22:41','By conducting complex diagnoses of immune system stimulation in patients with acute COVID-19, researchers at Karolinska Institutet have managed to spot several cell types that play a key part in the immune reaction to the new coronavirus and the hyperinflammation found in severe cases of the disease. The results are published in the scientific journal Cell Reports Medication.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ki.se/new-insights-into-the-immune-systems-role-in-severe-covid-19\">The researchers used a combination of advanced methods to analyse the whole composition and role of the immune system up to 14 repeated blood samples from each patient.</a></span>\r\n\"This has allowed us to create an unusually comprehensive analysis of immune system activation during severe COVID-19, and we have described several new details of immune response to the virus and its own hyperresponsiveness in severely ill patients,\" states Dr Brodin.\r\n\r\n<em>These findings are valuable in improving the clinical evaluation of patients and in the development of new treatments that modulate and mitigate the over-reaction of the immune system in patients with severe COVID-19.\"-Petter Brodin, principal investigator, pediatrician and researcher in immunology at the Departmentof Women\'s and Children\'s Health, Karolinska Institutet</em>\r\n\r\nTheir results show, among other things, that a kind of white blood cells known as eosinophils, which can be well-documented in asthma but whose function is less understood in respiratory infections in the lungs, play an important role in severe COVID-19. These cells grow in the blood soon before the sufferers suffer a deterioration due to pulmonary hyperinflammation, and ARDS (acute respiratory distress syndrome), requiring intensive care. Other white blood cells called basophils are located within this study to participate in the evolution of powerful antibody responsesduringthe disease. The researchers have also identified how the immune system recovers in the patients that recovered from severe COVID-19.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ki.se/new-insights-into-the-immune-systems-role-in-severe-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">Karolinska Institutet</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nRodriguez, L., <em>et al.</em> (2020) Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. <em>Cell Reports Medicine.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1016/j.xcrm.2020.100078\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.xcrm.2020.100078</a>.</span>\r\n\r\n</div>','Propelled investigation offers new experiences into safe framework\'s job in serious COVID-19','','inherit','closed','closed','','7011-revision-v1','','','2020-08-14 15:22:41','2020-08-14 15:22:41','',7011,'https://microbiozindia.com/uncategorized/7011-revision-v1/',0,'revision','',0),(7013,2,'2020-08-14 18:09:00','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-14 18:09:00','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7013',0,'post','',0),(7014,2,'2020-08-14 18:12:37','2020-08-14 18:12:37','Imagine if a person could simply offer a urine sample instead of experience a painful surgical process to find out if their cancer had been reacting to treatment? It may seem too good to be true, but researchers at Pavol Jozef Šafárik University in Košice, Slovakia, have identified fluorescent molecules in urine that may allow patients with malignant melanoma to do just that.1 Their research paper describes a bunch of fluorescent molecules--readily detectable in urine--which correlate with melanoma progression, creating new possibilities for monitoring the disease.\r\nTracking cancer progression is important as it allows doctors to see if someone is responding to therapy. Currently, malignant melanoma patients require invasive biopsies to diagnose and track the development of the cancer. Using this new approach, doctors could ask patients to provide a urine sample instead, and then fluorescent molecules in the sample could reveal disease progression rapidly and inexpensively.\r\n\r\nThis technique is badly required as malignant melanoma is particularly challenging to treat and monitor. This skin cancer is highly aggressive and frequently spreads to other websites within the body so tracking its development is very important. However, current techniques mean that patients have to undergo invasive surgery to remove tissue samples and then laboratory technicians must perform expensive and time-consuming analysis of these samples. Unfortunately, patients can avoid getting timely identification and treatment as they fear these invasive procedures.\r\n\r\nThey focused on particular fluorescent molecules that cancer cells create during metabolic processes involved in their own growth and progression, and which end up in urine.\r\n\r\nThe researchers analyzed urine samples from patients with malignant melanoma and healthy controls using fluorescence spectroscopy, a simple and inexpensive detection method, to see whether there were any gaps in levels of the fluorescent markers. They also performed genetic analysis for the same patients to test genes involved in melanoma progression.\r\n\r\nThe urine samples from the cancerous melanoma patients contained different levels of their metabolism-linked fluorescent markers as compared to those from healthy controls. Strikingly, the degrees of the fluorescent molecules in the urine correlated with the point of melanoma and the expression of genes which are linked to melanoma development, indicating that the molecules possess significant potential as biomarkers.\r\n\r\n\"Our results show that we are able to successfully utilize urine, a simply and non-invasively accumulated biological material, to ascertain the development and treatment response of malignant melanoma,\" says Špaková. \"The results highlight the capacity of\'waste metabolites\' in monitoring disease. This method is a user friendly and easy technique that could be performed using standard laboratory equipment.\"\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Ivana Špaková, Katarína Dubayová, Vladimíra Nagyová, Mária Mareková. Fluorescence biomarkers of malignant melanoma detectable in urine. <em>Open Chemistry</em>, 2020;18(1):898. doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1515/chem-2020-0143\" target=\"_blank\" rel=\"noopener noreferrer\">1515/chem-2020-0143</a>.</span>','Particles in Urine Could Allow Doctors to Monitor Skin Cancer','','publish','open','open','','particles-in-urine-could-allow-doctors-to-monitor-skin-cancer','','','2020-08-14 18:12:37','2020-08-14 18:12:37','',0,'https://microbiozindia.com/?p=7014',0,'post','',0),(7015,2,'2020-08-14 18:12:15','2020-08-14 18:12:15','','Cytek_cFluorM-reagent-bottle_2048x1280-466x291','','inherit','open','closed','','cytek_cfluorm-reagent-bottle_2048x1280-466x291','','','2020-08-14 18:12:15','2020-08-14 18:12:15','',7014,'https://microbiozindia.com/wp-content/uploads/2020/08/Cytek_cFluorM-reagent-bottle_2048x1280-466x291-1.jpg',0,'attachment','image/jpeg',0),(7016,2,'2020-08-14 18:12:15','2020-08-14 18:12:15','','Urinalysis-466x227','','inherit','open','closed','','urinalysis-466x227','','','2020-08-14 18:12:15','2020-08-14 18:12:15','',7014,'https://microbiozindia.com/wp-content/uploads/2020/08/Urinalysis-466x227-1.jpg',0,'attachment','image/jpeg',0),(7017,2,'2020-08-14 18:12:37','2020-08-14 18:12:37','Imagine if a person could simply offer a urine sample instead of experience a painful surgical process to find out if their cancer had been reacting to treatment? It may seem too good to be true, but researchers at Pavol Jozef Šafárik University in Košice, Slovakia, have identified fluorescent molecules in urine that may allow patients with malignant melanoma to do just that.1 Their research paper describes a bunch of fluorescent molecules--readily detectable in urine--which correlate with melanoma progression, creating new possibilities for monitoring the disease.\r\nTracking cancer progression is important as it allows doctors to see if someone is responding to therapy. Currently, malignant melanoma patients require invasive biopsies to diagnose and track the development of the cancer. Using this new approach, doctors could ask patients to provide a urine sample instead, and then fluorescent molecules in the sample could reveal disease progression rapidly and inexpensively.\r\n\r\nThis technique is badly required as malignant melanoma is particularly challenging to treat and monitor. This skin cancer is highly aggressive and frequently spreads to other websites within the body so tracking its development is very important. However, current techniques mean that patients have to undergo invasive surgery to remove tissue samples and then laboratory technicians must perform expensive and time-consuming analysis of these samples. Unfortunately, patients can avoid getting timely identification and treatment as they fear these invasive procedures.\r\n\r\nThey focused on particular fluorescent molecules that cancer cells create during metabolic processes involved in their own growth and progression, and which end up in urine.\r\n\r\nThe researchers analyzed urine samples from patients with malignant melanoma and healthy controls using fluorescence spectroscopy, a simple and inexpensive detection method, to see whether there were any gaps in levels of the fluorescent markers. They also performed genetic analysis for the same patients to test genes involved in melanoma progression.\r\n\r\nThe urine samples from the cancerous melanoma patients contained different levels of their metabolism-linked fluorescent markers as compared to those from healthy controls. Strikingly, the degrees of the fluorescent molecules in the urine correlated with the point of melanoma and the expression of genes which are linked to melanoma development, indicating that the molecules possess significant potential as biomarkers.\r\n\r\n\"Our results show that we are able to successfully utilize urine, a simply and non-invasively accumulated biological material, to ascertain the development and treatment response of malignant melanoma,\" says Špaková. \"The results highlight the capacity of\'waste metabolites\' in monitoring disease. This method is a user friendly and easy technique that could be performed using standard laboratory equipment.\"\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Ivana Špaková, Katarína Dubayová, Vladimíra Nagyová, Mária Mareková. Fluorescence biomarkers of malignant melanoma detectable in urine. <em>Open Chemistry</em>, 2020;18(1):898. doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1515/chem-2020-0143\" target=\"_blank\" rel=\"noopener noreferrer\">1515/chem-2020-0143</a>.</span>','Particles in Urine Could Allow Doctors to Monitor Skin Cancer','','inherit','closed','closed','','7014-revision-v1','','','2020-08-14 18:12:37','2020-08-14 18:12:37','',7014,'https://microbiozindia.com/uncategorized/7014-revision-v1/',0,'revision','',0),(7018,2,'2020-08-14 18:14:35','2020-08-14 18:14:35','These cFluorM reagents, short for\"Cytek Fluorochrome,\" will be the culmination of years of expertise comprehension complete spectrum cytometry and the way fluorophores respond together in shape panels. Cytek\'s cFluor reagents are all validated on its own Cytek Aurora and Cytek Northern Lights cell evaluation systems to ensure optimum performance for its users at a multicolor atmosphere.\r\n\r\nCytek\'s cell analysis instruments use a distinctive optical and electronics design to reveal the full spectrum of each dye. This technology has allowed Cytek\'s scientists to not only completely characterize thousands of commercially available reagents, but also to identify and evaluate dyes and antibody conjugates that operate optimally with full spectrum evaluation about Cytek\'s flow cytometers.\r\n\r\nEvery one of these reagents provides Cytek\'s users the capability to show more from their whole spectrum panel with a new choice excitable from the yellow-green, blue, and red lasers, respectively. Other dyes at the cFluor family will be arriving shortly, with demonstrated ability to work in a pre-optimized panel.\r\n\r\n\"Starting with our full range tools, and today with our cFluor reagents, we are devoted to redefining what is possible in flow cytometry and supplying a entire solution to our users,\" says Wenbin Jiang, PhD, CEO of Cytek Biosciences. \"One of our users, 30+ colour panels are now more commonplace, which would have been inconceivable just two short years back. We\'re now focused on empowering them so that they can go much further with their unique, state-of-the-art cell analyzers, all with increased ease and shorter time to outcomes.\"\r\n\r\nFor more information, visit <a href=\"http://www.cytekbio.com/\">Cytek Biosciences</a>.\r\n\r\n<strong>Featured image:</strong> Cytek’s new cFluor family of reagents ensure optimal results for users of its Cytek Aurora and Cytek Northern Lights full spectrum cell analysis systems. Courtesy Cytek Biosciences.','Flow Cytometry Reagents Line introduced by Cytek','','publish','open','open','','flow-cytometry-reagents-line-introduced-by-cytek','','','2020-08-14 18:14:35','2020-08-14 18:14:35','',0,'https://microbiozindia.com/?p=7018',0,'post','',0),(7019,2,'2020-08-14 18:14:35','2020-08-14 18:14:35','These cFluorM reagents, short for\"Cytek Fluorochrome,\" will be the culmination of years of expertise comprehension complete spectrum cytometry and the way fluorophores respond together in shape panels. Cytek\'s cFluor reagents are all validated on its own Cytek Aurora and Cytek Northern Lights cell evaluation systems to ensure optimum performance for its users at a multicolor atmosphere.\r\n\r\nCytek\'s cell analysis instruments use a distinctive optical and electronics design to reveal the full spectrum of each dye. This technology has allowed Cytek\'s scientists to not only completely characterize thousands of commercially available reagents, but also to identify and evaluate dyes and antibody conjugates that operate optimally with full spectrum evaluation about Cytek\'s flow cytometers.\r\n\r\nEvery one of these reagents provides Cytek\'s users the capability to show more from their whole spectrum panel with a new choice excitable from the yellow-green, blue, and red lasers, respectively. Other dyes at the cFluor family will be arriving shortly, with demonstrated ability to work in a pre-optimized panel.\r\n\r\n\"Starting with our full range tools, and today with our cFluor reagents, we are devoted to redefining what is possible in flow cytometry and supplying a entire solution to our users,\" says Wenbin Jiang, PhD, CEO of Cytek Biosciences. \"One of our users, 30+ colour panels are now more commonplace, which would have been inconceivable just two short years back. We\'re now focused on empowering them so that they can go much further with their unique, state-of-the-art cell analyzers, all with increased ease and shorter time to outcomes.\"\r\n\r\nFor more information, visit <a href=\"http://www.cytekbio.com/\">Cytek Biosciences</a>.\r\n\r\n<strong>Featured image:</strong> Cytek’s new cFluor family of reagents ensure optimal results for users of its Cytek Aurora and Cytek Northern Lights full spectrum cell analysis systems. Courtesy Cytek Biosciences.','Flow Cytometry Reagents Line introduced by Cytek','','inherit','closed','closed','','7018-revision-v1','','','2020-08-14 18:14:35','2020-08-14 18:14:35','',7018,'https://microbiozindia.com/uncategorized/7018-revision-v1/',0,'revision','',0),(7020,2,'2020-08-15 06:16:18','2020-08-15 06:16:18','Our mouths might be home to some recently discovered group of multi-tasking taste cells -;unlike most famous flavor cells, which discover individual preferences -;are effective at detecting sour, sweet, bitter and umami stimulation. A research team headed by Kathryn Medler at the University at Buffalo reports this discovery in a research published 13th August in PLOS Genetics.\r\n\r\nTaste buds in the mouth are critical to our survival and help us to decide whether or not a food is a good source of nourishment or a potential poison. To better understand how taste cells detect and indicate the presence of different tastes, the researchers used an engineered mouse model to investigate the signaling pathways which the animals use to relay taste information to the mind. They found a previously unknown subset of Type III cells that were\"widely responsive\" and may announce sour stimulation using one signaling pathway, also sweet, bitter and umami stimulation utilizing another.\r\n\r\n<em>Taste cells can be either selective or generally responsive to stimuli which is similar to the cells in the brain that process taste information. Future experiments will be focused on understanding how broadly responsive taste cells contribute to taste coding.\"-Kathryn Medler, Author</em>\r\n\r\nThe concept that mammals might possess broadly responsive taste cells has been put forth by multiple lab groups, but previously, no one had isolated and identified such cells. The researchers suspect that reactive cells make a substantial contribution to our ability to flavor. Their discovery offers new insight into the way that taste information is delivered to the brain for processing, also indicates that taste buds are far more complex than we now value.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.plos.org/\" target=\"_blank\" rel=\"noopener noreferrer\">PLOS</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nBanik, D.D., <em>et al.</em> (2020) A subset of broadly responsive Type III taste cells contribute to the detection of bitter, sweet and umami stimuli. <em>PLOS Genetics.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1371/journal.pgen.1008925\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1371/journal.pgen.1008925</a>.</span>\r\n\r\n</div>','Study recognizes new arrangement of performing multiple tasks taste cells','','publish','open','open','','study-recognizes-new-arrangement-of-performing-multiple-tasks-taste-cells','','','2020-08-15 06:16:18','2020-08-15 06:16:18','',0,'https://microbiozindia.com/?p=7020',0,'post','',0),(7021,2,'2020-08-15 06:15:56','2020-08-15 06:15:56','','download','','inherit','open','closed','','download-4','','','2020-08-15 06:15:56','2020-08-15 06:15:56','',7020,'https://microbiozindia.com/wp-content/uploads/2020/08/download.jpg',0,'attachment','image/jpeg',0),(7022,2,'2020-08-15 06:16:18','2020-08-15 06:16:18','Our mouths might be home to some recently discovered group of multi-tasking taste cells -;unlike most famous flavor cells, which discover individual preferences -;are effective at detecting sour, sweet, bitter and umami stimulation. A research team headed by Kathryn Medler at the University at Buffalo reports this discovery in a research published 13th August in PLOS Genetics.\r\n\r\nTaste buds in the mouth are critical to our survival and help us to decide whether or not a food is a good source of nourishment or a potential poison. To better understand how taste cells detect and indicate the presence of different tastes, the researchers used an engineered mouse model to investigate the signaling pathways which the animals use to relay taste information to the mind. They found a previously unknown subset of Type III cells that were\"widely responsive\" and may announce sour stimulation using one signaling pathway, also sweet, bitter and umami stimulation utilizing another.\r\n\r\n<em>Taste cells can be either selective or generally responsive to stimuli which is similar to the cells in the brain that process taste information. Future experiments will be focused on understanding how broadly responsive taste cells contribute to taste coding.\"-Kathryn Medler, Author</em>\r\n\r\nThe concept that mammals might possess broadly responsive taste cells has been put forth by multiple lab groups, but previously, no one had isolated and identified such cells. The researchers suspect that reactive cells make a substantial contribution to our ability to flavor. Their discovery offers new insight into the way that taste information is delivered to the brain for processing, also indicates that taste buds are far more complex than we now value.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.plos.org/\" target=\"_blank\" rel=\"noopener noreferrer\">PLOS</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nBanik, D.D., <em>et al.</em> (2020) A subset of broadly responsive Type III taste cells contribute to the detection of bitter, sweet and umami stimuli. <em>PLOS Genetics.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1371/journal.pgen.1008925\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1371/journal.pgen.1008925</a>.</span>\r\n\r\n</div>','Study recognizes new arrangement of performing multiple tasks taste cells','','inherit','closed','closed','','7020-revision-v1','','','2020-08-15 06:16:18','2020-08-15 06:16:18','',7020,'https://microbiozindia.com/uncategorized/7020-revision-v1/',0,'revision','',0),(7023,2,'2020-08-15 07:50:45','2020-08-15 07:50:45','In a study published in The Journal of Psychiatry, the team named social link as the strongest protective factor for depression, also suggested that reducing sedentary pursuits like TV watching and daytime napping could also help lower the risk of depression.\r\n\r\nTo this end, researchers took a two-stage strategy. The very first phase drew to a database of over 100,000 participants in the UK Biobank -- a world-renowned cohort study of adults - to systematically scan a broad range of modifiable factors that may be associated with the possibility of developing depression, such as social interaction, media use, sleep patterns, diet, physical activity, and environmental exposures. This method, called an exposure-wide institution scan (ExWAS), is analogous to genome-wide association studies (GWAS) which have been widely utilized to identify genetic risk factors for illness.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.massgeneral.org/news/press-release/Study-of-more-than-100-modifiable-factors-for-depression-identifies-social-connection-as-the-strongest-protective-factor\">The next stage took the strongest modifiable candidates from ExWAS and implemented a technique called Mendelian randomization (MR) to investigate which factors may have a causal relationship to depression risk.</a></span> MR is a statistical method that treats genetic difference between individuals as a sort of natural experiment to ascertain whether an association is likely to reflect causation rather than just correlation.\r\n\r\nThis two-stage approach enabled the MGH researchers to narrow the area to a more compact set of promising and potentially causal targets for melancholy. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.massgeneral.org/news/press-release/Study-of-more-than-100-modifiable-factors-for-depression-identifies-social-connection-as-the-strongest-protective-factor\">\"Far and away the most prominent of these factors was frequency of confiding in others, but also visits with family and friends, all which emphasized the important protective effect of social connection and social cohesion,\" points out Jordan Smoller, MD,</a> </span>ScD associate chief for research at the MGH Department of Psychiatry, and senior author of this analysis. The protective effects of social connection exist even for people who were at greater risk for depression as a result of genetic vulnerability or early life trauma.\r\n\r\nOn the flip side, factors related to depression danger included time spent viewing TV, although the authors note that further research is required to determine if that danger was due to media exposure per se or whether time in front of the TV was a proxy to be sedentary. Perhaps more surprising, the tendency for daytime napping and regular use of multivitamins appeared to be related to depression threat, though more research is required to ascertain how these might lead.\r\n\r\nThe MGH study demonstrates an important new approach for evaluating a wide assortment of modifiable factors, and using this proof to prioritize targets for preventive interventions for depression. \"Depression takes a huge toll on individuals, families, and society, however we still know very little about how to prevent it,\" says Smoller. \"We have shown that it is now possible to tackle these questions of public health significance through a large scale, data-based strategy that wasn\'t available even a few years back. We hope this work will motivate additional efforts to develop actionable strategies for preventing depression\" The study\'s two-stage approach could also be used to inform the avoidance of other health ailments.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.massgeneral.org/news/press-release/Study-of-more-than-100-modifiable-factors-for-depression-identifies-social-connection-as-the-strongest-protective-factor\" target=\"_blank\" rel=\"noopener noreferrer\">Massachusetts General Hospital</a></span>\r\n\r\n</div>','Social connection found to be the strongest protective factor for depression','','publish','open','open','','social-connection-found-to-be-the-strongest-protective-factor-for-depression','','','2020-08-15 07:50:45','2020-08-15 07:50:45','',0,'https://microbiozindia.com/?p=7023',0,'post','',0),(7024,2,'2020-08-15 07:50:38','2020-08-15 07:50:38','','despair-513529_640','','inherit','open','closed','','despair-513529_640','','','2020-08-15 07:50:38','2020-08-15 07:50:38','',7023,'https://microbiozindia.com/wp-content/uploads/2020/08/despair-513529_640.jpg',0,'attachment','image/jpeg',0),(7025,2,'2020-08-15 07:50:45','2020-08-15 07:50:45','In a study published in The Journal of Psychiatry, the team named social link as the strongest protective factor for depression, also suggested that reducing sedentary pursuits like TV watching and daytime napping could also help lower the risk of depression.\r\n\r\nTo this end, researchers took a two-stage strategy. The very first phase drew to a database of over 100,000 participants in the UK Biobank -- a world-renowned cohort study of adults - to systematically scan a broad range of modifiable factors that may be associated with the possibility of developing depression, such as social interaction, media use, sleep patterns, diet, physical activity, and environmental exposures. This method, called an exposure-wide institution scan (ExWAS), is analogous to genome-wide association studies (GWAS) which have been widely utilized to identify genetic risk factors for illness.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.massgeneral.org/news/press-release/Study-of-more-than-100-modifiable-factors-for-depression-identifies-social-connection-as-the-strongest-protective-factor\">The next stage took the strongest modifiable candidates from ExWAS and implemented a technique called Mendelian randomization (MR) to investigate which factors may have a causal relationship to depression risk.</a></span> MR is a statistical method that treats genetic difference between individuals as a sort of natural experiment to ascertain whether an association is likely to reflect causation rather than just correlation.\r\n\r\nThis two-stage approach enabled the MGH researchers to narrow the area to a more compact set of promising and potentially causal targets for melancholy. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.massgeneral.org/news/press-release/Study-of-more-than-100-modifiable-factors-for-depression-identifies-social-connection-as-the-strongest-protective-factor\">\"Far and away the most prominent of these factors was frequency of confiding in others, but also visits with family and friends, all which emphasized the important protective effect of social connection and social cohesion,\" points out Jordan Smoller, MD,</a> </span>ScD associate chief for research at the MGH Department of Psychiatry, and senior author of this analysis. The protective effects of social connection exist even for people who were at greater risk for depression as a result of genetic vulnerability or early life trauma.\r\n\r\nOn the flip side, factors related to depression danger included time spent viewing TV, although the authors note that further research is required to determine if that danger was due to media exposure per se or whether time in front of the TV was a proxy to be sedentary. Perhaps more surprising, the tendency for daytime napping and regular use of multivitamins appeared to be related to depression threat, though more research is required to ascertain how these might lead.\r\n\r\nThe MGH study demonstrates an important new approach for evaluating a wide assortment of modifiable factors, and using this proof to prioritize targets for preventive interventions for depression. \"Depression takes a huge toll on individuals, families, and society, however we still know very little about how to prevent it,\" says Smoller. \"We have shown that it is now possible to tackle these questions of public health significance through a large scale, data-based strategy that wasn\'t available even a few years back. We hope this work will motivate additional efforts to develop actionable strategies for preventing depression\" The study\'s two-stage approach could also be used to inform the avoidance of other health ailments.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.massgeneral.org/news/press-release/Study-of-more-than-100-modifiable-factors-for-depression-identifies-social-connection-as-the-strongest-protective-factor\" target=\"_blank\" rel=\"noopener noreferrer\">Massachusetts General Hospital</a></span>\r\n\r\n</div>','Social connection found to be the strongest protective factor for depression','','inherit','closed','closed','','7023-revision-v1','','','2020-08-15 07:50:45','2020-08-15 07:50:45','',7023,'https://microbiozindia.com/uncategorized/7023-revision-v1/',0,'revision','',0),(7026,2,'2020-08-15 16:37:58','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-15 16:37:58','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7026',0,'post','',0),(7027,2,'2020-08-15 16:40:12','2020-08-15 16:40:12','Russia has begun manufacturing its new vaccine for COVID-19, \'\' the Interfax news agency reported Saturday, citing the health ministry.\r\n\r\nRussia has said that the vaccine, developed by Moscow\'s Gamaleya Institute along with the earliest to the coronavirus to go into production, will be rolled out by the end of this month. Some scientists said they dread Moscow might be putting national prestige before security.','Russia begins production of COVID-19 immunization','','publish','open','open','','russia-begins-production-of-covid-19-immunization','','','2020-08-15 16:40:12','2020-08-15 16:40:12','',0,'https://microbiozindia.com/?p=7027',0,'post','',0),(7028,2,'2020-08-15 16:40:12','2020-08-15 16:40:12','Russia has begun manufacturing its new vaccine for COVID-19, \'\' the Interfax news agency reported Saturday, citing the health ministry.\r\n\r\nRussia has said that the vaccine, developed by Moscow\'s Gamaleya Institute along with the earliest to the coronavirus to go into production, will be rolled out by the end of this month. Some scientists said they dread Moscow might be putting national prestige before security.','Russia begins production of COVID-19 immunization','','inherit','closed','closed','','7027-revision-v1','','','2020-08-15 16:40:12','2020-08-15 16:40:12','',7027,'https://microbiozindia.com/uncategorized/7027-revision-v1/',0,'revision','',0),(7029,2,'2020-08-15 16:48:44','2020-08-15 16:48:44','Eric Ross and Sean Cascarina, natural chemistry and atomic science researchers at Colorado State University, have delivered an research paper distinguishing a protein encoded by SARS-CoV-2, the infection that causes COVID-19, that might be related with the snappy spread of the infection through cells in the human body.\r\n\r\nThrough ground-breaking utilization of the basic sciences and bioinformatic investigation, their examination features key attributes of the infection that might one be able to day be significant in the advancement of a treatment for COVID-19.\r\n\r\nBefore COVID-19, Ross and Cascarina had been contemplating prions - misfolded proteins that can communicate their irregular shape onto ordinary variations of a similar protein. Prions cause a few deadly and contagious neurodegenerative illnesses, remembering Mad Cow Disease for dairy cattle and Creutzfeldt-Jakob infection in people.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://natsci.source.colostate.edu/researchers-identify-a-protein-that-may-help-sars-cov-2-spread-rapidly-through-cells\"> Cascarina\'s sub-center has been around low-multifaceted nature spaces - districts in a protein\'s arrangement that vary from run of the mill locales in their amino corrosive structure and substance conduct.</a></span>\r\n\r\nWhat makes these low-multifaceted nature protein spaces fascinating is their inclination toward fluid stage division, like oil isolating from water. A portion of these proteins structure \"biomolecular condensates\" in a cell, which are little regions in a cell where the protein is profoundly focused, comparable to the oil beads that structure when oil isolates from water.\r\n\r\n<strong>Making new virus packages</strong>\r\n\r\nAt the point when Ross and Cascarina rotated to examine COVID-19 recently, they found that the nucleocapsid, or N, protein in the SARS-CoV-2 infection has a low-multifaceted nature area that may use fluid stage partition to encourage the bundling of viral RNA into new infection particles that can contaminate neighboring cells.\r\n\r\nThe N protein may likewise be related with diminishing a contaminated cell\'s enemy of viral pressure reaction. Cells regularly structure something many refer to as pressure granules, a sort of biomolecular condensate, to react to an adjustment in their condition, and these granules may have an enemy of viral impact. \"The cell can respond to a pressure occasion by making changes in the cell condition,\" said Ross, \"counting making these alterations to certain proteins.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://natsci.source.colostate.edu/researchers-identify-a-protein-that-may-help-sars-cov-2-spread-rapidly-through-cells\">\"Be that as it may, infections clearly need to maintain a strategic distance from a cell\'s guards,\" Cascarina included. \"They need to be irresistible, so now and again they can control these pressure granules.\" By commandeering the typical pressure reaction, the infection might have the option to diminish the phone\'s antiviral reaction abilities.</a></span>\r\n\r\nSince the acknowledgment of their paper on May 31, four different labs the nation over have affirmed portions of Cascarina\'s theory about the N protein.The utilization of this examination could be for the improvement of medicines once an individual has just gotten the infection, instead of forestalling contamination like an antibody. Both of these territories of examination are fundamental to slow and finishing the COVID-19 pandemic.\r\n\r\n<em>Medically, if you could counteract the virus\' ability to interfere with a cell\'s immune response, then you could help the cells to fight off the virus. I think this falls into the category of very basic science: if we understand the viral process, then conceivably we can try to design a drug that reverses that process.\"</em>\r\n\r\n<em>Eric Ross, Researcher. Department of Biochemistry and Molecular Biology, Colorado State University</em>\r\n\r\n<strong>Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://natsci.source.colostate.edu/researchers-identify-a-protein-that-may-help-sars-cov-2-spread-rapidly-through-cells\">Colorado State University</a></span>\r\n\r\n<strong>Journal reference:</strong>\r\n\r\nCascarina, S, M &amp; Ross, E, D. (2020) A proposed role for the SARS‐CoV‐2 nucleocapsid protein in the formation and regulation of biomolecular condensates. <em>FASEB Journal</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1096/fj.202001351\">doi.org/10.1096/fj.202001351.</a></span>','Scientists recognize a protein that encourages spread of covid-19 infection through cells','','publish','open','open','','scientists-recognize-a-protein-that-encourages-spread-of-covid-19-infection-through-cells','','','2020-08-15 16:48:44','2020-08-15 16:48:44','',0,'https://microbiozindia.com/?p=7029',0,'post','',0),(7030,2,'2020-08-15 16:48:44','2020-08-15 16:48:44','Eric Ross and Sean Cascarina, natural chemistry and atomic science researchers at Colorado State University, have delivered an research paper distinguishing a protein encoded by SARS-CoV-2, the infection that causes COVID-19, that might be related with the snappy spread of the infection through cells in the human body.\r\n\r\nThrough ground-breaking utilization of the basic sciences and bioinformatic investigation, their examination features key attributes of the infection that might one be able to day be significant in the advancement of a treatment for COVID-19.\r\n\r\nBefore COVID-19, Ross and Cascarina had been contemplating prions - misfolded proteins that can communicate their irregular shape onto ordinary variations of a similar protein. Prions cause a few deadly and contagious neurodegenerative illnesses, remembering Mad Cow Disease for dairy cattle and Creutzfeldt-Jakob infection in people.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://natsci.source.colostate.edu/researchers-identify-a-protein-that-may-help-sars-cov-2-spread-rapidly-through-cells\"> Cascarina\'s sub-center has been around low-multifaceted nature spaces - districts in a protein\'s arrangement that vary from run of the mill locales in their amino corrosive structure and substance conduct.</a></span>\r\n\r\nWhat makes these low-multifaceted nature protein spaces fascinating is their inclination toward fluid stage division, like oil isolating from water. A portion of these proteins structure \"biomolecular condensates\" in a cell, which are little regions in a cell where the protein is profoundly focused, comparable to the oil beads that structure when oil isolates from water.\r\n\r\n<strong>Making new virus packages</strong>\r\n\r\nAt the point when Ross and Cascarina rotated to examine COVID-19 recently, they found that the nucleocapsid, or N, protein in the SARS-CoV-2 infection has a low-multifaceted nature area that may use fluid stage partition to encourage the bundling of viral RNA into new infection particles that can contaminate neighboring cells.\r\n\r\nThe N protein may likewise be related with diminishing a contaminated cell\'s enemy of viral pressure reaction. Cells regularly structure something many refer to as pressure granules, a sort of biomolecular condensate, to react to an adjustment in their condition, and these granules may have an enemy of viral impact. \"The cell can respond to a pressure occasion by making changes in the cell condition,\" said Ross, \"counting making these alterations to certain proteins.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://natsci.source.colostate.edu/researchers-identify-a-protein-that-may-help-sars-cov-2-spread-rapidly-through-cells\">\"Be that as it may, infections clearly need to maintain a strategic distance from a cell\'s guards,\" Cascarina included. \"They need to be irresistible, so now and again they can control these pressure granules.\" By commandeering the typical pressure reaction, the infection might have the option to diminish the phone\'s antiviral reaction abilities.</a></span>\r\n\r\nSince the acknowledgment of their paper on May 31, four different labs the nation over have affirmed portions of Cascarina\'s theory about the N protein.The utilization of this examination could be for the improvement of medicines once an individual has just gotten the infection, instead of forestalling contamination like an antibody. Both of these territories of examination are fundamental to slow and finishing the COVID-19 pandemic.\r\n\r\n<em>Medically, if you could counteract the virus\' ability to interfere with a cell\'s immune response, then you could help the cells to fight off the virus. I think this falls into the category of very basic science: if we understand the viral process, then conceivably we can try to design a drug that reverses that process.\"</em>\r\n\r\n<em>Eric Ross, Researcher. Department of Biochemistry and Molecular Biology, Colorado State University</em>\r\n\r\n<strong>Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://natsci.source.colostate.edu/researchers-identify-a-protein-that-may-help-sars-cov-2-spread-rapidly-through-cells\">Colorado State University</a></span>\r\n\r\n<strong>Journal reference:</strong>\r\n\r\nCascarina, S, M &amp; Ross, E, D. (2020) A proposed role for the SARS‐CoV‐2 nucleocapsid protein in the formation and regulation of biomolecular condensates. <em>FASEB Journal</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1096/fj.202001351\">doi.org/10.1096/fj.202001351.</a></span>','Scientists recognize a protein that encourages spread of covid-19 infection through cells','','inherit','closed','closed','','7029-revision-v1','','','2020-08-15 16:48:44','2020-08-15 16:48:44','',7029,'https://microbiozindia.com/uncategorized/7029-revision-v1/',0,'revision','',0),(7031,2,'2020-08-16 08:10:33','2020-08-16 08:10:33','Although studies about assistive navigation and technologies are becoming more popular in recent decades, the researchers assert that current studies have been too narrow in its perspective of people with disabilities.\r\n\r\nFor this particular study, researchers worked with technology users with a broad and diverse range of disabilities to discover similarities and differences in their own navigation tastes. Then they used those findings to create a schema that can inform the design of future technologies.\r\n\r\nThe project was led by Maya Gupta, an alumna of UMBC\'s data systems program and current UCI graduate student in informatics; Ravi Kuber, associate professor of information systems in UMBC; and Stacy Branham, assistant professor of informatics at UCI. The study was accepted from the 2020 Conference on Human Factors in Computing Systems (CHI 2020).\r\n\r\nAlthough the conference was cancelled because of COVID-19, the study was published in online conference event and made accessible as a digital presentation on May 20. The research was funded by Toyota, as part of the University Mobility Challenge to improve navigation experiences.\r\n\r\nThe participants in this research have visual, mobility, cognitive, and hearing disabilities, in addition to disabilities related to aging.\r\n\r\n<em>We greatly believe that understanding common needs of different groups will eventually lead to a more universal design for future technologies towards having more equal life experience in the society.\"Ali Abdolrahmani, UMBC Ph.D. student</em>\r\n\r\nIn the information, the researchers could identify main themes within the navigation techniques used by people within this study. They revealed crucial similarities in preferences across individuals with various types of disabilities, such as experiencing difficulty navigating in the existence of a massive crowd. In addition they noted key differences in tastes, such as proximity of visitors. By way of instance, individuals with visual impairments preferred to utilize the sound of nearby traffic for a way of maintaining to a straight path, but it induced distraction and disorientation for others.\r\n\r\nBased on the preferences of their research participants, the researchers were able to identify a schema for designers to use so as to think about the consumer experience for people with a range of abilities. This fits inside a relevant trend in technology design: universal usability. Having the ability to make navigation technologies which are useable for as broad and diverse a population as possible helps to promote accessibility for all users. It also reduces stigma against people with diverse skills.\r\nUMBC Ph.D. student Ali Abdolrahmani, that has assisted in conducting interviews with participants and analyzing the collected data, has a private interest in expanding technologies for those who have disabilities, as he explains as blind.\r\n\r\nThe findings of the research may be used to produce prototypes and systems that better support navigation according to an individual\'s preferences.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.umbc.edu/\" target=\"_blank\" rel=\"noopener noreferrer\">University of Maryland Baltimore County</a></span>\r\n\r\n</div>','Researchers create a Layout schema for navigation technologies to Assist Individuals with disabilities','','publish','open','open','','researchers-create-a-layout-schema-for-navigation-technologies-to-assist-individuals-with-disabilities','','','2020-08-16 08:11:40','2020-08-16 08:11:40','',0,'https://microbiozindia.com/?p=7031',0,'post','',0),(7032,2,'2020-08-16 08:10:19','2020-08-16 08:10:19','','marketing-to-people-with-disabilities','','inherit','open','closed','','marketing-to-people-with-disabilities','','','2020-08-16 08:10:19','2020-08-16 08:10:19','',7031,'https://microbiozindia.com/wp-content/uploads/2020/08/marketing-to-people-with-disabilities.jpeg',0,'attachment','image/jpeg',0),(7033,2,'2020-08-16 08:10:33','2020-08-16 08:10:33','Although studies about assistive navigation and technologies are becoming more popular in recent decades, the researchers assert that current studies have been too narrow in its perspective of people with disabilities.\r\n\r\nFor this particular study, researchers worked with technology users with a broad and diverse range of disabilities to discover similarities and differences in their own navigation tastes. Then they used those findings to create a schema that can inform the design of future technologies.\r\n\r\nThe project was led by Maya Gupta, an alumna of UMBC\'s data systems program and current UCI graduate student in informatics; Ravi Kuber, associate professor of information systems in UMBC; and Stacy Branham, assistant professor of informatics at UCI. The study was accepted from the 2020 Conference on Human Factors in Computing Systems (CHI 2020).\r\n\r\nAlthough the conference was cancelled because of COVID-19, the study was published in online conference event and made accessible as a digital presentation on May 20. The research was funded by Toyota, as part of the University Mobility Challenge to improve navigation experiences.\r\n\r\nThe participants in this research have visual, mobility, cognitive, and hearing disabilities, in addition to disabilities related to aging.\r\n\r\n<em>We greatly believe that understanding common needs of different groups will eventually lead to a more universal design for future technologies towards having more equal life experience in the society.\"Ali Abdolrahmani, UMBC Ph.D. student</em>\r\n\r\nIn the information, the researchers could identify main themes within the navigation techniques used by people within this study. They revealed crucial similarities in preferences across individuals with various types of disabilities, such as experiencing difficulty navigating in the existence of a massive crowd. In addition they noted key differences in tastes, such as proximity of visitors. By way of instance, individuals with visual impairments preferred to utilize the sound of nearby traffic for a way of maintaining to a straight path, but it induced distraction and disorientation for others.\r\n\r\nBased on the preferences of their research participants, the researchers were able to identify a schema for designers to use so as to think about the consumer experience for people with a range of abilities. This fits inside a relevant trend in technology design: universal usability. Having the ability to make navigation technologies which are useable for as broad and diverse a population as possible helps to promote accessibility for all users. It also reduces stigma against people with diverse skills.\r\nUMBC Ph.D. student Ali Abdolrahmani, that has assisted in conducting interviews with participants and analyzing the collected data, has a private interest in expanding technologies for those who have disabilities, as he explains as blind.\r\n\r\nThe findings of the research may be used to produce prototypes and systems that better support navigation according to an individual\'s preferences.','Researchers create a Layout schema for navigation technologies to Assist Individuals with disabilities','','inherit','closed','closed','','7031-revision-v1','','','2020-08-16 08:10:33','2020-08-16 08:10:33','',7031,'https://microbiozindia.com/uncategorized/7031-revision-v1/',0,'revision','',0),(7034,2,'2020-08-16 08:11:37','2020-08-16 08:11:37','Although studies about assistive navigation and technologies are becoming more popular in recent decades, the researchers assert that current studies have been too narrow in its perspective of people with disabilities.\n\nFor this particular study, researchers worked with technology users with a broad and diverse range of disabilities to discover similarities and differences in their own navigation tastes. Then they used those findings to create a schema that can inform the design of future technologies.\n\nThe project was led by Maya Gupta, an alumna of UMBC\'s data systems program and current UCI graduate student in informatics; Ravi Kuber, associate professor of information systems in UMBC; and Stacy Branham, assistant professor of informatics at UCI. The study was accepted from the 2020 Conference on Human Factors in Computing Systems (CHI 2020).\n\nAlthough the conference was cancelled because of COVID-19, the study was published in online conference event and made accessible as a digital presentation on May 20. The research was funded by Toyota, as part of the University Mobility Challenge to improve navigation experiences.\n\nThe participants in this research have visual, mobility, cognitive, and hearing disabilities, in addition to disabilities related to aging.\n\n<em>We greatly believe that understanding common needs of different groups will eventually lead to a more universal design for future technologies towards having more equal life experience in the society.\"Ali Abdolrahmani, UMBC Ph.D. student</em>\n\nIn the information, the researchers could identify main themes within the navigation techniques used by people within this study. They revealed crucial similarities in preferences across individuals with various types of disabilities, such as experiencing difficulty navigating in the existence of a massive crowd. In addition they noted key differences in tastes, such as proximity of visitors. By way of instance, individuals with visual impairments preferred to utilize the sound of nearby traffic for a way of maintaining to a straight path, but it induced distraction and disorientation for others.\n\nBased on the preferences of their research participants, the researchers were able to identify a schema for designers to use so as to think about the consumer experience for people with a range of abilities. This fits inside a relevant trend in technology design: universal usability. Having the ability to make navigation technologies which are useable for as broad and diverse a population as possible helps to promote accessibility for all users. It also reduces stigma against people with diverse skills.\nUMBC Ph.D. student Ali Abdolrahmani, that has assisted in conducting interviews with participants and analyzing the collected data, has a private interest in expanding technologies for those who have disabilities, as he explains as blind.\n\nThe findings of the research may be used to produce prototypes and systems that better support navigation according to an individual\'s preferences.\n<div class=\"content-src-label\"><strong>Source:</strong></div>\n<div class=\"content-src-value\">\n\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.umbc.edu/\" target=\"_blank\" rel=\"noopener noreferrer\">University of Maryland Baltimore County</a></span>\n\n</div>','Researchers create a Layout schema for navigation technologies to Assist Individuals with disabilities','','inherit','closed','closed','','7031-autosave-v1','','','2020-08-16 08:11:37','2020-08-16 08:11:37','',7031,'https://microbiozindia.com/uncategorized/7031-autosave-v1/',0,'revision','',0),(7035,2,'2020-08-16 08:11:40','2020-08-16 08:11:40','Although studies about assistive navigation and technologies are becoming more popular in recent decades, the researchers assert that current studies have been too narrow in its perspective of people with disabilities.\r\n\r\nFor this particular study, researchers worked with technology users with a broad and diverse range of disabilities to discover similarities and differences in their own navigation tastes. Then they used those findings to create a schema that can inform the design of future technologies.\r\n\r\nThe project was led by Maya Gupta, an alumna of UMBC\'s data systems program and current UCI graduate student in informatics; Ravi Kuber, associate professor of information systems in UMBC; and Stacy Branham, assistant professor of informatics at UCI. The study was accepted from the 2020 Conference on Human Factors in Computing Systems (CHI 2020).\r\n\r\nAlthough the conference was cancelled because of COVID-19, the study was published in online conference event and made accessible as a digital presentation on May 20. The research was funded by Toyota, as part of the University Mobility Challenge to improve navigation experiences.\r\n\r\nThe participants in this research have visual, mobility, cognitive, and hearing disabilities, in addition to disabilities related to aging.\r\n\r\n<em>We greatly believe that understanding common needs of different groups will eventually lead to a more universal design for future technologies towards having more equal life experience in the society.\"Ali Abdolrahmani, UMBC Ph.D. student</em>\r\n\r\nIn the information, the researchers could identify main themes within the navigation techniques used by people within this study. They revealed crucial similarities in preferences across individuals with various types of disabilities, such as experiencing difficulty navigating in the existence of a massive crowd. In addition they noted key differences in tastes, such as proximity of visitors. By way of instance, individuals with visual impairments preferred to utilize the sound of nearby traffic for a way of maintaining to a straight path, but it induced distraction and disorientation for others.\r\n\r\nBased on the preferences of their research participants, the researchers were able to identify a schema for designers to use so as to think about the consumer experience for people with a range of abilities. This fits inside a relevant trend in technology design: universal usability. Having the ability to make navigation technologies which are useable for as broad and diverse a population as possible helps to promote accessibility for all users. It also reduces stigma against people with diverse skills.\r\nUMBC Ph.D. student Ali Abdolrahmani, that has assisted in conducting interviews with participants and analyzing the collected data, has a private interest in expanding technologies for those who have disabilities, as he explains as blind.\r\n\r\nThe findings of the research may be used to produce prototypes and systems that better support navigation according to an individual\'s preferences.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.umbc.edu/\" target=\"_blank\" rel=\"noopener noreferrer\">University of Maryland Baltimore County</a></span>\r\n\r\n</div>','Researchers create a Layout schema for navigation technologies to Assist Individuals with disabilities','','inherit','closed','closed','','7031-revision-v1','','','2020-08-16 08:11:40','2020-08-16 08:11:40','',7031,'https://microbiozindia.com/uncategorized/7031-revision-v1/',0,'revision','',0),(7036,2,'2020-08-16 09:05:51','2020-08-16 09:05:51','An vaccine candidate against the publication coronavirus or SARS-Cov-2, developed by Sinopharm, has demonstrated promising effects in immune reaction trials, researchers assert.\r\n\r\nThe vaccine candidate is apparently secure and have triggered antibody-based immune reaction in ancient and mid-stage trials and has been moved into late-stage trials for regulatory acceptance, the Hindustan Times reported.\r\n\r\nAccording to a newspaper released by Sinopharm scientists and disease management authorities from China from the Journal of the American Medical Association, Stage 1 and 2 evaluations results in 320 healthy adults revealed the candidate vaccine didn\'t have any severe side effects.\r\n\r\nThe business is forecast to test 15,000 men and women in the Phase 3 trials, \'\' the report stated.\r\n\r\nAccording to a trial arrangement, the business will also furnish candidate dosages to Pakistan.\r\n\r\nAmerica said it would guarantee all taxpayers receive free vaccination after a prosperous COVID-19 vaccine comes up. Senior Health Department official Paul Mango nevertheless said that regulatory approval and evaluation procedures would continue to become strict.','Coronavirus vaccine Offender in China Reveals immune Reaction, enters Stage 3 trial','','publish','open','open','','coronavirus-vaccine-offender-in-china-reveals-immune-reaction-enters-stage-3-trial','','','2020-08-16 09:05:51','2020-08-16 09:05:51','',0,'https://microbiozindia.com/?p=7036',0,'post','',0),(7037,2,'2020-08-16 09:05:51','2020-08-16 09:05:51','An vaccine candidate against the publication coronavirus or SARS-Cov-2, developed by Sinopharm, has demonstrated promising effects in immune reaction trials, researchers assert.\r\n\r\nThe vaccine candidate is apparently secure and have triggered antibody-based immune reaction in ancient and mid-stage trials and has been moved into late-stage trials for regulatory acceptance, the Hindustan Times reported.\r\n\r\nAccording to a newspaper released by Sinopharm scientists and disease management authorities from China from the Journal of the American Medical Association, Stage 1 and 2 evaluations results in 320 healthy adults revealed the candidate vaccine didn\'t have any severe side effects.\r\n\r\nThe business is forecast to test 15,000 men and women in the Phase 3 trials, \'\' the report stated.\r\n\r\nAccording to a trial arrangement, the business will also furnish candidate dosages to Pakistan.\r\n\r\nAmerica said it would guarantee all taxpayers receive free vaccination after a prosperous COVID-19 vaccine comes up. Senior Health Department official Paul Mango nevertheless said that regulatory approval and evaluation procedures would continue to become strict.','Coronavirus vaccine Offender in China Reveals immune Reaction, enters Stage 3 trial','','inherit','closed','closed','','7036-revision-v1','','','2020-08-16 09:05:51','2020-08-16 09:05:51','',7036,'https://microbiozindia.com/uncategorized/7036-revision-v1/',0,'revision','',0),(7038,2,'2020-08-16 09:12:38','2020-08-16 09:12:38','New Delhi, Aug 16 (PTI) Medicine manufacturer Ipca Laboratories is in the process of getting environmental clearance for a new production plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report.\r\nSharing information with the firm\"s shareholders, the drug maker said the company has already acquired land to the job.\r\n\r\n\"The organization is in the process of setting up a brand new API (active pharmaceutical ingredients) manufacturing unit in Dewas (MP) having an initial capital cost of about Rs 250 crore,\" the Mumbai-based drug manufacturer said adding it is now in process of obtaining the environmental approvals.\r\n\r\nCurrently, Ipca Laboratories generates over 80 APIs in 12 production facilities, accounting for nearly 25 per of its turnover.\r\n\r\nThe company is also a major exporter of all APIs to over 70 nations.\r\n\r\nDuring 2019-20, the company\"s API and intermediate business recorded revenue of Rs 1,173.13 crore as against Rs 884.56 crore in the previous fiscal year, thus registering an increase of 33 per cent.\r\n\r\nAround, 79 percent of the firm\"s API/intermediate business is now generated from export markets.\r\n\r\nThe company also has substantial existence in branded formulations in India using a portfolio of about 350 merchandise.\r\n\r\nThe drug company has presence across various foreign markets too including the US, with a variety of generic products.\r\n\r\nFor 2019-20, overall income of the business on a combined basis stood at Rs 4,715.71 crore, up 23 percent from Rs 3,830.86 crore in the last financial year.\r\n\r\nAccording to the business outlook, the business stated that domestic pharmaceutical firms were focusing on global generic and API organization, R&amp;D actions, contract research and production alliances.\r\n\r\nIndia is also quickly emerging as a favorite manufacturing location for pharma products, hence the industry is poised for an accelerated increase in the coming years, it mentioned.\r\n\r\n\"But, poor public healthcare financing and infrastructure, reduce per capita consumption of drugs in developing and under-developed countries including India, currency changes, regulatory issues, government mandated price controls, inflation and consequent all round increase in input prices are several causes of concern,\" it noted.\r\n\r\nOn regulatory issues, the business said the US Food and Drug Adminisration (USFDA) recently inspected the company\"s formulations manufacturing unit situated at Piparia (Silvassa).\r\n\r\n\"This review resulted to issue of 3 observations in Form 483 from USFDA. Your organization has filed comprehensive response to such observations to the USFDA. The company is awaiting re-inspection by USFDA of its other two manufacturing facilities which are under export alert,\" it noted. PTI MSS MKJ','In procedure of acquiring natural freedom for new plant in Madhya Pradesh: Ipca Labs','','publish','open','open','','in-procedure-of-acquiring-natural-freedom-for-new-plant-in-madhya-pradesh-ipca-labs','','','2020-08-16 09:12:38','2020-08-16 09:12:38','',0,'https://microbiozindia.com/?p=7038',0,'post','',0),(7039,2,'2020-08-16 09:12:22','2020-08-16 09:12:22','','Ipca_Logo_JPG','','inherit','open','closed','','ipca_logo_jpg','','','2020-08-16 09:12:22','2020-08-16 09:12:22','',7038,'https://microbiozindia.com/wp-content/uploads/2020/08/Ipca_Logo_JPG.jpg',0,'attachment','image/jpeg',0),(7040,2,'2020-08-16 09:12:38','2020-08-16 09:12:38','New Delhi, Aug 16 (PTI) Medicine manufacturer Ipca Laboratories is in the process of getting environmental clearance for a new production plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report.\r\nSharing information with the firm\"s shareholders, the drug maker said the company has already acquired land to the job.\r\n\r\n\"The organization is in the process of setting up a brand new API (active pharmaceutical ingredients) manufacturing unit in Dewas (MP) having an initial capital cost of about Rs 250 crore,\" the Mumbai-based drug manufacturer said adding it is now in process of obtaining the environmental approvals.\r\n\r\nCurrently, Ipca Laboratories generates over 80 APIs in 12 production facilities, accounting for nearly 25 per of its turnover.\r\n\r\nThe company is also a major exporter of all APIs to over 70 nations.\r\n\r\nDuring 2019-20, the company\"s API and intermediate business recorded revenue of Rs 1,173.13 crore as against Rs 884.56 crore in the previous fiscal year, thus registering an increase of 33 per cent.\r\n\r\nAround, 79 percent of the firm\"s API/intermediate business is now generated from export markets.\r\n\r\nThe company also has substantial existence in branded formulations in India using a portfolio of about 350 merchandise.\r\n\r\nThe drug company has presence across various foreign markets too including the US, with a variety of generic products.\r\n\r\nFor 2019-20, overall income of the business on a combined basis stood at Rs 4,715.71 crore, up 23 percent from Rs 3,830.86 crore in the last financial year.\r\n\r\nAccording to the business outlook, the business stated that domestic pharmaceutical firms were focusing on global generic and API organization, R&amp;D actions, contract research and production alliances.\r\n\r\nIndia is also quickly emerging as a favorite manufacturing location for pharma products, hence the industry is poised for an accelerated increase in the coming years, it mentioned.\r\n\r\n\"But, poor public healthcare financing and infrastructure, reduce per capita consumption of drugs in developing and under-developed countries including India, currency changes, regulatory issues, government mandated price controls, inflation and consequent all round increase in input prices are several causes of concern,\" it noted.\r\n\r\nOn regulatory issues, the business said the US Food and Drug Adminisration (USFDA) recently inspected the company\"s formulations manufacturing unit situated at Piparia (Silvassa).\r\n\r\n\"This review resulted to issue of 3 observations in Form 483 from USFDA. Your organization has filed comprehensive response to such observations to the USFDA. The company is awaiting re-inspection by USFDA of its other two manufacturing facilities which are under export alert,\" it noted. PTI MSS MKJ','In procedure of acquiring natural freedom for new plant in Madhya Pradesh: Ipca Labs','','inherit','closed','closed','','7038-revision-v1','','','2020-08-16 09:12:38','2020-08-16 09:12:38','',7038,'https://microbiozindia.com/uncategorized/7038-revision-v1/',0,'revision','',0),(7041,2,'2020-08-16 09:14:26','2020-08-16 09:14:26','Houston, Aug 16 (PTI) The US health watchdog has authorised the emergency use of some new and expensive saliva established laboratory diagnostic test for COVID-19 which might be a game changer in the identification of the infection because it will enable rapid testing among more people easily.\r\nStephen Hahn, the Food and Drugs Administration Commissioner, stated that the new saliva test will increase efficiency and prevent shortage of vital evaluation components including reagents.\r\n\r\n\"Providing this kind of endurance for processing saliva samples to test for COVID-19 disease is groundbreaking in terms of efficacy and preventing shortages of critical evaluation elements such as reagents,\" he said in an announcement.\r\n\r\nThe bureau has previously authorised four additional tests which use spit for sampling, however these yielded varying results. Authorisation of this new evaluation occurs amid ongoing disarray over COVID-19 testing.\r\n\r\nThe US has been plagued by an inconsistent plan for detecting the virus, thanks partly to persistent shortages and also the use of a number of unique tests which have occasionally yielded devastating consequences.\r\n\r\nThe new method named SalivaDirect has been further confirmed as a test for asymptomatic people through a programme that assesses players and personnel in the National Basketball Association (NBA).\r\n\r\nResults so far have found that SalivaDirect is highly sensitive and yields similar results as NP swabbing.\r\n\r\nWith the FDA\'s emergency use authorisation, the testing technique is immediately available to additional diagnostic labs that are looking to start using the new evaluation, which is scaled up quickly for use throughout the country and, possibly, beyond -- in the coming weeks, researchers said.\r\n\r\nA key part of SalivaDirect, the researchers note, is that the procedure has been validated with reagents and instruments from several vendors.\r\n\r\nThis flexibility enables continued testing if some vendors experience supply chain issues as experienced in the pandemic.\r\n\r\n\"This started off as an idea in our laboratory shortly after we found saliva to be a promising sample sort of the detection of SARS-CoV-2, and it has the capacity to be employed on a massive scale to help safeguard public health. We\'re delighted to make this contribution to the fight against coronavirus,\" he said.\r\n\r\nImprovement of SalivaDirect as a means of quickly expanding SARS-CoV-2 testing was spearheaded this spring by Nathan Grubaugh and Anne Wyllie, assistant professor and associate researcher, respectively, at Yale School of Public Health.\r\n\r\nAfter discovering spit for a promising sample form for SARS-CoV-2 detection, they wanted to improve the procedure further.\r\n\r\n\"With saliva being quick and simple to collect, we realised that it might be a game-changer at COVID-19 diagnostics,\" said Wyllie.\r\n\r\nWith testing desperately required, the Yale group was decided to decrease both testing times and prices, to make testing broadly accessible.\r\n\r\n\"Wide-spread testing is critical for our control efforts. We assessed the test so that it just costs a few dollars for reagents and also we expect that labs will only charge approximately USD 10 percent sample. If cheap alternatives like SalivaDirect can be put into place throughout the nation, we may finally get a handle on this pandemic, even before a vaccine,\" explained Grubaugh.\r\n\r\nGrubaugh and Wyllie stated that they aren\'t trying to commercialise the procedure rather need the simplified testing approach to help those most in need.\r\n\r\nTesting for SARS-CoV-2 was a significant stumbling block in the fight against the outbreak, with lengthy delays and shortages of testing.\r\n\r\nSome experts have said that up to 4 million tests are needed daily and SalivaDirect supplies one particular pathway toward this goal, the investigators said.\r\n\r\n\"With SalivaDirectour laboratory can double our testing capability,\" said Professor Chen Liu, seat of Yale Pathology, who oversaw the clinical analysis of the analysis.\r\n\r\nGlobally, coronavirus has infected 20,950,402 people while the disease has killed to date 760,213 many others. PTI SHK RUP RUP','USFDA clears basic salivation test for quicker identification of COVID-19','','publish','open','open','','usfda-clears-basic-salivation-test-for-quicker-identification-of-covid-19','','','2020-08-16 09:14:26','2020-08-16 09:14:26','',0,'https://microbiozindia.com/?p=7041',0,'post','',0),(7042,2,'2020-08-16 09:13:57','2020-08-16 09:13:57','','spit-test-nut-l','','inherit','open','closed','','spit-test-nut-l','','','2020-08-16 09:13:57','2020-08-16 09:13:57','',7041,'https://microbiozindia.com/wp-content/uploads/2020/08/spit-test-nut-l.jpg',0,'attachment','image/jpeg',0),(7043,2,'2020-08-16 09:14:26','2020-08-16 09:14:26','Houston, Aug 16 (PTI) The US health watchdog has authorised the emergency use of some new and expensive saliva established laboratory diagnostic test for COVID-19 which might be a game changer in the identification of the infection because it will enable rapid testing among more people easily.\r\nStephen Hahn, the Food and Drugs Administration Commissioner, stated that the new saliva test will increase efficiency and prevent shortage of vital evaluation components including reagents.\r\n\r\n\"Providing this kind of endurance for processing saliva samples to test for COVID-19 disease is groundbreaking in terms of efficacy and preventing shortages of critical evaluation elements such as reagents,\" he said in an announcement.\r\n\r\nThe bureau has previously authorised four additional tests which use spit for sampling, however these yielded varying results. Authorisation of this new evaluation occurs amid ongoing disarray over COVID-19 testing.\r\n\r\nThe US has been plagued by an inconsistent plan for detecting the virus, thanks partly to persistent shortages and also the use of a number of unique tests which have occasionally yielded devastating consequences.\r\n\r\nThe new method named SalivaDirect has been further confirmed as a test for asymptomatic people through a programme that assesses players and personnel in the National Basketball Association (NBA).\r\n\r\nResults so far have found that SalivaDirect is highly sensitive and yields similar results as NP swabbing.\r\n\r\nWith the FDA\'s emergency use authorisation, the testing technique is immediately available to additional diagnostic labs that are looking to start using the new evaluation, which is scaled up quickly for use throughout the country and, possibly, beyond -- in the coming weeks, researchers said.\r\n\r\nA key part of SalivaDirect, the researchers note, is that the procedure has been validated with reagents and instruments from several vendors.\r\n\r\nThis flexibility enables continued testing if some vendors experience supply chain issues as experienced in the pandemic.\r\n\r\n\"This started off as an idea in our laboratory shortly after we found saliva to be a promising sample sort of the detection of SARS-CoV-2, and it has the capacity to be employed on a massive scale to help safeguard public health. We\'re delighted to make this contribution to the fight against coronavirus,\" he said.\r\n\r\nImprovement of SalivaDirect as a means of quickly expanding SARS-CoV-2 testing was spearheaded this spring by Nathan Grubaugh and Anne Wyllie, assistant professor and associate researcher, respectively, at Yale School of Public Health.\r\n\r\nAfter discovering spit for a promising sample form for SARS-CoV-2 detection, they wanted to improve the procedure further.\r\n\r\n\"With saliva being quick and simple to collect, we realised that it might be a game-changer at COVID-19 diagnostics,\" said Wyllie.\r\n\r\nWith testing desperately required, the Yale group was decided to decrease both testing times and prices, to make testing broadly accessible.\r\n\r\n\"Wide-spread testing is critical for our control efforts. We assessed the test so that it just costs a few dollars for reagents and also we expect that labs will only charge approximately USD 10 percent sample. If cheap alternatives like SalivaDirect can be put into place throughout the nation, we may finally get a handle on this pandemic, even before a vaccine,\" explained Grubaugh.\r\n\r\nGrubaugh and Wyllie stated that they aren\'t trying to commercialise the procedure rather need the simplified testing approach to help those most in need.\r\n\r\nTesting for SARS-CoV-2 was a significant stumbling block in the fight against the outbreak, with lengthy delays and shortages of testing.\r\n\r\nSome experts have said that up to 4 million tests are needed daily and SalivaDirect supplies one particular pathway toward this goal, the investigators said.\r\n\r\n\"With SalivaDirectour laboratory can double our testing capability,\" said Professor Chen Liu, seat of Yale Pathology, who oversaw the clinical analysis of the analysis.\r\n\r\nGlobally, coronavirus has infected 20,950,402 people while the disease has killed to date 760,213 many others. PTI SHK RUP RUP','USFDA clears basic salivation test for quicker identification of COVID-19','','inherit','closed','closed','','7041-revision-v1','','','2020-08-16 09:14:26','2020-08-16 09:14:26','',7041,'https://microbiozindia.com/uncategorized/7041-revision-v1/',0,'revision','',0),(7044,2,'2020-08-17 09:02:38','2020-08-17 09:02:38','KUALA LUMPUR: A mutation of this COVID-19 virus that is\"10 times\" more infectious was detected in Malaysia.\r\n\r\nThe state\'s Health Ministry director-general Noor Hisham Abdullah said the neighborhood needed to be careful, after a D614G mutation of the novel coronavirus was discovered.\r\n\r\n\"It\'s is found to be 10 times easier to infect different people and easier to spread, if spread by\'super spreader\' individuals,\" Dr Noor Hisham said in a statement posted on his Facebook page on Sunday (Aug 16).\r\n\r\nThe mutation was detected by the Malaysian Institute for Medical Research, because of culture and isolation tests on three instances from the nation\'s Sivagangga audience and one case from the Ulu Tiram cluster.\r\n\r\n\"So far, these two clusters have been found to be under control as a consequence of the rapid public health management actions,\" explained Dr Noor Hisham. \"This first test and many follow-up evaluations are being conducted to examine several different cases, including for the index case for both clusters\"\r\n\r\nHe included that the D614G mutation was detected by scientists in July, also is likely to induce current vaccine research to be faulty or ineffective towards this mutation.\r\n\r\nDr Noor Hisham advised the public to continue to apply preventive measures and general health management by taking steps involving physical distancing, self-hygiene practices and wearing face masks.\r\n\r\n\"Public cooperation is needed so that we can collectively break the string of the COVID-19 infection from all types of mutations,\" he added.\r\n\r\nMalaysia reported 25 brand new COVID-19 cases on Sunday, nine of which were local broadcasts while 16 were imported.\r\n\r\nIn another announcement, Dr Noor Hisham said this brings the cumulative total of COVID-19 instances in Malaysia to 9,200, together with 216 active cases.\r\n\r\nHe said the nine nearby transmissions included seven Malaysians, one of whom had been a pre-surgery screening instance in the Queen Elizabeth Hospital in Kota Kinabalu, Sabah.\r\n\r\nSix cases were from the Tawar bunch in Baling, Kedah, five of which have been in Kedah and yet another in Penang.\r\n\r\n\"Two more local infections were detected among non-Malaysians at Kuala Lumpur where both cases were eatery workers after random screenings were performed at their workplaces,\" Dr Noor Hisham said.\r\n\"News about the close of this eatery has gone viral about social media and this has generated some anxiety among clients,\" he added.\r\n\r\n\"The district health office will conduct active case detection at which further investigations and samplings will be carried out. The store itself has been closed down temporarily for disinfection and sanitisation.\"\r\n\r\nHe said 28 more instances had recovered from COVID-19, carrying the cumulative amount of recoveries into 8,859, or 96.3 percent of the total.\r\n\"To date, there are just seven COVID-19 positive cases from the intensive care unit, of which two need ventilator support,\" he explained.\r\n\r\nNo fatalities were reported Sunday, together with the death toll staying at 125 cases.\r\n\r\nElaborating on the Tawar bunch, Dr Noor Hisham stated that with all the new cases reported overnight, there were now 39 cases from this cluster.\r\n\r\n\"As much as noon now, some 899 individuals are screened from this cluster, of which 727 were screened in Kedah with 35 testing positive for COVID-19, 643 analyzed negative and 49 longer are awaiting outcomes.\r\n\r\n\"Still another 164 more were screened in Penang and from those, four individuals tested positive, 155 tested negative and five more are pending results.\r\n\r\n\"Back in Perak, eight were screened with five analyzing negative and three more awaiting consequences,\" he explained.\r\n\r\nActive case detection and contact screenings are ongoing for this cluster, he added.\r\n\r\nMalaysia\'s Health Ministry said on Twitter three more clusters were shut - the Kuala Lumpur restaurant bunch as well as the Ramnad and Kuching Jetty clusters, bringing the amount of planets that are closed into 78.','COVID-19 virus mutation that is \'10 times\' more irresistible recognized in Malaysia','','publish','open','open','','covid-19-virus-mutation-that-is-10-times-more-irresistible-recognized-in-malaysia','','','2020-08-17 09:02:38','2020-08-17 09:02:38','',0,'https://microbiozindia.com/?p=7044',0,'post','',0),(7045,2,'2020-08-17 09:02:28','2020-08-17 09:02:28','','coronavirus-4810201_640','','inherit','open','closed','','coronavirus-4810201_640-2','','','2020-08-17 09:02:28','2020-08-17 09:02:28','',7044,'https://microbiozindia.com/wp-content/uploads/2020/08/coronavirus-4810201_640.jpg',0,'attachment','image/jpeg',0),(7046,2,'2020-08-17 09:02:38','2020-08-17 09:02:38','KUALA LUMPUR: A mutation of this COVID-19 virus that is\"10 times\" more infectious was detected in Malaysia.\r\n\r\nThe state\'s Health Ministry director-general Noor Hisham Abdullah said the neighborhood needed to be careful, after a D614G mutation of the novel coronavirus was discovered.\r\n\r\n\"It\'s is found to be 10 times easier to infect different people and easier to spread, if spread by\'super spreader\' individuals,\" Dr Noor Hisham said in a statement posted on his Facebook page on Sunday (Aug 16).\r\n\r\nThe mutation was detected by the Malaysian Institute for Medical Research, because of culture and isolation tests on three instances from the nation\'s Sivagangga audience and one case from the Ulu Tiram cluster.\r\n\r\n\"So far, these two clusters have been found to be under control as a consequence of the rapid public health management actions,\" explained Dr Noor Hisham. \"This first test and many follow-up evaluations are being conducted to examine several different cases, including for the index case for both clusters\"\r\n\r\nHe included that the D614G mutation was detected by scientists in July, also is likely to induce current vaccine research to be faulty or ineffective towards this mutation.\r\n\r\nDr Noor Hisham advised the public to continue to apply preventive measures and general health management by taking steps involving physical distancing, self-hygiene practices and wearing face masks.\r\n\r\n\"Public cooperation is needed so that we can collectively break the string of the COVID-19 infection from all types of mutations,\" he added.\r\n\r\nMalaysia reported 25 brand new COVID-19 cases on Sunday, nine of which were local broadcasts while 16 were imported.\r\n\r\nIn another announcement, Dr Noor Hisham said this brings the cumulative total of COVID-19 instances in Malaysia to 9,200, together with 216 active cases.\r\n\r\nHe said the nine nearby transmissions included seven Malaysians, one of whom had been a pre-surgery screening instance in the Queen Elizabeth Hospital in Kota Kinabalu, Sabah.\r\n\r\nSix cases were from the Tawar bunch in Baling, Kedah, five of which have been in Kedah and yet another in Penang.\r\n\r\n\"Two more local infections were detected among non-Malaysians at Kuala Lumpur where both cases were eatery workers after random screenings were performed at their workplaces,\" Dr Noor Hisham said.\r\n\"News about the close of this eatery has gone viral about social media and this has generated some anxiety among clients,\" he added.\r\n\r\n\"The district health office will conduct active case detection at which further investigations and samplings will be carried out. The store itself has been closed down temporarily for disinfection and sanitisation.\"\r\n\r\nHe said 28 more instances had recovered from COVID-19, carrying the cumulative amount of recoveries into 8,859, or 96.3 percent of the total.\r\n\"To date, there are just seven COVID-19 positive cases from the intensive care unit, of which two need ventilator support,\" he explained.\r\n\r\nNo fatalities were reported Sunday, together with the death toll staying at 125 cases.\r\n\r\nElaborating on the Tawar bunch, Dr Noor Hisham stated that with all the new cases reported overnight, there were now 39 cases from this cluster.\r\n\r\n\"As much as noon now, some 899 individuals are screened from this cluster, of which 727 were screened in Kedah with 35 testing positive for COVID-19, 643 analyzed negative and 49 longer are awaiting outcomes.\r\n\r\n\"Still another 164 more were screened in Penang and from those, four individuals tested positive, 155 tested negative and five more are pending results.\r\n\r\n\"Back in Perak, eight were screened with five analyzing negative and three more awaiting consequences,\" he explained.\r\n\r\nActive case detection and contact screenings are ongoing for this cluster, he added.\r\n\r\nMalaysia\'s Health Ministry said on Twitter three more clusters were shut - the Kuala Lumpur restaurant bunch as well as the Ramnad and Kuching Jetty clusters, bringing the amount of planets that are closed into 78.','COVID-19 virus mutation that is \'10 times\' more irresistible recognized in Malaysia','','inherit','closed','closed','','7044-revision-v1','','','2020-08-17 09:02:38','2020-08-17 09:02:38','',7044,'https://microbiozindia.com/uncategorized/7044-revision-v1/',0,'revision','',0),(7047,2,'2020-08-17 18:15:48','2020-08-17 18:15:48','Vaccine maker Biological E (BE), on August 17 stated it has acquired Akorn India, a subsidiary of US-based Akorn which generates speciality generic injectable medicines and vaccines for around $10 million in money.\r\n\r\nBE said the acquisition will allow the Hyderabad-based organization to boost its manufacturing capabilities and abilities to produce and furnish its vaccines and injectable medications.\r\n\r\n\"BE is in the process of developing a more COVID-19 vaccine and could be able to use the facilities at Akorn India Paonta Sahib Plant at Himachal Pradesh to get commercial-scale manufacture of the vaccine at the suitable moment,\" BE said in a statement.\r\n\r\nThe Akorn India plant at Paonta Sahib, Himachal Pradesh has a completely staffed sterile injectable manufacturing facility with a 39,000 sq. metres of built-up region spread on a 14-acre campus having an yearly capacity for around 135 million units with the potential for instantaneous expansion of a further 30 million units.\r\n\r\n\"We\'d leverage BE\'s and Akorn India\'s abilities to boost our supply capacities both in vaccines as well as at generic injectables,\" said Mahima Datla, Managing Director of BE.\r\n\r\n\"The time of this acquisition is fortuitous because it will immediately allow us to expand our capability to fabricate our investigational COVID-19 vaccine. With these capacities, we\'d be in a place to provide more than 1 billion doses per annum,\" BE stated in a declaration.\r\n\r\nBE has tied up with Johnson and Johnson to manufacture 400-500 million doses of the latter\'s COVID-19 vaccine for India and other nations. BE has entered into a licencing deal with Baylor College of Medicine Medicine of the University of Houston, Texas, such as the development of COVID-19 vaccine.','Vaccine firm Biological E gains Akorn\'s injectable plant in India for $10 million','','publish','open','open','','vaccine-firm-biological-e-gains-akorns-injectable-plant-in-india-for-10-million','','','2020-08-17 18:15:48','2020-08-17 18:15:48','',0,'https://microbiozindia.com/?p=7047',0,'post','',0),(7048,2,'2020-08-17 18:15:36','2020-08-17 18:15:36','','0_76BuvhNKMrAOSLFH','','inherit','open','closed','','0_76buvhnkmraoslfh','','','2020-08-17 18:15:36','2020-08-17 18:15:36','',7047,'https://microbiozindia.com/wp-content/uploads/2020/08/0_76BuvhNKMrAOSLFH.jpg',0,'attachment','image/jpeg',0),(7049,2,'2020-08-17 18:15:37','2020-08-17 18:15:37','','thumbs_b_c_09b7c2429af88799efe9b1b16f0fd931','','inherit','open','closed','','thumbs_b_c_09b7c2429af88799efe9b1b16f0fd931','','','2020-08-19 16:16:53','2020-08-19 16:16:53','',7047,'https://microbiozindia.com/wp-content/uploads/2020/08/thumbs_b_c_09b7c2429af88799efe9b1b16f0fd931.jpg',0,'attachment','image/jpeg',0),(7050,2,'2020-08-17 18:15:38','2020-08-17 18:15:38','','unnamed','','inherit','open','closed','','unnamed-6','','','2020-08-17 18:15:38','2020-08-17 18:15:38','',7047,'https://microbiozindia.com/wp-content/uploads/2020/08/unnamed.jpg',0,'attachment','image/jpeg',0),(7051,2,'2020-08-17 18:15:48','2020-08-17 18:15:48','Vaccine maker Biological E (BE), on August 17 stated it has acquired Akorn India, a subsidiary of US-based Akorn which generates speciality generic injectable medicines and vaccines for around $10 million in money.\r\n\r\nBE said the acquisition will allow the Hyderabad-based organization to boost its manufacturing capabilities and abilities to produce and furnish its vaccines and injectable medications.\r\n\r\n\"BE is in the process of developing a more COVID-19 vaccine and could be able to use the facilities at Akorn India Paonta Sahib Plant at Himachal Pradesh to get commercial-scale manufacture of the vaccine at the suitable moment,\" BE said in a statement.\r\n\r\nThe Akorn India plant at Paonta Sahib, Himachal Pradesh has a completely staffed sterile injectable manufacturing facility with a 39,000 sq. metres of built-up region spread on a 14-acre campus having an yearly capacity for around 135 million units with the potential for instantaneous expansion of a further 30 million units.\r\n\r\n\"We\'d leverage BE\'s and Akorn India\'s abilities to boost our supply capacities both in vaccines as well as at generic injectables,\" said Mahima Datla, Managing Director of BE.\r\n\r\n\"The time of this acquisition is fortuitous because it will immediately allow us to expand our capability to fabricate our investigational COVID-19 vaccine. With these capacities, we\'d be in a place to provide more than 1 billion doses per annum,\" BE stated in a declaration.\r\n\r\nBE has tied up with Johnson and Johnson to manufacture 400-500 million doses of the latter\'s COVID-19 vaccine for India and other nations. BE has entered into a licencing deal with Baylor College of Medicine Medicine of the University of Houston, Texas, such as the development of COVID-19 vaccine.','Vaccine firm Biological E gains Akorn\'s injectable plant in India for $10 million','','inherit','closed','closed','','7047-revision-v1','','','2020-08-17 18:15:48','2020-08-17 18:15:48','',7047,'https://microbiozindia.com/uncategorized/7047-revision-v1/',0,'revision','',0),(7052,2,'2020-08-17 18:18:08','2020-08-17 18:18:08','The development of chemotherapeutic agents with discerning anti-cancer actions is unattractive due to the emergence of resistance, inadequate targeting of cancer tissues, and subsequent metastasis.\r\n\r\nOne of tumor attribute cellular types, cancer stem cells have become associated with cancer development and metastasis, representing self-renewal and their propensity to join the flow.\r\n\r\nScientists at Japan Advanced Institute of Science and Technology (JAIST) have created a regulation technology of fatal cancer stemness working with the combination of nanotechnology and genetic engineering called\"photothermogenetics\" that allows for successful cancer elimination.\r\n\r\nDeveloped by Associate Professor Eijiro Miyako along with his group from JAIST, photo-active functional nanocarbon complexes, that manufactured from polyethylene glycol (PEG)-modified carbon nanohorns (CNH) with an antibody against the receptor potential vanilloid family type 2 (TRPV2), showed high potential as a targeting cancer chemotherapeutic agent.\r\nIn fact, that the nanocomplexes are effectively heated by biologically permeable near-infrared mild. Following program to cells and mice enzyme versions, these complexes photo-thermally triggered calcium influx into target cells overexpressing TRPV2 (temperature-responsive tissue protein), resulting in increased cancer cell death and effective regulation of cancer stemness.\r\n\r\nThe current experiments warrant additional consideration of the novel chemotherapeutic approach using the best combination of nanotechnology and genetic technology for treating refractory cancers and management of fatal cancer stemness.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.jaist.ac.jp/english\" target=\"_blank\" rel=\"noopener noreferrer\">Japan Advanced Institute of Science and Technology</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nYu, Y., <em>et al</em>. (2020) Photothermogenetic inhibition of cancer stemness by near-infrared-light-activatable nanocomplexes. <em>Nature Communications</em>.<a href=\"https://doi.org/10.1038/s41467-020-17768-3\" target=\"_blank\" rel=\"noopener noreferrer\"> <span style=\"color: #ff6600;\">doi.org/10.1038/s41467-020-17768-3.</span></a>\r\n\r\n</div>','Blend of nanotechnology and hereditary designing for managing lethal malignant growth stemness','','publish','open','open','','blend-of-nanotechnology-and-hereditary-designing-for-managing-lethal-malignant-growth-stemness','','','2020-08-17 18:18:08','2020-08-17 18:18:08','',0,'https://microbiozindia.com/?p=7052',0,'post','',0),(7053,2,'2020-08-17 18:18:08','2020-08-17 18:18:08','The development of chemotherapeutic agents with discerning anti-cancer actions is unattractive due to the emergence of resistance, inadequate targeting of cancer tissues, and subsequent metastasis.\r\n\r\nOne of tumor attribute cellular types, cancer stem cells have become associated with cancer development and metastasis, representing self-renewal and their propensity to join the flow.\r\n\r\nScientists at Japan Advanced Institute of Science and Technology (JAIST) have created a regulation technology of fatal cancer stemness working with the combination of nanotechnology and genetic engineering called\"photothermogenetics\" that allows for successful cancer elimination.\r\n\r\nDeveloped by Associate Professor Eijiro Miyako along with his group from JAIST, photo-active functional nanocarbon complexes, that manufactured from polyethylene glycol (PEG)-modified carbon nanohorns (CNH) with an antibody against the receptor potential vanilloid family type 2 (TRPV2), showed high potential as a targeting cancer chemotherapeutic agent.\r\nIn fact, that the nanocomplexes are effectively heated by biologically permeable near-infrared mild. Following program to cells and mice enzyme versions, these complexes photo-thermally triggered calcium influx into target cells overexpressing TRPV2 (temperature-responsive tissue protein), resulting in increased cancer cell death and effective regulation of cancer stemness.\r\n\r\nThe current experiments warrant additional consideration of the novel chemotherapeutic approach using the best combination of nanotechnology and genetic technology for treating refractory cancers and management of fatal cancer stemness.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.jaist.ac.jp/english\" target=\"_blank\" rel=\"noopener noreferrer\">Japan Advanced Institute of Science and Technology</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nYu, Y., <em>et al</em>. (2020) Photothermogenetic inhibition of cancer stemness by near-infrared-light-activatable nanocomplexes. <em>Nature Communications</em>.<a href=\"https://doi.org/10.1038/s41467-020-17768-3\" target=\"_blank\" rel=\"noopener noreferrer\"> <span style=\"color: #ff6600;\">doi.org/10.1038/s41467-020-17768-3.</span></a>\r\n\r\n</div>','Blend of nanotechnology and hereditary designing for managing lethal malignant growth stemness','','inherit','closed','closed','','7052-revision-v1','','','2020-08-17 18:18:08','2020-08-17 18:18:08','',7052,'https://microbiozindia.com/uncategorized/7052-revision-v1/',0,'revision','',0),(7054,2,'2020-08-17 18:27:13','2020-08-17 18:27:13','Delhi based Oscar Medicare Pvt. Ltd., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\r\n\r\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\r\n\r\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dbtindia.gov.in/\">Dept of Biotechnology (DBT)</a></span>, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.birac.nic.in/\">BIRAC</a> </span>and other Govt agencies including THSTI for support in the development of 100% Indian test.\r\n\r\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://thsti.res.in/\"><strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong></a></span> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\r\n\r\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\r\n\r\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\r\n\r\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\r\n\r\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\r\n\r\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\r\n\r\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\r\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\r\n<strong><u>For any clarification feel free to contact : </u></strong>\r\n\r\nMr. Umesh Kaushik\r\n\r\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT/BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','publish','open','open','','dbt-birac-supported-rapid-test-for-covid-antibody-detection-100-indigenous','','','2020-08-19 16:10:46','2020-08-19 16:10:46','',0,'https://microbiozindia.com/?p=7054',0,'post','',0),(7055,2,'2020-08-17 18:27:13','2020-08-17 18:27:13','Delhi based <strong>Oscar Medicare Pvt. Ltd</strong>., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\r\n\r\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\r\n\r\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach Dept of Biotechnology (DBT), BIRAC and other Govt agencies including THSTI for support in the development of 100% Indian test.\r\n\r\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\r\n\r\n<strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\r\n\r\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\r\n\r\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\r\n\r\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\r\n\r\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\r\n\r\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\r\n\r\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\r\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\r\n<strong><u>For any clarification feel free to contact : </u></strong>\r\n\r\nMr. Umesh Kaushik\r\n\r\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT / BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','inherit','closed','closed','','7054-revision-v1','','','2020-08-17 18:27:13','2020-08-17 18:27:13','',7054,'https://microbiozindia.com/uncategorized/7054-revision-v1/',0,'revision','',0),(7056,2,'2020-08-17 18:28:18','2020-08-17 18:28:18','Delhi based <strong>Oscar Medicare Pvt. Ltd</strong>., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\n\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\n\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dbtindia.gov.in/\">Dept of Biotechnology (DBT)</a></span>, BIRAC and other Govt agencies including THSTI for support in the development of 100% Indian test.\n\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\n\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://thsti.res.in/\"><strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong></a></span> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\n\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\n\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\n\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\n\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\n\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\n\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\n<strong><u>For any clarification feel free to contact : </u></strong>\n\nMr. Umesh Kaushik\n\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT / BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','inherit','closed','closed','','7054-autosave-v1','','','2020-08-17 18:28:18','2020-08-17 18:28:18','',7054,'https://microbiozindia.com/uncategorized/7054-autosave-v1/',0,'revision','',0),(7057,2,'2020-08-17 18:28:45','2020-08-17 18:28:45','Delhi based <strong>Oscar Medicare Pvt. Ltd</strong>., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\r\n\r\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\r\n\r\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dbtindia.gov.in/\">Dept of Biotechnology (DBT)</a></span>, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.birac.nic.in/\">BIRAC</a> </span>and other Govt agencies including THSTI for support in the development of 100% Indian test.\r\n\r\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://thsti.res.in/\"><strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong></a></span> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\r\n\r\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\r\n\r\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\r\n\r\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\r\n\r\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\r\n\r\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\r\n\r\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\r\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\r\n<strong><u>For any clarification feel free to contact : </u></strong>\r\n\r\nMr. Umesh Kaushik\r\n\r\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT / BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','inherit','closed','closed','','7054-revision-v1','','','2020-08-17 18:28:45','2020-08-17 18:28:45','',7054,'https://microbiozindia.com/uncategorized/7054-revision-v1/',0,'revision','',0),(7058,2,'2020-08-17 18:30:54','2020-08-17 18:30:54','Delhi based <strong>Oscar Medicare Pvt. Ltd</strong>., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\r\n\r\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\r\n\r\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dbtindia.gov.in/\">Dept of Biotechnology (DBT)</a></span>, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.birac.nic.in/\">BIRAC</a> </span>and other Govt agencies including THSTI for support in the development of 100% Indian test.\r\n\r\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://thsti.res.in/\"><strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong></a></span> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\r\n\r\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\r\n\r\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\r\n\r\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\r\n\r\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\r\n\r\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\r\n\r\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\r\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\r\n<strong><u>For any clarification feel free to contact : </u></strong>\r\n\r\nMr. Umesh Kaushik\r\n\r\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT and BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','inherit','closed','closed','','7054-revision-v1','','','2020-08-17 18:30:54','2020-08-17 18:30:54','',7054,'https://microbiozindia.com/uncategorized/7054-revision-v1/',0,'revision','',0),(7059,2,'2020-08-17 18:31:34','2020-08-17 18:31:34','Delhi based <strong>Oscar Medicare Pvt. Ltd</strong>., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\r\n\r\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\r\n\r\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dbtindia.gov.in/\">Dept of Biotechnology (DBT)</a></span>, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.birac.nic.in/\">BIRAC</a> </span>and other Govt agencies including THSTI for support in the development of 100% Indian test.\r\n\r\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://thsti.res.in/\"><strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong></a></span> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\r\n\r\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\r\n\r\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\r\n\r\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\r\n\r\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\r\n\r\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\r\n\r\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\r\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\r\n<strong><u>For any clarification feel free to contact : </u></strong>\r\n\r\nMr. Umesh Kaushik\r\n\r\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT/BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','inherit','closed','closed','','7054-revision-v1','','','2020-08-17 18:31:34','2020-08-17 18:31:34','',7054,'https://microbiozindia.com/uncategorized/7054-revision-v1/',0,'revision','',0),(7060,2,'2020-08-17 18:31:49','2020-08-17 18:31:49','Delhi based Oscar Medicare Pvt. Ltd., manufacturer of various in-vitro diagnostic kits, has developed a rapid test for detection of COVID antibody using recombinant proteins of 100% Indian origin in collaboration with <strong>Dhiti Life Sciences Pvt. Ltd. (DLSPL)</strong>. The product has been validated and approved by ICMR lab-National Institute of Virology-Pune. As per ICMR report, OSCAR CORONA Antibody test has sensitivity of more than 97% and specificity of 99%.\r\n\r\nDLPLS is engaged in the R&amp;D and manufacturing of recombinant proteins and monoclonal antibodies used in the IVD kits. The recombinant protein of Corona virus was developed by the scientific team under guidance of <strong>Dr. Abhinav Shrestha, </strong>a young scientist and Ph.D\r\n\r\nfrom National Institute of Immunology-Delhi, told that developmental work of recombinant protein of COVID-19 was initiated in month of April-May 2020 looking dependency of the active raw material on foreign suppliers and urgent need of country to support the vision of the Govt. of India “Atmanirbhar Bharat’. Being a DSIR approved biotechnology lab, it was easy for the team Dhiti Life Science to approach <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dbtindia.gov.in/\">Dept of Biotechnology (DBT)</a></span>, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.birac.nic.in/\">BIRAC</a> </span>and other Govt agencies including THSTI for support in the development of 100% Indian test.\r\n\r\nDhiti Life Sciences has received BIRAC grant under their COVID-19 call for the project titled as “Development of Lateral flow test for the detection of anti-corona virus SARS-COV-2 specific IgG &amp; IgM from human sera”. Under the same project above antigen and hence fully indigenous lateral flow device has been developed in collaboration with Oscar Medicare Pvt. Ltd.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://thsti.res.in/\"><strong>THSTI (Translational   Health Science and Technology Institute-An AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA)</strong></a></span> has provided the COVID-19 validated positive serum samples for the internal development and quality control of the developed rapid test).  The support of THSTI is highly appreciable the in the process of rapid test.\r\n\r\n<strong>Mr. Umesh Kaushik, Director-Technical</strong> of Oscar Medicare said that being a manufacturer of various IVD tests kits, it was very easy to receive a test license permission on MD-13 from the Drugs Controller General of India for Corona Antibody Rapid test kits, a move that takes it one step closer to the launching them in Indian market as per guidelines of the Govt of India. Oscar Medicare immediately started the developmental work of COVID-19 antibody on high priority.\r\n\r\n<strong> </strong><strong>Mr. Umesh Kaushik, Director-Technical</strong> said that developed Oscar COVID Antibody test is a rapid test kit which is quite simple to use and perform the even at bed side of the patient or at home. A small drop of whole blood or Serum / plasma is sufficient to perform the tests and visual results can be obtained within 5 to 20 minutes in the patient sample. It is a qualitative test which provides the information that whether suspected person has\r\n\r\ndeveloped antibodies or not. The test is quite simple to perform in any general healthcare facilities without needs of specialized laboratory technologist and additional equipment. The kit is very stable at room temperature and its storage and transportation will not be an issue as per Indian climate.\r\n\r\n<strong>Dr. Arvind Saxena, Director- R&amp;D</strong>, updated that antibodies are developed in any individual within 7-14 days of COVID-19 infection. IgM type antibodies are generated first and appears in the body after infection, the presence of IgM antibody in the patient specimen directly indicates the current infection of COVID-19 (Corona Virus). The shelf life of the IgM antibodies is exceedingly small and remain for a shorter period in the blood circulation. Another type of antibodies which is IgG, it develops and appears in the body on later stage of infection and remains in the blood circulation for longer time. The Presence of IgG antibodies also indicates that immunity has developed for the COVID-19.\r\n\r\n<strong>Dr. Savita Sekhri</strong>, Head-QA, updated that validation and performance evaluation of the developed product is done at the specified centers as per guidelines of Govt of India before commercial launch of the product. Our CORONA antibody Rapid Test meets desired sensitivity and specificity as per guidelines of ICMR and it happened only due to incorporation of 100% Indian &amp; highly specific recombinant protein of COVID-19 in the test formulation.\r\n\r\n<strong>Mr. Anand Sekhri, Group CEO</strong> of Oscar Medicare Group of companies appreciated to the regulatory agencies DCGI, ICMR, BDT, BIRAC, THSTI and NIV-Pune for the cooperation, prompt approvals &amp; validations of the product of 100% Indian origin. Oscar has enough capacity and capabilities to produce bulk quantities of tests if required to Govt agencies for the mass screening. The product will be available in the market very soon only after regulatory approvals from DCGI for the commercial manufacturing and marketing of the product. He added that our entire team is ready to serve the Nation in the ongoing crisis of COVID-19 by way of providing diagnostic tests. Mr. Sekhri updated that we are committed to the society and will donate 1.0 lac tests of COVID Antibody tests to Govt of India / ICMR.\r\n<blockquote>Among the few manufacturer of rapid tests kits in Delhi NCR, Oscar is the first company to develop and validate the product with recombinant proteins of 100% Indian origin. Our COVID antigen rapid test is also under validation from ICMR and hopefully it will be cleared soon with the set criteria of the validation by the ICMR.</blockquote>\r\n<strong><u>For any clarification feel free to contact : </u></strong>\r\n\r\nMr. Umesh Kaushik\r\n\r\n<a href=\"mailto:umesh.kaushik@oscarmedcare.com\">umesh.kaushik@oscarmedcare.com</a>','DBT/BIRAC Supported Rapid test for COVID antibody detection: 100% Indigenous','','inherit','closed','closed','','7054-revision-v1','','','2020-08-17 18:31:49','2020-08-17 18:31:49','',7054,'https://microbiozindia.com/uncategorized/7054-revision-v1/',0,'revision','',0),(7061,2,'2020-08-19 08:52:23','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-19 08:52:23','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7061',0,'post','',0),(7062,2,'2020-08-19 08:53:53','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-19 08:53:53','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7062',0,'post','',0),(7063,2,'2020-08-19 08:54:45','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-19 08:54:45','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7063',0,'post','',0),(7064,2,'2020-08-19 08:54:54','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-19 08:54:54','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7064',0,'post','',0),(7065,2,'2020-08-19 08:55:02','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-19 08:55:02','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7065',0,'post','',0),(7066,0,'2020-08-19 09:35:47','2020-08-19 09:35:47','','Default Kit','','publish','closed','closed','','default-kit','','','2020-08-19 09:35:47','2020-08-19 09:35:47','',0,'https://microbiozindia.com/?elementor_library=default-kit',0,'elementor_library','',0),(7067,2,'2020-08-19 14:43:02','2020-08-19 14:43:02','Eight binational groups of researchers from India and the US are chosen for following cutting-edge study in pathogenesis and disease control of COVID-19, based on an official announcement on Tuesday.\r\n\r\nThe teams will pursue research in areas such as anti fungal coatings, and immune modulation, tracking SARS CoV-2 from wastewaterand illness detection mechanics, reverse genetics strategies and medication repurposing.\r\n\r\nThe study awards have been declared by the Indo-US Science and Technology Forum (IUSSTF), a sovereign bilateral organisation jointly funded by the governments of India and the US, which promotes science, engineering, engineering and innovation via purposeful interaction among government, academia and business.\r\n\r\nThe Department of Science and Technology (DST) under the Ministry of Science and Technology, along with the US Department of States are various nodal departments.\r\n\r\nThe assignment of this Indo-US Science and Technology Forum will be to serve as a catalyst to promote long-term scientific collaborations between India and the USA through partnerships among individual scientists, scientific institutions, and the scientific community at large, \'\' the DST statement said.\r\n\r\n\"The eight groups are among the very best couple who had submitted proposals in response to an invitation of suggestions to harness the combined expertise of the Indian and US Science &amp; Technology communities, facilitate partnerships between teams of Indian and US engineers and scientists now engaged in COVID-related research, and leverage existing infrastructure from both nations to further advance the research and accelerate advancement,\" the statement said.\r\n\r\nAshutosh Sharma, DST Secretary and also IUSSTF India Co-Chair, said an overwhelming reaction in a short period to the distinctive call on COVID-19 shows a broad spectrum of cooperation between India and the US in the basic studies on the behaviour of SARS-Cov-2 virus to its transmission to diagnostics and therapeutic strategies.\r\n\r\n\"Our existing strong cooperation in S&amp;T on health, energy, artificial intelligence and so on also continues to deliver attention and attests to the value of Indo-US collaborations in providing compelling solutions,\" Sharma explained.\r\n\r\nJonathan Margolis, Deputy Assistant Secretary for Science, Space and Health, Bureau of Oceans and International Environmental and Scientific Affairs, US Department of State, along with IUSSTF US Co-Chair, said the United States of America and India were able to quickly mobilise, through IUSSTF, to encourage jointly developed inventions to Resist COVID-19.\r\n\r\n\"Our people and savings both rely on technology and science to recognize tools to tackle the pressing challenges of the present pandemic,\" the statement quoting Margolis said.','Eight groups of researchers from India and US chose for seeking after exploration on COVID-19','','publish','open','open','','eight-groups-of-researchers-from-india-and-us-chose-for-seeking-after-exploration-on-covid-19','','','2020-08-19 14:43:02','2020-08-19 14:43:02','',0,'https://microbiozindia.com/?p=7067',0,'post','',0),(7068,2,'2020-08-19 14:43:02','2020-08-19 14:43:02','Eight binational groups of researchers from India and the US are chosen for following cutting-edge study in pathogenesis and disease control of COVID-19, based on an official announcement on Tuesday.\r\n\r\nThe teams will pursue research in areas such as anti fungal coatings, and immune modulation, tracking SARS CoV-2 from wastewaterand illness detection mechanics, reverse genetics strategies and medication repurposing.\r\n\r\nThe study awards have been declared by the Indo-US Science and Technology Forum (IUSSTF), a sovereign bilateral organisation jointly funded by the governments of India and the US, which promotes science, engineering, engineering and innovation via purposeful interaction among government, academia and business.\r\n\r\nThe Department of Science and Technology (DST) under the Ministry of Science and Technology, along with the US Department of States are various nodal departments.\r\n\r\nThe assignment of this Indo-US Science and Technology Forum will be to serve as a catalyst to promote long-term scientific collaborations between India and the USA through partnerships among individual scientists, scientific institutions, and the scientific community at large, \'\' the DST statement said.\r\n\r\n\"The eight groups are among the very best couple who had submitted proposals in response to an invitation of suggestions to harness the combined expertise of the Indian and US Science &amp; Technology communities, facilitate partnerships between teams of Indian and US engineers and scientists now engaged in COVID-related research, and leverage existing infrastructure from both nations to further advance the research and accelerate advancement,\" the statement said.\r\n\r\nAshutosh Sharma, DST Secretary and also IUSSTF India Co-Chair, said an overwhelming reaction in a short period to the distinctive call on COVID-19 shows a broad spectrum of cooperation between India and the US in the basic studies on the behaviour of SARS-Cov-2 virus to its transmission to diagnostics and therapeutic strategies.\r\n\r\n\"Our existing strong cooperation in S&amp;T on health, energy, artificial intelligence and so on also continues to deliver attention and attests to the value of Indo-US collaborations in providing compelling solutions,\" Sharma explained.\r\n\r\nJonathan Margolis, Deputy Assistant Secretary for Science, Space and Health, Bureau of Oceans and International Environmental and Scientific Affairs, US Department of State, along with IUSSTF US Co-Chair, said the United States of America and India were able to quickly mobilise, through IUSSTF, to encourage jointly developed inventions to Resist COVID-19.\r\n\r\n\"Our people and savings both rely on technology and science to recognize tools to tackle the pressing challenges of the present pandemic,\" the statement quoting Margolis said.','Eight groups of researchers from India and US chose for seeking after exploration on COVID-19','','inherit','closed','closed','','7067-revision-v1','','','2020-08-19 14:43:02','2020-08-19 14:43:02','',7067,'https://microbiozindia.com/uncategorized/7067-revision-v1/',0,'revision','',0),(7069,2,'2020-08-19 14:45:47','2020-08-19 14:45:47','The World Health Organization\'s (WHO) chief <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.who.int/dg/election/tedros/en/\">Tedros Adhanom Ghebreyesus</a></span> stated on August 18 that nations placing their own interests ahead of the others in trying to make sure supplies of a potential coronavirus vaccine are creating the pandemic worse.\r\n\r\n\"(Acting) strategically and globally is in fact in each country\'s national interest - no one is safe until everyone is protected,\" he informed a digital briefing calling for the end to\"vaccine nationalism\".\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.npr.org/sections/coronavirus-live-updates/2020/08/18/903617560/who-chief-urges-nations-to-join-in-preventing-vaccine-nationalism\">Ghebreysus stated he\'d delivered a letter to all WHO members requesting them to join with the multilateral COVAX vaccine campaign.</a></span>\r\n\r\nOver 21.9 million individuals are reported to be infected from the novel coronavirus globally and 772,647 have died, according to a Reuters tally.','WHO boss Tedros Adhanom Ghebreyesus calls for end to \'immunization patriotism\'','','publish','open','open','','who-boss-tedros-adhanom-ghebreyesus-calls-for-end-to-immunization-patriotism','','','2020-08-19 14:45:47','2020-08-19 14:45:47','',0,'https://microbiozindia.com/?p=7069',0,'post','',0),(7070,2,'2020-08-19 14:45:47','2020-08-19 14:45:47','The World Health Organization\'s (WHO) chief <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.who.int/dg/election/tedros/en/\">Tedros Adhanom Ghebreyesus</a></span> stated on August 18 that nations placing their own interests ahead of the others in trying to make sure supplies of a potential coronavirus vaccine are creating the pandemic worse.\r\n\r\n\"(Acting) strategically and globally is in fact in each country\'s national interest - no one is safe until everyone is protected,\" he informed a digital briefing calling for the end to\"vaccine nationalism\".\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.npr.org/sections/coronavirus-live-updates/2020/08/18/903617560/who-chief-urges-nations-to-join-in-preventing-vaccine-nationalism\">Ghebreysus stated he\'d delivered a letter to all WHO members requesting them to join with the multilateral COVAX vaccine campaign.</a></span>\r\n\r\nOver 21.9 million individuals are reported to be infected from the novel coronavirus globally and 772,647 have died, according to a Reuters tally.','WHO boss Tedros Adhanom Ghebreyesus calls for end to \'immunization patriotism\'','','inherit','closed','closed','','7069-revision-v1','','','2020-08-19 14:45:47','2020-08-19 14:45:47','',7069,'https://microbiozindia.com/uncategorized/7069-revision-v1/',0,'revision','',0),(7071,2,'2020-08-19 14:48:27','2020-08-19 14:48:27','The head of a major state-owned Chinese pharmaceutical company explained its coronavirus vaccine will be commercially available at the end of the year. Liu Jingzhen, \'\' the chairman of SinoPharm, advised that a Chinese Communist Party newspaper that the vaccine would cost less than 1,000 yuan ($140) and be awarded in two shots, 28 weeks apart.\r\n\r\nHe said students and employees in major cities would must find the vaccine, but not those living in densely populated rural areas.\r\n\r\n\"Not all of the 1.4 billion people in our country have to carry action,\" he said in an interview published in Tuesday in the Guangming Daily.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.trtworld.com/life/china-s-sinopharm-covid-19-vaccine-to-be-available-at-end-of-2020-38989\">SinoPharm, that has two vaccines in trial, has an annual manufacturing capacity of 220 million doses,\'\' Liu said.</a></span>\r\n\r\nLiu, who is also the corporation\'s Communist Party secretary, told the newspaper that he had been injected with the vaccine.\r\n\r\nReports that Chinese researchers and executives have received shots of their vaccines have raised ethical questions in some scientific circles.','Coronavirus immunization will be prepared by December-end, says Chinese organization SinoPharm','','publish','open','open','','coronavirus-immunization-will-be-prepared-by-december-end-says-chinese-organization-sinopharm','','','2020-08-19 14:48:27','2020-08-19 14:48:27','',0,'https://microbiozindia.com/?p=7071',0,'post','',0),(7072,2,'2020-08-19 14:47:00','2020-08-19 14:47:00','','cansino-1597650287','','inherit','open','closed','','cansino-1597650287','','','2020-08-19 14:47:00','2020-08-19 14:47:00','',7071,'https://microbiozindia.com/wp-content/uploads/2020/08/cansino-1597650287.jpg',0,'attachment','image/jpeg',0),(7073,2,'2020-08-19 14:48:27','2020-08-19 14:48:27','The head of a major state-owned Chinese pharmaceutical company explained its coronavirus vaccine will be commercially available at the end of the year. Liu Jingzhen, \'\' the chairman of SinoPharm, advised that a Chinese Communist Party newspaper that the vaccine would cost less than 1,000 yuan ($140) and be awarded in two shots, 28 weeks apart.\r\n\r\nHe said students and employees in major cities would must find the vaccine, but not those living in densely populated rural areas.\r\n\r\n\"Not all of the 1.4 billion people in our country have to carry action,\" he said in an interview published in Tuesday in the Guangming Daily.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.trtworld.com/life/china-s-sinopharm-covid-19-vaccine-to-be-available-at-end-of-2020-38989\">SinoPharm, that has two vaccines in trial, has an annual manufacturing capacity of 220 million doses,\'\' Liu said.</a></span>\r\n\r\nLiu, who is also the corporation\'s Communist Party secretary, told the newspaper that he had been injected with the vaccine.\r\n\r\nReports that Chinese researchers and executives have received shots of their vaccines have raised ethical questions in some scientific circles.','Coronavirus immunization will be prepared by December-end, says Chinese organization SinoPharm','','inherit','closed','closed','','7071-revision-v1','','','2020-08-19 14:48:27','2020-08-19 14:48:27','',7071,'https://microbiozindia.com/uncategorized/7071-revision-v1/',0,'revision','',0),(7074,2,'2020-08-19 15:02:33','2020-08-19 15:02:33','Dr Reddy\'s Laboratories on August 19 announced the launch of Avigan (Favipiravir) pills, used for treating mild to moderate COVID-19 sufferers in India.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.news18.com/news/india/dr-reddys-launches-home-delivery-of-covid-19-treatment-drug-avigan-in-42-cities-2801861.html\">Dr Reddy\'s stated Avigan was approved by the Drugs Controller General of India (DCGI) for treating patients with moderate to medium COVID-19.</a></span>\r\n\r\n\"The need for high efficacy and quality, affordability and improved disease control are essential priorities for us. We think that Avigan would offer an effective treatment alternative to the COVID-19 affected sufferers in India,\" M Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy\'s Laboratories, stated.','Dr Reddy\'s dispatches Avigan (Favipiravir) tablets in India','','publish','open','open','','dr-reddys-dispatches-avigan-favipiravir-tablets-in-india','','','2020-08-19 15:02:33','2020-08-19 15:02:33','',0,'https://microbiozindia.com/?p=7074',0,'post','',0),(7075,2,'2020-08-19 15:01:52','2020-08-19 15:01:52','','open_mouth-860x478','','inherit','open','closed','','open_mouth-860x478','','','2020-08-19 15:01:52','2020-08-19 15:01:52','',7074,'https://microbiozindia.com/wp-content/uploads/2020/08/open_mouth-860x478-1.png',0,'attachment','image/png',0),(7076,2,'2020-08-19 15:01:52','2020-08-19 15:01:52','','philippines-begin-clinical-trials-of-the-japanese-antiflu-drug-avigan-to-treat-covid19','','inherit','open','closed','','philippines-begin-clinical-trials-of-the-japanese-antiflu-drug-avigan-to-treat-covid19','','','2020-08-19 15:01:52','2020-08-19 15:01:52','',7074,'https://microbiozindia.com/wp-content/uploads/2020/08/philippines-begin-clinical-trials-of-the-japanese-antiflu-drug-avigan-to-treat-covid19.jpeg',0,'attachment','image/jpeg',0),(7077,2,'2020-08-19 15:02:33','2020-08-19 15:02:33','Dr Reddy\'s Laboratories on August 19 announced the launch of Avigan (Favipiravir) pills, used for treating mild to moderate COVID-19 sufferers in India.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.news18.com/news/india/dr-reddys-launches-home-delivery-of-covid-19-treatment-drug-avigan-in-42-cities-2801861.html\">Dr Reddy\'s stated Avigan was approved by the Drugs Controller General of India (DCGI) for treating patients with moderate to medium COVID-19.</a></span>\r\n\r\n\"The need for high efficacy and quality, affordability and improved disease control are essential priorities for us. We think that Avigan would offer an effective treatment alternative to the COVID-19 affected sufferers in India,\" M Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy\'s Laboratories, stated.','Dr Reddy\'s dispatches Avigan (Favipiravir) tablets in India','','inherit','closed','closed','','7074-revision-v1','','','2020-08-19 15:02:33','2020-08-19 15:02:33','',7074,'https://microbiozindia.com/uncategorized/7074-revision-v1/',0,'revision','',0),(7078,2,'2020-08-19 15:04:24','2020-08-19 15:04:24','To get a runny or blocked noseand cannot detect sweet or bitter tastes, a new study published on August 19 has discovered. The study is the first to evaluate how people with COVID-19 smell and taste disorders differ from people with other causes of upper respiratory tract infections, according to the researchers, including those in the University of East Anglia (UEA) in the united kingdom.\r\n\r\nThe researchers hope their work might help develop odor and taste evaluations for fast COVID-19 screening - in primary care and emergency sections.\r\n\r\nThe findings, released in the journal Rhinology, lend weight to the theory that COVID-19 interrupts the brain and central nervous system.\r\n\r\n\"The reduction of smell and taste is a prominent symptom of COVID-19, but it\'s also a frequent symptom of using a terrible cold,\" said lead researcher Carl Philpott, a professor at UEA\'s Norwich Medical School.\r\n\r\n\"We wanted to learn exactly what differentiates COVID -19 odor loss together with the kind of odor loss you might have using a cold and blocked-up nose,\" Philpott said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.firstpost.com/health/loss-of-taste-in-covid-19-patients-study-suggests-inflammation-and-not-sars-cov-2-virus-causes-ageusia-8694751.html\">The research team carried out odor and taste tests on 10 COVID-19 sufferers, 10 people with bad colds along with a control group of 10 healthy people -- all paired for sex and age.</a></span>\r\n\r\n\"We wanted to see whether their smell and taste test scores might help discriminate between COVID-19 sufferers and those with a heavy cold,\" Philpott said.\r\n\r\nThe researchers noticed COVID-19 behaves differently to other respiratory ailments, such as by inducing the body\'s immune system to over-react, known as a cytokine storm, and by changing the nervous system.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.businessinsider.in/science/news/the-loss-of-taste-and-smell-the-coronavirus-causes-is-different-than-that-from-a-common-cold-pointing-to-neurological-underpinnings/articleshow/77624791.cms\">They found that odor loss was a lot more profound from the COVID-19 patents, plus they have been unable to spot scents, and so were unable to recognize sweet or bitter tastes.</a></span>\r\n\r\nThe investigators said it was this reduction of true taste which seemed to be found from the COVID-19 patients in comparison to those with a cold.\r\n\r\n\"This is extremely exciting because it usually means that odor and taste tests could be employed to discriminate between COVID-19 patients and individuals with a normal cold or flu,\" Philpott said.\r\n\r\n\"Although such evaluations could not replace formal analytical tools such as throat swabs, they can provide an alternative when traditional tests are not available or if quick screening is required -- particularly at the level of care, in emergency departments or at airports,\" he added.\r\n\r\nThe analysis also indicates that there are completely different things going on as it pertains to smell and flavor loss for COVID-19 sufferers, compared to people who have a terrible cold, the researchers said.','How COVID-19 smell, taste misfortune varies from basic virus decoded','','publish','open','open','','how-covid-19-smell-taste-misfortune-varies-from-basic-virus-decoded','','','2020-08-19 15:04:24','2020-08-19 15:04:24','',0,'https://microbiozindia.com/?p=7078',0,'post','',0),(7079,2,'2020-08-19 15:04:24','2020-08-19 15:04:24','To get a runny or blocked noseand cannot detect sweet or bitter tastes, a new study published on August 19 has discovered. The study is the first to evaluate how people with COVID-19 smell and taste disorders differ from people with other causes of upper respiratory tract infections, according to the researchers, including those in the University of East Anglia (UEA) in the united kingdom.\r\n\r\nThe researchers hope their work might help develop odor and taste evaluations for fast COVID-19 screening - in primary care and emergency sections.\r\n\r\nThe findings, released in the journal Rhinology, lend weight to the theory that COVID-19 interrupts the brain and central nervous system.\r\n\r\n\"The reduction of smell and taste is a prominent symptom of COVID-19, but it\'s also a frequent symptom of using a terrible cold,\" said lead researcher Carl Philpott, a professor at UEA\'s Norwich Medical School.\r\n\r\n\"We wanted to learn exactly what differentiates COVID -19 odor loss together with the kind of odor loss you might have using a cold and blocked-up nose,\" Philpott said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.firstpost.com/health/loss-of-taste-in-covid-19-patients-study-suggests-inflammation-and-not-sars-cov-2-virus-causes-ageusia-8694751.html\">The research team carried out odor and taste tests on 10 COVID-19 sufferers, 10 people with bad colds along with a control group of 10 healthy people -- all paired for sex and age.</a></span>\r\n\r\n\"We wanted to see whether their smell and taste test scores might help discriminate between COVID-19 sufferers and those with a heavy cold,\" Philpott said.\r\n\r\nThe researchers noticed COVID-19 behaves differently to other respiratory ailments, such as by inducing the body\'s immune system to over-react, known as a cytokine storm, and by changing the nervous system.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.businessinsider.in/science/news/the-loss-of-taste-and-smell-the-coronavirus-causes-is-different-than-that-from-a-common-cold-pointing-to-neurological-underpinnings/articleshow/77624791.cms\">They found that odor loss was a lot more profound from the COVID-19 patents, plus they have been unable to spot scents, and so were unable to recognize sweet or bitter tastes.</a></span>\r\n\r\nThe investigators said it was this reduction of true taste which seemed to be found from the COVID-19 patients in comparison to those with a cold.\r\n\r\n\"This is extremely exciting because it usually means that odor and taste tests could be employed to discriminate between COVID-19 patients and individuals with a normal cold or flu,\" Philpott said.\r\n\r\n\"Although such evaluations could not replace formal analytical tools such as throat swabs, they can provide an alternative when traditional tests are not available or if quick screening is required -- particularly at the level of care, in emergency departments or at airports,\" he added.\r\n\r\nThe analysis also indicates that there are completely different things going on as it pertains to smell and flavor loss for COVID-19 sufferers, compared to people who have a terrible cold, the researchers said.','How COVID-19 smell, taste misfortune varies from basic virus decoded','','inherit','closed','closed','','7078-revision-v1','','','2020-08-19 15:04:24','2020-08-19 15:04:24','',7078,'https://microbiozindia.com/uncategorized/7078-revision-v1/',0,'revision','',0),(7080,2,'2020-08-19 15:06:30','2020-08-19 15:06:30','Amid the COVID-19 pandemic, India appears for Oxford-AstraZeneca vaccine candidate are the likely first shot available for Indians at the end of 2020.\r\n\r\nAdditionally, there are two indigenously developed vaccine candidates, that are likewise being anticipated to have started with a gap few weeks if removed in trials, said a report from The Times of India citing officers.\r\n\r\nOn the other hand, the COVID-19 vaccine candidate produced at the University of Oxford is ahead of the other two local vaccine candidates that have entered the human clinical trials,\'\' the report said.\r\n\r\nThe SII, that has been allowed for conducting advanced phases of human clinical trials from the candidate from India, has started Phases two and three trials, stated the report.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bbc.com/news/world-australia-53826846\">The locally designed vaccine candidates -- Bharat Biotech\'s Covaxin, jointly developed with the Indian Council of Medical Research (ICMR), also Zydus Cadila\'s Zycov D are equally in early phases of clinical trials, as per the report.</a></span>\r\n\r\nThe trials by SII are the largest, which is being conducted with around 1,600 people aged over 18 years in over 17 selected sites across the country, for the COVID-19 vaccine from the country up to now. For the trials of the other vaccine candidates, that there have been approximately 1,000-1,100 participants registered in five to eight sites, said that the report.\r\n\r\nAlso, in contrast of other offenses being developed beyond India, the Oxford vaccine candidate has scored much better as it has an Indian company -- SII -- as a production and distribution partner.\r\n\r\nSII, that plans to make 100 million doses of vaccine every month and 400 million doses of the Oxford vaccine by the end of 2020, lately obtained $150 million from Bill &amp; Melinda Gates Foundation for its vaccine development and distribution. GAVI has also announced funding for producing initial shots of this vaccine in the nation, added the record.','Oxford-AstraZeneca antibody might be the main shot accessible for Indians','','publish','open','open','','oxford-astrazeneca-antibody-might-be-the-main-shot-accessible-for-indians','','','2020-08-19 16:32:33','2020-08-19 16:32:33','',0,'https://microbiozindia.com/?p=7080',0,'post','',0),(7081,2,'2020-08-19 15:06:30','2020-08-19 15:06:30','Amid the COVID-19 pandemic, India appears for Oxford-AstraZeneca vaccine candidate are the likely first shot available for Indians at the end of 2020.\r\n\r\nAdditionally, there are two indigenously developed vaccine candidates, that are likewise being anticipated to have started with a gap few weeks if removed in trials, said a report from The Times of India citing officers.\r\n\r\nOn the other hand, the COVID-19 vaccine candidate produced at the University of Oxford is ahead of the other two local vaccine candidates that have entered the human clinical trials,\'\' the report said.\r\n\r\nThe SII, that has been allowed for conducting advanced phases of human clinical trials from the candidate from India, has started Phases two and three trials, stated the report.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bbc.com/news/world-australia-53826846\">The locally designed vaccine candidates -- Bharat Biotech\'s Covaxin, jointly developed with the Indian Council of Medical Research (ICMR), also Zydus Cadila\'s Zycov D are equally in early phases of clinical trials, as per the report.</a></span>\r\n\r\nThe trials by SII are the largest, which is being conducted with around 1,600 people aged over 18 years in over 17 selected sites across the country, for the COVID-19 vaccine from the country up to now. For the trials of the other vaccine candidates, that there have been approximately 1,000-1,100 participants registered in five to eight sites, said that the report.\r\n\r\nAlso, in contrast of other offenses being developed beyond India, the Oxford vaccine candidate has scored much better as it has an Indian company -- SII -- as a production and distribution partner.\r\n\r\nSII, that plans to make 100 million doses of vaccine every month and 400 million doses of the Oxford vaccine by the end of 2020, lately obtained $150 million from Bill &amp; Melinda Gates Foundation for its vaccine development and distribution. GAVI has also announced funding for producing initial shots of this vaccine in the nation, added the record.','Oxford-AstraZeneca antibody might be the main shot accessible for Indians','','inherit','closed','closed','','7080-revision-v1','','','2020-08-19 15:06:30','2020-08-19 15:06:30','',7080,'https://microbiozindia.com/uncategorized/7080-revision-v1/',0,'revision','',0),(7082,2,'2020-08-19 15:15:16','2020-08-19 15:15:16','Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the United Kingdom and the US, and is led by VRI-Inserm <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.boehringer-ingelheim.com/press-release/launch-care-consortium\">(French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of those Janssen Pharmaceutical Companies of Johnson &amp; Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG, (Zurich, Switzerland). It integrates partners\' COVID-19 jobs continuing since February 2020.</a></span>\r\n\r\n<em>The COVID-19 pandemic has emerged as the largest global health threat to humanity in this century, requiring the global scientific community to join forces in unprecedented ways. Beyond the scientific excellence of the different teams involved in this very ambitious project, CARE is bringing together 37 partners in an alliance pooling their expertise and know-how around an ambitious five-year work plan to develop therapeutics against the current COVID-19 pandemic. We are very grateful for the financial support provided by the Innovative Medicine Initiative that will enable us to implement this plan.”-</em>Professor Yves Lévy, Executive Director of the VRI-Inserm and CARE coordinator\r\n\r\nWithout a licensed vaccines and just limited treatment options contrary to COVID-19, the pandemic is ongoing, highlighting more deaths and cases every day. Uniting several of the most innovative and seasoned scientists from all applicable areas in a unique collaborative spirit CARE will optimize synergies and complementarities with other endeavors such as the Gates Foundation-supported COVID-19 Therapeutics Accelerator, MANCO1, SCORE2, and the ECRAID3 system, to accelerate the road to supplying options for the current COVID-19 pandemic as well as potential coronavirus outbreaks. After studying in the lab, the project will advance the most promising drug candidates into clinical trials in people.\r\n\r\n<em>It is humbling to see such a large collection of the best scientific minds in Europe come together to solve this complex problem with such urgency. COVID-19 is a once in a lifetime scientific challenge for our generation. CARE aims to create effective therapies with a positive safety profile for current and future coronaviral outbreaks. We hope to move fast and have a meaningful impact in a timely manner.”-Kumar Saikatendu, Ph.D., Director, Global Research Externalization, Takeda</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.boehringer-ingelheim.com/press-release/launch-care-consortium\">\"We\'re very excited to start the CARE consortium and collaborate with other leading specialists to desperately identify new medicines against SARS-CoV-2 along with other coronaviruses that will possess the capacity to cause epidemics,\" additional CARE project leader Marnix Van Loock, Senior Scientific</a></span> Director and R&amp;D Lead of Emerging Pathogens, Global Public Health, Janssen Pharmaceutica NV. \"As part of the initiative, we anticipate applying learnings from a continuous collaboration on COVID-19 with all the Rega Institute for Medical Research, a part of KU Leuven, to display a medication repurposing library of thousands of existing drug substances.\"\r\n\r\n<strong>Comprehensive quick - and long-term reaction to COVID-19</strong>\r\nCARE aims to produce effective therapies with a favorable security profile for your COVID-19 pandemic (drug repositioning), and create new drugs and antibodies specially designed to tackle the SARS-CoV-2 virus.\r\n\r\nThe consortium builds on three pillars:\r\n\r\n1.Drug repositioning, by viewing and profiling compound libraries led by partners with the goal of quickly progressing molecules to complex stages of clinical testing.\r\n2.Small-molecule drug discovery based on at silico screening and profiling of candidate substances directed against SARS-CoV-2 and future coronavirus targets.\r\n3.Virus neutralizing antibody discovery using fully human phage and yeast display, immunisation of all humanised animal models, patient B cells and in silico layout.\r\n\r\nClosely integrated with these pillars are work streams focusing on the refinement of candidate substances via a comprehensive medicinal chemistry campaign, systems research study and pre-clinical and clinical analysis of atoms from all 3 pillars. The systems biology work package will investigate the viral pathophysiology to improve our understanding of the interplay between virus disease stages and individual immune reactions. It will identify infection markers, to notify therapy growth and improve clinical trial monitoring and design of Phase 1 and 2 trials investigating new therapeutics created by CARE.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.boehringer-ingelheim.com/press-release/launch-care-consortium\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Boehringer Ingelheim</a></span>\r\n\r\n</div>','CARE consortium dispatches to quicken drug discovery and improvement for COVID-19','','publish','open','open','','care-consortium-dispatches-to-quicken-drug-discovery-and-improvement-for-covid-19','','','2020-08-19 15:15:16','2020-08-19 15:15:16','',0,'https://microbiozindia.com/?p=7082',0,'post','',0),(7083,2,'2020-08-19 15:15:08','2020-08-19 15:15:08','','humanbody81','','inherit','open','closed','','humanbody81','','','2020-08-19 15:15:08','2020-08-19 15:15:08','',7082,'https://microbiozindia.com/wp-content/uploads/2020/08/drug-discovery.jpg',0,'attachment','image/jpeg',0),(7084,2,'2020-08-19 15:15:16','2020-08-19 15:15:16','Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the United Kingdom and the US, and is led by VRI-Inserm <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.boehringer-ingelheim.com/press-release/launch-care-consortium\">(French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of those Janssen Pharmaceutical Companies of Johnson &amp; Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG, (Zurich, Switzerland). It integrates partners\' COVID-19 jobs continuing since February 2020.</a></span>\r\n\r\n<em>The COVID-19 pandemic has emerged as the largest global health threat to humanity in this century, requiring the global scientific community to join forces in unprecedented ways. Beyond the scientific excellence of the different teams involved in this very ambitious project, CARE is bringing together 37 partners in an alliance pooling their expertise and know-how around an ambitious five-year work plan to develop therapeutics against the current COVID-19 pandemic. We are very grateful for the financial support provided by the Innovative Medicine Initiative that will enable us to implement this plan.”-</em>Professor Yves Lévy, Executive Director of the VRI-Inserm and CARE coordinator\r\n\r\nWithout a licensed vaccines and just limited treatment options contrary to COVID-19, the pandemic is ongoing, highlighting more deaths and cases every day. Uniting several of the most innovative and seasoned scientists from all applicable areas in a unique collaborative spirit CARE will optimize synergies and complementarities with other endeavors such as the Gates Foundation-supported COVID-19 Therapeutics Accelerator, MANCO1, SCORE2, and the ECRAID3 system, to accelerate the road to supplying options for the current COVID-19 pandemic as well as potential coronavirus outbreaks. After studying in the lab, the project will advance the most promising drug candidates into clinical trials in people.\r\n\r\n<em>It is humbling to see such a large collection of the best scientific minds in Europe come together to solve this complex problem with such urgency. COVID-19 is a once in a lifetime scientific challenge for our generation. CARE aims to create effective therapies with a positive safety profile for current and future coronaviral outbreaks. We hope to move fast and have a meaningful impact in a timely manner.”-Kumar Saikatendu, Ph.D., Director, Global Research Externalization, Takeda</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.boehringer-ingelheim.com/press-release/launch-care-consortium\">\"We\'re very excited to start the CARE consortium and collaborate with other leading specialists to desperately identify new medicines against SARS-CoV-2 along with other coronaviruses that will possess the capacity to cause epidemics,\" additional CARE project leader Marnix Van Loock, Senior Scientific</a></span> Director and R&amp;D Lead of Emerging Pathogens, Global Public Health, Janssen Pharmaceutica NV. \"As part of the initiative, we anticipate applying learnings from a continuous collaboration on COVID-19 with all the Rega Institute for Medical Research, a part of KU Leuven, to display a medication repurposing library of thousands of existing drug substances.\"\r\n\r\n<strong>Comprehensive quick - and long-term reaction to COVID-19</strong>\r\nCARE aims to produce effective therapies with a favorable security profile for your COVID-19 pandemic (drug repositioning), and create new drugs and antibodies specially designed to tackle the SARS-CoV-2 virus.\r\n\r\nThe consortium builds on three pillars:\r\n\r\n1.Drug repositioning, by viewing and profiling compound libraries led by partners with the goal of quickly progressing molecules to complex stages of clinical testing.\r\n2.Small-molecule drug discovery based on at silico screening and profiling of candidate substances directed against SARS-CoV-2 and future coronavirus targets.\r\n3.Virus neutralizing antibody discovery using fully human phage and yeast display, immunisation of all humanised animal models, patient B cells and in silico layout.\r\n\r\nClosely integrated with these pillars are work streams focusing on the refinement of candidate substances via a comprehensive medicinal chemistry campaign, systems research study and pre-clinical and clinical analysis of atoms from all 3 pillars. The systems biology work package will investigate the viral pathophysiology to improve our understanding of the interplay between virus disease stages and individual immune reactions. It will identify infection markers, to notify therapy growth and improve clinical trial monitoring and design of Phase 1 and 2 trials investigating new therapeutics created by CARE.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.boehringer-ingelheim.com/press-release/launch-care-consortium\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Boehringer Ingelheim</a></span>\r\n\r\n</div>','CARE consortium dispatches to quicken drug discovery and improvement for COVID-19','','inherit','closed','closed','','7082-revision-v1','','','2020-08-19 15:15:16','2020-08-19 15:15:16','',7082,'https://microbiozindia.com/uncategorized/7082-revision-v1/',0,'revision','',0),(7085,2,'2020-08-20 09:17:10','0000-00-00 00:00:00','','Auto Draft','','auto-draft','open','open','','','','','2020-08-20 09:17:10','0000-00-00 00:00:00','',0,'https://microbiozindia.com/?p=7085',0,'post','',0),(7086,2,'2020-08-20 09:24:08','2020-08-20 09:24:08','India, Mumbai, August 20<sup>th</sup> , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.\r\n\r\nThe product has been developed by Stempeutics over a period of twelve years. The company’s proprietary pooling approach provides for an efficient manufacturing process thereby enabling the product to be made accessible to patients at an affordable cost. More than one million doses can be produced from a single set of master cell banks, which is unique in regenerative medicine, thus providing consistent product to patients. The proprietary technology also helps Stempeucel® extend the therapeutic potential of the drug across multiple disease categories. Under the agreement signed between the two companies, Cipla has received exclusive rights to market and distribute the product in India by leveraging its expansive distribution strengths across the country.\r\n\r\nCLI is a progressive form of peripheral arterial disease that is caused by severe blockage in the arteries thereby reducing blood flow. This may result in the development of sores and wounds in legs and feet with a high risk of limb amputation. It is estimated that about 5 million patients in India are impacted by this debilitating disease. With the current contemporary vascular techniques, it is estimated only 25% of patients can be managed with satisfactory clinical outcomes.\r\n\r\nStempeucel® is a breakthrough treatment which is designed to enhance the body’s limited capability to restore blood flow in ischemic tissue. It is derived from allogeneic pooled mesenchymal stromal cells isolated from the bone marrow of healthy, adult voluntary donors. It directly addresses the root cause of the disease by reducing inflammation, stimulating growth of collateral blood vessels and repairing damaged muscle, thereby reducing the pain, healing the ulcers and salvaging the affected limb. The drug is administered through intramuscular injections around the calf muscle region and around the site of ulcers.\r\n\r\nCurrently, Stempeutics is working on a strategy for other international markets including US, EU and Japan. The global critical limb ischemia treatment market expected to generate USD 5,390 million by 2025, at a CAGR of 8.1% between 2020 and 2025.\r\n\r\nCommenting on the DCGI approval, <strong>Mr. Manohar BN, MD &amp; CEO of Stempeutics </strong>said, “Obtaining DCGI approval for Stempeucel® is an important and historic milestone for Stempeutics. It is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work and underscores our global leadership in allogeneic, pooled MSC technology. We believe that the Stempeucel® product is a game-changer, offering an advanced therapeutic treatment for millions of patients suffering from this dreadful disease.”\r\n\r\n<strong>Mr. Umang Vohra, Managing Director and Global CEO of Cipla, </strong>said, “Our focus on innovation is guided by our strong sense of responsibility to address unmet patient needs and alleviate suffering. We are pleased to see that our decade-long partnership with Stempeutics has achieved a significant milestone. CLI is a serious and painful condition that impacts patients worldwide and we are happy that we are able to introduce this stem cell therapy in the country at an affordable cost.\"\r\n\r\n<strong>Dr Pawan Kumar Gupta, Senior VP, Medical &amp; Regulatory Affairs, Stempeutics</strong>, said, “We are excited to receive this marketing approval from DCGI for this very important indication. In CLI, fatty deposits block arteries in the leg, leading to greatly reduced blood flow, pain at rest, non-healing ulcers, and gangrene. Patients with CLI are at an immediate risk for limb amputation and death. Now Stempeucel® provides hope for a new, effective treatment and a better quality of life for such CLI patients. Also, Stempeutics is committed to advancing its peripheral artery disease programs in CLI to other parts of the World.”\r\n\r\nFor more cipla news <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiozindia.com/tag/cipla/\">click here...</a></span>','Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI)','','publish','open','open','','cipla-and-stempeutics-collaborate-for-launch-of-stempeucel-first-made-in-india-cell-therapy-to-treat-critical-limb-ischemia-cli','','','2020-08-20 09:28:17','2020-08-20 09:28:17','',0,'https://microbiozindia.com/?p=7086',0,'post','',0),(7087,2,'2020-08-20 09:24:08','2020-08-20 09:24:08','India, Mumbai, August 20<sup>th</sup> , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.\r\n\r\nThe product has been developed by Stempeutics over a period of twelve years. The company’s proprietary pooling approach provides for an efficient manufacturing process thereby enabling the product to be made accessible to patients at an affordable cost. More than one million doses can be produced from a single set of master cell banks, which is unique in regenerative medicine, thus providing consistent product to patients. The proprietary technology also helps Stempeucel® extend the therapeutic potential of the drug across multiple disease categories. Under the agreement signed between the two companies, Cipla has received exclusive rights to market and distribute the product in India by leveraging its expansive distribution strengths across the country.\r\n\r\nCLI is a progressive form of peripheral arterial disease that is caused by severe blockage in the arteries thereby reducing blood flow. This may result in the development of sores and wounds in legs and feet with a high risk of limb amputation. It is estimated that about 5 million patients in India are impacted by this debilitating disease. With the current contemporary vascular techniques, it is estimated only 25% of patients can be managed with satisfactory clinical outcomes.\r\n\r\nStempeucel® is a breakthrough treatment which is designed to enhance the body’s limited capability to restore blood flow in ischemic tissue. It is derived from allogeneic pooled mesenchymal stromal cells isolated from the bone marrow of healthy, adult voluntary donors. It directly addresses the root cause of the disease by reducing inflammation, stimulating growth of collateral blood vessels and repairing damaged muscle, thereby reducing the pain, healing the ulcers and salvaging the affected limb. The drug is administered through intramuscular injections around the calf muscle region and around the site of ulcers.\r\n\r\nCurrently, Stempeutics is working on a strategy for other international markets including US, EU and Japan. The global critical limb ischemia treatment market expected to generate USD 5,390 million by 2025, at a CAGR of 8.1% between 2020 and 2025.\r\n\r\nCommenting on the DCGI approval, <strong>Mr. Manohar BN, MD &amp; CEO of Stempeutics </strong>said, “Obtaining DCGI approval for Stempeucel® is an important and historic milestone for Stempeutics. It is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work and underscores our global leadership in allogeneic, pooled MSC technology. We believe that the Stempeucel® product is a game-changer, offering an advanced therapeutic treatment for millions of patients suffering from this dreadful disease.”\r\n\r\n<strong>Mr. Umang Vohra, Managing Director and Global CEO of Cipla, </strong>said, “Our focus on innovation is guided by our strong sense of responsibility to address unmet patient needs and alleviate suffering. We are pleased to see that our decade-long partnership with Stempeutics has achieved a significant milestone. CLI is a serious and painful condition that impacts patients worldwide and we are happy that we are able to introduce this stem cell therapy in the country at an affordable cost.\"\r\n\r\n<strong>Dr Pawan Kumar Gupta, Senior VP, Medical &amp; Regulatory Affairs, Stempeutics</strong>, said, “We are excited to receive this marketing approval from DCGI for this very important indication. In CLI, fatty deposits block arteries in the leg, leading to greatly reduced blood flow, pain at rest, non-healing ulcers, and gangrene. Patients with CLI are at an immediate risk for limb amputation and death. Now Stempeucel® provides hope for a new, effective treatment and a better quality of life for such CLI patients. Also, Stempeutics is committed to advancing its peripheral artery disease programs in CLI to other parts of the World.”\r\n\r\nFor more cipla news <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiozindia.com/tag/cipla/\">click here...</a></span>','Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI)','','inherit','closed','closed','','7086-revision-v1','','','2020-08-20 09:24:08','2020-08-20 09:24:08','',7086,'https://microbiozindia.com/uncategorized/7086-revision-v1/',0,'revision','',0),(7088,2,'2020-08-20 10:46:44','2020-08-20 10:46:44','August 20, 2020: Lincoln Pharmaceuticals Limited, one of India\'s leading healthcare companies has reported net profit of Rs. 14.99 crore for the Q1FY21 Ended June 2020 as against net profit of Rs. 12.16 crore in the corresponding period last year, growth of 23.2%. Net revenue for the quarter ended June 2020 reported at Rs. 103.01 crore, higher by 7.11% over previous fiscal’s same period net revenue of Rs. 96.17 crore. EBITDA for the quarter ended June 2020 was reported at Rs.22.42crores as compared to Rs.19.04 crores in the corresponding period last year. EPS was at Rs.7.50 per share for Q1FY21 as compared to Rs.6.08 in the corresponding period last year.\r\n\r\nCompany has received European Union (EU) GMP certification from Germany FDA for its manufacturing facility located at Khatraj in Gujarat. The certification will allow the company to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company looks to enter the EU markets during the current financial year with its dermatology, gastro and pain management products and gradually expand product portfolio.\r\nCommenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We are pleased to announce that Lincoln Pharma has become a zero net-debt company by paying all its outstanding debt. Despite a challenging economic and business environment due to COVID 19, company has delivered a robust financial performance quarter over quarter maintaining healthy growth in revenue, profitability and expects to continue the growth momentum in the coming years.\r\n\r\nExports sales (FOB) for the Q1 increased 40% to Rs. 82.08 crore and expected to get further boost post-EU approval. Strategic growth initiatives, strong performance in the domestic and international markets, EU approval, new product approvals, better margin products along with operational efficiency are likely to contribute healthy growth and maximise value for all stakeholders in the near to medium term. \"\r\nExport the business of the company has shown remarkable growth in the last few years. Exports have increased to 56% of total sales in FY20 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East &amp; West Africa, Central &amp; Latin America and Southeast Asia and has got many product registrations in these countries and is also awarded with number of global tenders. With the EU certification, company will expand its business network to 90 plus countries.\r\n\r\nCompany has recently launched Chewable Vitamin C + Zinc Tablet for Indian market. The tablet is an evidence-based bio-active for natural immunity in a combination of zinc that boosts antiviral activity and protection against COVID 19. Market size for Vitamin C and Zinc tablets is estimated at around Rs. 150 crore in India and growing at 15% per annum.\r\n\r\nLincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio &amp; CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiozindia.com/pharma-news/lincoln-pharma-gets-gujarat-food-and-drug-controller-gesture-to-make-hcq-tablets/\">More about lincoln news....</a></span>','Lincoln Pharmaceuticals Ltd reports 23% rise in the Standalone Net Profit at Rs.14.99 crore in Q1FY21','','publish','open','open','','lincoln-pharmaceuticals-ltd-reports-23-rise-in-the-standalone-net-profit-at-rs-14-99-crore-in-q1fy21','','','2020-08-20 10:46:44','2020-08-20 10:46:44','',0,'https://microbiozindia.com/?p=7088',0,'post','',0),(7089,2,'2020-08-20 10:43:57','2020-08-20 10:43:57','','Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd','','inherit','open','closed','','mr-mahendra-patel-md-lincoln-pharmaceuticals-ltd','','','2020-08-20 10:43:57','2020-08-20 10:43:57','',7088,'https://microbiozindia.com/wp-content/uploads/2020/08/Mr.-Mahendra-Patel-MD-Lincoln-Pharmaceuticals-Ltd.jpg',0,'attachment','image/jpeg',0),(7090,2,'2020-08-20 10:46:44','2020-08-20 10:46:44','August 20, 2020: Lincoln Pharmaceuticals Limited, one of India\'s leading healthcare companies has reported net profit of Rs. 14.99 crore for the Q1FY21 Ended June 2020 as against net profit of Rs. 12.16 crore in the corresponding period last year, growth of 23.2%. Net revenue for the quarter ended June 2020 reported at Rs. 103.01 crore, higher by 7.11% over previous fiscal’s same period net revenue of Rs. 96.17 crore. EBITDA for the quarter ended June 2020 was reported at Rs.22.42crores as compared to Rs.19.04 crores in the corresponding period last year. EPS was at Rs.7.50 per share for Q1FY21 as compared to Rs.6.08 in the corresponding period last year.\r\n\r\nCompany has received European Union (EU) GMP certification from Germany FDA for its manufacturing facility located at Khatraj in Gujarat. The certification will allow the company to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company looks to enter the EU markets during the current financial year with its dermatology, gastro and pain management products and gradually expand product portfolio.\r\nCommenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We are pleased to announce that Lincoln Pharma has become a zero net-debt company by paying all its outstanding debt. Despite a challenging economic and business environment due to COVID 19, company has delivered a robust financial performance quarter over quarter maintaining healthy growth in revenue, profitability and expects to continue the growth momentum in the coming years.\r\n\r\nExports sales (FOB) for the Q1 increased 40% to Rs. 82.08 crore and expected to get further boost post-EU approval. Strategic growth initiatives, strong performance in the domestic and international markets, EU approval, new product approvals, better margin products along with operational efficiency are likely to contribute healthy growth and maximise value for all stakeholders in the near to medium term. \"\r\nExport the business of the company has shown remarkable growth in the last few years. Exports have increased to 56% of total sales in FY20 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East &amp; West Africa, Central &amp; Latin America and Southeast Asia and has got many product registrations in these countries and is also awarded with number of global tenders. With the EU certification, company will expand its business network to 90 plus countries.\r\n\r\nCompany has recently launched Chewable Vitamin C + Zinc Tablet for Indian market. The tablet is an evidence-based bio-active for natural immunity in a combination of zinc that boosts antiviral activity and protection against COVID 19. Market size for Vitamin C and Zinc tablets is estimated at around Rs. 150 crore in India and growing at 15% per annum.\r\n\r\nLincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio &amp; CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiozindia.com/pharma-news/lincoln-pharma-gets-gujarat-food-and-drug-controller-gesture-to-make-hcq-tablets/\">More about lincoln news....</a></span>','Lincoln Pharmaceuticals Ltd reports 23% rise in the Standalone Net Profit at Rs.14.99 crore in Q1FY21','','inherit','closed','closed','','7088-revision-v1','','','2020-08-20 10:46:44','2020-08-20 10:46:44','',7088,'https://microbiozindia.com/uncategorized/7088-revision-v1/',0,'revision','',0),(7091,2,'2020-08-20 15:59:34','2020-08-20 15:59:34','Viruses multiply by injecting their DNA into a host cell. Once it passes the intracellular fluid, then this foreign substance triggers a defense mechanism referred to as the cGAS-STING pathway. This, in turn, binds to another protein named Stimulator of Interferon Genes (STING), which induces an inflammatory immune reaction.\r\n\r\nFrom time to time, the material contained within the fluid - and also connected with the cGAS protein - comes not out of a virus but from the cell itself, for example after the nucleus has inadvertently ruptured. While this happens, the cGAS-STING pathway is not activated. Researchers at EPFL have shown how cells can respond differently to their own DNA and also to genetic material from a pathogen - and prevent attacking the wrong target. Their discovery, published in a paper in the journal Science, sheds new light on the complex processes at work in the human body\'s inflammatory response.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/how-a-protein-stops-cells-from-attacking-their-own\">The group, headed by Prof. Andrea Ablasser and working together with colleagues from the labs of Prof. Conquer Fierz and Prof. Selman Sakar, found new insights to the key job of a small protein known as Barrier-to-Autointegration Factor (BAF).</a> </span>They revealed that, by binding to the inoffensive DNA, BAF prevents the cGAS protein by doing the same, thereby stopping the cGAS-STING pathway in its paths.\r\n\r\nBAF reinforces the cell nucleus, linking the nuclear envelope (or membrane) into the DNA inside. Experiments have demonstrated that if this protein is removed from lab-grown cells, the nucleus ruptures. This violation releases the genetic material to the intracellular fluid, in which it comes into contact with the cGAS protein and activates the cGAS-STING pathway - exactly as if it were foreign DNA.\r\n<blockquote>We can therefore conclude that BAF plays a key role in preventing the cell from attacking its own DNA.\"\r\n\r\nBaptiste Guey, one of the paper\'s lead authors</blockquote>\r\nThere are various approaches to create a nucleus to rupture, like by applying mechanical strain. However, based on Baptiste Guey, among the paper\'s lead writers, only one of those methods - eliminating the BAF protein - based causes an immune response.\r\n\r\nThe protein\'s inhibitor function is extremely important: although the cGAS-STING pathway enables the body fight off infections, in addition, it should be kept in check. \"Nuclei do occasionally rupture, but cells are able to repair the damage,\" says Marilena Wischnewski, yet another lead author of this paper. \"If cGAS jumped to the DNA every time that occurred, the consequences would be more serious.\"\r\n\r\nThe hazards of an overactive cGAS-STING pathway can be seen in Aicardi-Goutières syndrome: a rare and usually fatal hereditary disorder which causes an excessive inflammatory reaction as though the body\'s cells were under continuous assault from invading pathogens.\r\n\r\nBAF is also believed to play a role in some kinds of tumor. Based on Wischnewski, a high concentration of the protein in cancer cells might be associated with a poorer prognosis. \"It might be that BAF makes tumors more resistant,\" she clarifies. \"By preventing activation of the cGAS-STING pathway, it may enable cancer cells to evade the body\'s immune system.\"\r\n\r\nThe protein is found in varying quantities in various kinds of cells. The group is planning to dig deeper into those variations as they seek to know how distinct tissue types respond to infection and inflammation.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/how-a-protein-stops-cells-from-attacking-their-own\" target=\"_blank\" rel=\"noopener noreferrer\">Ecole Polytechnique Fédérale de Lausanne</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nGuey, B., <em>et al.</em> (2020) BAF restricts cGAS on nuclear DNA to prevent innate immune activation. <em>Science.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://science.sciencemag.org/content/369/6505/823\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1126/science.aaw6421</a>.</span>\r\n\r\n</div>','Examination shows how a protein prevents cells from assaulting their own DNA','','publish','open','open','','examination-shows-how-a-protein-prevents-cells-from-assaulting-their-own-dna','','','2020-08-20 15:59:34','2020-08-20 15:59:34','',0,'https://microbiozindia.com/?p=7091',0,'post','',0),(7092,2,'2020-08-20 15:59:27','2020-08-20 15:59:27','','dna-1388696_640','','inherit','open','closed','','dna-1388696_640','','','2020-08-20 15:59:27','2020-08-20 15:59:27','',7091,'https://microbiozindia.com/wp-content/uploads/2020/08/dna-1388696_640.jpg',0,'attachment','image/jpeg',0),(7093,2,'2020-08-20 15:59:34','2020-08-20 15:59:34','Viruses multiply by injecting their DNA into a host cell. Once it passes the intracellular fluid, then this foreign substance triggers a defense mechanism referred to as the cGAS-STING pathway. This, in turn, binds to another protein named Stimulator of Interferon Genes (STING), which induces an inflammatory immune reaction.\r\n\r\nFrom time to time, the material contained within the fluid - and also connected with the cGAS protein - comes not out of a virus but from the cell itself, for example after the nucleus has inadvertently ruptured. While this happens, the cGAS-STING pathway is not activated. Researchers at EPFL have shown how cells can respond differently to their own DNA and also to genetic material from a pathogen - and prevent attacking the wrong target. Their discovery, published in a paper in the journal Science, sheds new light on the complex processes at work in the human body\'s inflammatory response.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/how-a-protein-stops-cells-from-attacking-their-own\">The group, headed by Prof. Andrea Ablasser and working together with colleagues from the labs of Prof. Conquer Fierz and Prof. Selman Sakar, found new insights to the key job of a small protein known as Barrier-to-Autointegration Factor (BAF).</a> </span>They revealed that, by binding to the inoffensive DNA, BAF prevents the cGAS protein by doing the same, thereby stopping the cGAS-STING pathway in its paths.\r\n\r\nBAF reinforces the cell nucleus, linking the nuclear envelope (or membrane) into the DNA inside. Experiments have demonstrated that if this protein is removed from lab-grown cells, the nucleus ruptures. This violation releases the genetic material to the intracellular fluid, in which it comes into contact with the cGAS protein and activates the cGAS-STING pathway - exactly as if it were foreign DNA.\r\n<blockquote>We can therefore conclude that BAF plays a key role in preventing the cell from attacking its own DNA.\"\r\n\r\nBaptiste Guey, one of the paper\'s lead authors</blockquote>\r\nThere are various approaches to create a nucleus to rupture, like by applying mechanical strain. However, based on Baptiste Guey, among the paper\'s lead writers, only one of those methods - eliminating the BAF protein - based causes an immune response.\r\n\r\nThe protein\'s inhibitor function is extremely important: although the cGAS-STING pathway enables the body fight off infections, in addition, it should be kept in check. \"Nuclei do occasionally rupture, but cells are able to repair the damage,\" says Marilena Wischnewski, yet another lead author of this paper. \"If cGAS jumped to the DNA every time that occurred, the consequences would be more serious.\"\r\n\r\nThe hazards of an overactive cGAS-STING pathway can be seen in Aicardi-Goutières syndrome: a rare and usually fatal hereditary disorder which causes an excessive inflammatory reaction as though the body\'s cells were under continuous assault from invading pathogens.\r\n\r\nBAF is also believed to play a role in some kinds of tumor. Based on Wischnewski, a high concentration of the protein in cancer cells might be associated with a poorer prognosis. \"It might be that BAF makes tumors more resistant,\" she clarifies. \"By preventing activation of the cGAS-STING pathway, it may enable cancer cells to evade the body\'s immune system.\"\r\n\r\nThe protein is found in varying quantities in various kinds of cells. The group is planning to dig deeper into those variations as they seek to know how distinct tissue types respond to infection and inflammation.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://actu.epfl.ch/news/how-a-protein-stops-cells-from-attacking-their-own\" target=\"_blank\" rel=\"noopener noreferrer\">Ecole Polytechnique Fédérale de Lausanne</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nGuey, B., <em>et al.</em> (2020) BAF restricts cGAS on nuclear DNA to prevent innate immune activation. <em>Science.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://science.sciencemag.org/content/369/6505/823\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1126/science.aaw6421</a>.</span>\r\n\r\n</div>','Examination shows how a protein prevents cells from assaulting their own DNA','','inherit','closed','closed','','7091-revision-v1','','','2020-08-20 15:59:34','2020-08-20 15:59:34','',7091,'https://microbiozindia.com/uncategorized/7091-revision-v1/',0,'revision','',0),(7094,2,'2020-08-21 06:58:04','2020-08-21 06:58:04','Gargled water samples might be a feasible alternative to swabs for detection of COVID-19, enabling easy self-collection and taking away the need for trained health care workers for sample collection, according to a study published at the ICMR\'s Indian Journal of Medical Research.\r\n\r\nAdoption of gargle lavage for sample group will have a significant effect as it also leads to substantial cost savings by cutting the demand for swabs and personal protective equipment, the analysis emphasized.\r\n\r\nThe authors of the analysis\"Gargle lavage as a viable choice to swab for detection of SARS-CoV-2\" comprise Dr Naveet Wig, Dr Manish Soneja, Dr Neeraj Nischal and also Dr Ankit Mittal in the department of Medicine at AIIMS, Dr Anjan Trikha and Dr Kapil Dev Soni from the department of Anaesthesia and Critical Care Medicine in AIIMS among others.\r\n\r\n\"Swab group has a lot of drawbacks also because it takes training, exposes the healthcare employees to the virus including aerosols, has poor patient acceptability and is resource intensive.\r\n\r\n\"An alternate sample collection method which may overcome the majority of these constraints without compromising the return of the test is the need of the hour,\" the study underlined.\r\n\r\nOne such method is the assortment of gargle lavage, it mentioned. Even though the usage of gargle specimens is not brand new, at present, there is little published information about the compilation of gargle specimens to diagnose SARSCoV-2 disease, the analysis stated.\r\n\r\nThis analysis was, therefore, conducted to assess the performance of gargle lavage in comparison with nasopharyngeal and oropharyngeal swabs for the discovery of novel coronavirus.\r\n\r\nPaired swab and gargle samples were obtained within 72 hours of their diagnosis.\r\n\r\nPost-sample collection, a 10-point scale was administered to estimate the level of distress with either of the collection procedures, the analysis stated.\r\n\r\n\"All gargle samples were favorable and comparable for their own corresponding swab samples no matter the symptoms and duration of illness. The cycle threshold (Ct ) values for gargle samples were marginally higher but equal to those of swabs. Bland-Altman plot revealed good agreement between the two methods,\" the analysis said.\r\n\r\nA majority (72 percent) of those patients reported moderate-to-severe distress with swab collection in comparison to 24 percent reporting just moderate discomfort with gargle collection.\r\n\r\n\"In conclusion, the study highlights the viability of gargle lavage as an appropriate respiratory sample collection approach.\r\n\r\n\"It is a workable alternative to conventional swab collection with several distinct advantages and will have significant clinical and public health impacts in relation to better acceptability, easy self-collection, sparing of healthcare workers and cost-effectiveness,\" the analysis said.\r\n\r\nThe significant limitation of this analysis was its cross-sectional layout also it was performed only on a limited number of favorable cases.\r\n\r\nAdditionally, it would be necessary to assess the operation using distinct viral RNA isolation platforms, the study stated.','Gargled water tests might be feasible option in contrast to swabs for identification of COVID-19: Study','','publish','open','open','','gargled-water-tests-might-be-feasible-option-in-contrast-to-swabs-for-identification-of-covid-19-study','','','2020-08-21 06:58:04','2020-08-21 06:58:04','',0,'https://microbiozindia.com/?p=7094',0,'post','',0),(7095,2,'2020-08-21 06:57:35','2020-08-21 06:57:35','','_methode_times_prod_web_bin_649727b2-b641-11ea-8f3e-e50b85a09cc5','','inherit','open','closed','','_methode_times_prod_web_bin_649727b2-b641-11ea-8f3e-e50b85a09cc5','','','2020-08-21 06:57:35','2020-08-21 06:57:35','',7094,'https://microbiozindia.com/wp-content/uploads/2020/08/methode_times_prod_web_bin_649727b2-b641-11ea-8f3e-e50b85a09cc5.jpg',0,'attachment','image/jpeg',0),(7096,2,'2020-08-21 06:58:04','2020-08-21 06:58:04','Gargled water samples might be a feasible alternative to swabs for detection of COVID-19, enabling easy self-collection and taking away the need for trained health care workers for sample collection, according to a study published at the ICMR\'s Indian Journal of Medical Research.\r\n\r\nAdoption of gargle lavage for sample group will have a significant effect as it also leads to substantial cost savings by cutting the demand for swabs and personal protective equipment, the analysis emphasized.\r\n\r\nThe authors of the analysis\"Gargle lavage as a viable choice to swab for detection of SARS-CoV-2\" comprise Dr Naveet Wig, Dr Manish Soneja, Dr Neeraj Nischal and also Dr Ankit Mittal in the department of Medicine at AIIMS, Dr Anjan Trikha and Dr Kapil Dev Soni from the department of Anaesthesia and Critical Care Medicine in AIIMS among others.\r\n\r\n\"Swab group has a lot of drawbacks also because it takes training, exposes the healthcare employees to the virus including aerosols, has poor patient acceptability and is resource intensive.\r\n\r\n\"An alternate sample collection method which may overcome the majority of these constraints without compromising the return of the test is the need of the hour,\" the study underlined.\r\n\r\nOne such method is the assortment of gargle lavage, it mentioned. Even though the usage of gargle specimens is not brand new, at present, there is little published information about the compilation of gargle specimens to diagnose SARSCoV-2 disease, the analysis stated.\r\n\r\nThis analysis was, therefore, conducted to assess the performance of gargle lavage in comparison with nasopharyngeal and oropharyngeal swabs for the discovery of novel coronavirus.\r\n\r\nPaired swab and gargle samples were obtained within 72 hours of their diagnosis.\r\n\r\nPost-sample collection, a 10-point scale was administered to estimate the level of distress with either of the collection procedures, the analysis stated.\r\n\r\n\"All gargle samples were favorable and comparable for their own corresponding swab samples no matter the symptoms and duration of illness. The cycle threshold (Ct ) values for gargle samples were marginally higher but equal to those of swabs. Bland-Altman plot revealed good agreement between the two methods,\" the analysis said.\r\n\r\nA majority (72 percent) of those patients reported moderate-to-severe distress with swab collection in comparison to 24 percent reporting just moderate discomfort with gargle collection.\r\n\r\n\"In conclusion, the study highlights the viability of gargle lavage as an appropriate respiratory sample collection approach.\r\n\r\n\"It is a workable alternative to conventional swab collection with several distinct advantages and will have significant clinical and public health impacts in relation to better acceptability, easy self-collection, sparing of healthcare workers and cost-effectiveness,\" the analysis said.\r\n\r\nThe significant limitation of this analysis was its cross-sectional layout also it was performed only on a limited number of favorable cases.\r\n\r\nAdditionally, it would be necessary to assess the operation using distinct viral RNA isolation platforms, the study stated.','Gargled water tests might be feasible option in contrast to swabs for identification of COVID-19: Study','','inherit','closed','closed','','7094-revision-v1','','','2020-08-21 06:58:04','2020-08-21 06:58:04','',7094,'https://microbiozindia.com/uncategorized/7094-revision-v1/',0,'revision','',0),(7097,2,'2020-08-21 08:19:56','2020-08-21 08:19:56','Kids play a larger part in the community spread of COVID-19 than previously thought, according to a study which found that the younger individuals might not be as inclined to become seriously sick as adults, but they can spread infection and bring the virus into their houses. The study, published in the Journal of Pediatrics, also challenges the present hypothesis that because children have lower numbers of immune receptors for SARS-CoV2, the virus that causes COVID-19, this makes them less likely to become infected or severely ill.\r\n\r\nIn the analysis of 192 children ages 0-22, 49 kids tested positive for SARS-CoV-2, and an additional 18 children had late-onset, COVID-19-related illness, according to the researchers from Massachusetts General Hospital (MGH) in the united states.\r\n\r\nThe contaminated children were demonstrated to possess a significantly high level of virus in their airways compared to hospitalised adults in ICUs for COVID-19 treatment, they stated.\r\n\r\n\"I was amazed by the high levels of virus we discovered in children of all ages, particularly in the first two days of disease,\" said Lael Yonker, from MGH, and lead author of this analysis.\r\n\r\n\"I was not anticipating the viral load to be this high. You think of a hospital, as well as all the precautions taken to treat severely ill adults, however, the viral loads of those hospitalised patients are significantly lower than a\'healthy kid\' who is walking around having a tall SARS-CoV-2 viral load,\" Yonker said.\r\n\r\nThe findings in nose and throat swabs and blood samples take consequences for the reopening of schools, healthcare centres and other places with a high density of children and intimate discussion with instructors and team members.\r\n\r\n\"Children aren\'t immune against this disease, and their symptoms don\'t correlate with exposure and infection,\" said Alessio Fasano, director of the Mucosal Immunology and Biology Research Center at MGH.\r\n\r\n\"During this COVID-19 pandemic, we have mainly screened symptomatic subjects, so we\'ve reached the incorrect conclusion that the vast majority of individuals infected are adults.\r\n\r\nHowever, our results show that kids are not protected against this virus. We shouldn\'t discount children as potential spreaders for this particular virus,\" Fasano said.','Kids are quiet spreaders of COVID-19: Study','','publish','open','open','','kids-are-quiet-spreaders-of-covid-19-study','','','2020-08-21 08:19:56','2020-08-21 08:19:56','',0,'https://microbiozindia.com/?p=7097',0,'post','',0),(7098,2,'2020-08-21 08:18:43','2020-08-21 08:18:43','','fountain-5320595_640','','inherit','open','closed','','fountain-5320595_640','','','2020-08-21 08:18:43','2020-08-21 08:18:43','',7097,'https://microbiozindia.com/wp-content/uploads/2020/08/fountain-5320595_640.jpg',0,'attachment','image/jpeg',0),(7099,2,'2020-08-21 08:19:56','2020-08-21 08:19:56','Kids play a larger part in the community spread of COVID-19 than previously thought, according to a study which found that the younger individuals might not be as inclined to become seriously sick as adults, but they can spread infection and bring the virus into their houses. The study, published in the Journal of Pediatrics, also challenges the present hypothesis that because children have lower numbers of immune receptors for SARS-CoV2, the virus that causes COVID-19, this makes them less likely to become infected or severely ill.\r\n\r\nIn the analysis of 192 children ages 0-22, 49 kids tested positive for SARS-CoV-2, and an additional 18 children had late-onset, COVID-19-related illness, according to the researchers from Massachusetts General Hospital (MGH) in the united states.\r\n\r\nThe contaminated children were demonstrated to possess a significantly high level of virus in their airways compared to hospitalised adults in ICUs for COVID-19 treatment, they stated.\r\n\r\n\"I was amazed by the high levels of virus we discovered in children of all ages, particularly in the first two days of disease,\" said Lael Yonker, from MGH, and lead author of this analysis.\r\n\r\n\"I was not anticipating the viral load to be this high. You think of a hospital, as well as all the precautions taken to treat severely ill adults, however, the viral loads of those hospitalised patients are significantly lower than a\'healthy kid\' who is walking around having a tall SARS-CoV-2 viral load,\" Yonker said.\r\n\r\nThe findings in nose and throat swabs and blood samples take consequences for the reopening of schools, healthcare centres and other places with a high density of children and intimate discussion with instructors and team members.\r\n\r\n\"Children aren\'t immune against this disease, and their symptoms don\'t correlate with exposure and infection,\" said Alessio Fasano, director of the Mucosal Immunology and Biology Research Center at MGH.\r\n\r\n\"During this COVID-19 pandemic, we have mainly screened symptomatic subjects, so we\'ve reached the incorrect conclusion that the vast majority of individuals infected are adults.\r\n\r\nHowever, our results show that kids are not protected against this virus. We shouldn\'t discount children as potential spreaders for this particular virus,\" Fasano said.','Kids are quiet spreaders of COVID-19: Study','','inherit','closed','closed','','7097-revision-v1','','','2020-08-21 08:19:56','2020-08-21 08:19:56','',7097,'https://microbiozindia.com/uncategorized/7097-revision-v1/',0,'revision','',0);

--
